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ABSTRACT 
Diabetic wounds frequently undergo impaired and prolonged wound healing due to a 
multitude of factors including hypoxia, impaired angiogenesis, hyperglycaemia, 
formation of ROS and AGEs, and infection - all of which may lead to cellular 
dysfunction. To date, however, treatment options for individuals suffering from 
impaired diabetic wound healing are limited, non-specific, and generally 
unsuccessful. The search for new and effective treatment strategies is severely 
hampered by the availability of adequately characterized screening models which 
comprehensively mimic the complexity of the diabetic wound healing process. In 
order to explore natural products as potential therapeutics to treat diabetic wounds 
and to  encourage more research on this topic, this study sought out to develop and 
characterize a more convenient and cost effective in vitro screening assay which  
mimics the effects of protein glycation on the healing process of diabetic wounds. As 
proof of principal, this model was subsequently used to screen the potential of five 
wild mushroom species (P. tinctorius, R. capensis, B. badius, P. ostreatus and G. 
lucidum) as suitable diabetic wound healing therapies.  
The glycated gelatin model developed during this study was found to suitably mimic 
the diabetic state as it successfully simulated the major cellular dysfunctions in 
macrophages (NO production, phagocytosis, macrophage polarization, NF-ĸB 
translocation and COX-2 expression) and fibroblasts (proliferation and migration) 
documented during diabetic wound healing. Together these findings provide 
confidence that the model may serve as a valuable tool to study the poorly 
understood mechanisms which characterize cellular dysfunction in response to AGE 
accumulation and also to aid the identification of novel therapeutic agents to treat 
this pathology.  Screening a number of mushroom extracts revealed that the ethanol 
extracts of R. capensis and P. ostreatus had the greatest potential for attenuating 
chronic inflammation due to their ability to promote macrophage phagocytosis, 
increased M2 activation (R. capensis) and decreased M1 activation (P. ostreatus) as 
well as reduced COX-2 expression while the water extract of G. lucidum proved to 
be the most promising candidate for stimulating fibroplasia as it was the most 
successful at promoting both fibroblast proliferation and migration. Different 
mushroom species were thus shown to promote different stages of the wound 
iv 
 
healing process providing sufficient evidence to support further studies related to the 
use of macrofungi as therapeutic agents in the search for more cost-effective and 
efficient treatment strategies for impaired diabetic wound healing. 
Keywords: diabetic wound healing; macrofungi; AGEs 
 
 
v 
 
LIST OF FIGURES 
Figure 1.1: Global projections of the prevalence of diabetes between the years 
2015 and 2040 in people aged 20-79 years ........................................ 1 
Figure 1.2: Skin anatomy and cellular components ............................................... 2 
Figure 1.3: A schematic representation of the normal phases of wound healing 
and the functions of the major cells responsible for each phase ......... 7 
Figure 1.4: A summary of the classical and alternative pathways of complement 
activation ........................................................................................... 11 
Figure 1.5: Triggers and responses for classical and alternative macrophage 
activation ........................................................................................... 13 
Figure 1.6: Arginine metabolism in M1 and M2 macrophages ............................. 14 
Figure 1.7: The role of M1 and M2 macrophages in cutaneous wound healing... 15 
Figure 1.8: NO biosynthesis from L-arginine ....................................................... 16 
Figure 1.9: Regulators of iNOS gene expression and consequent NO production
 .......................................................................................................... 17 
Figure 1.10: The intracellular destruction of microbes through phagocytosis ........ 20 
Figure 1.11: Schematic diagram of the basic antibody structure ........................... 21 
Figure 1.12: Classical and alternative pathways of NF-ĸB activation .................... 23 
Figure 1.13: The biosynthetic pathway of prostanoids ........................................... 24 
Figure 1.14: Proposed model for NF-ĸB in inflammation ....................................... 25 
Figure 1.15: A diagrammatic illustration of some of the mechanisms responsible for 
impaired wound healing in diabetes .................................................. 31 
Figure 1.16: Reactions leading to the formation of AGEs ...................................... 33 
vi 
 
Figure 1.17: Photographs of the mushroom species collected for this study  ........ 37 
 
Figure 3.1: Chemical structure of trypan blue ...................................................... 44 
Figure 3.2: Chemical structure of Hoechst 33342 ................................................ 46 
Figure 3.3: Chemical structure of propidium iodide ............................................. 46 
Figure 3.4: Spatial distribution of image sites acquired during the cytotoxicity 
screening assay ................................................................................. 47 
Figure 3.5: The chemical structure of crystal violet .............................................. 47 
Figure 3.6: Reaction occurring during the FRAP assay ....................................... 49 
Figure 3.7: Reaction occurring during the DPPH assay....................................... 50 
Figure 3.8: Chemical reactions occurring during the quantification of NO2
- using 
the Griess reagent for nitrite .............................................................. 54 
Figure 3.9: Chemical structure of Polymyxin B sulfate......................................... 55 
Figure 3.10: Fluorescence emission spectrum of the pHrodo™ Green conjugate 
utilised in the pHrodo™ Green BioParticles® Conjugate system for 
measuring phagocytosis .................................................................... 57 
Figure 3.11: Spatial distribution of image sites acquired during the phagocytosis 
assay ................................................................................................. 58 
Figure 3.12: Spatial distribution of image sites acquired during the NF-ĸB assay . 60 
Figure 3.13: Spatial distribution of image sites acquired during the COX-2 assay 61 
Figure 3.14: Schematic of the Cell Migration Assay adapted from Enzo® ............. 62 
Figure 3.15: Diagram illustrating a segmentation overlay and the filter sets used 
during this study. ............................................................................... 63 
vii 
 
Figure 3.16: The workflow of the TScratch software  ............................................. 63 
 
Figure 4.1: A comparison of the relative fluorescence of unglycated gelatin and 
glucose stocks used to produce glycated gelatin after being 
autoclaved for 1 hour ......................................................................... 65 
Figure 4.2: Fluorescent micrographs captured during the gelatin cytotoxicity 
screening assay ................................................................................. 67 
Figure 4.3: Cytotoxicity screening of gelatin comparing cell number with cell 
density for RAW 264.7 cells and MRHF fibroblasts ........................... 68 
Figure 4.4: NO production of RAW 264.7 cells in response to glycated and 
unglycated gelatin  ............................................................................. 69 
Figure 4.5: NO scavenging activity of glycated and unglycated gelatin  .............. 70 
Figure 4.6: Fluorescent micrographs captured during the phagocytosis assay ... 71 
Figure 4.7: Effect of gelatin on RAW 264.7 cell phagocytosis and acidic vacuole 
formation............................................................................................ 72 
Figure 4.8: Fluorescent micrographs captured during the macrophage polarization 
assay ................................................................................................. 73 
Figure 4.9: Macrophage polarization following treatment with gelatin ................. 74 
Figure 4.10: Fluorescent micrographs captured during the phospho-p65 NF-ĸB 
nuclear translocation assay ............................................................... 75 
Figure 4.11: NF-ĸB nuclear translocation following treatment with gelatin ............ 75 
Figure 4.12: Fluorescent micrographs captured during the COX-2 assay ............. 76 
Figure 4.13: COX-2 antibody staining following treatment with gelatin .................. 77 
Figure 4.14: MRHF fibroblast proliferation in response to gelatin .......................... 78 
viii 
 
Figure 4.15: MRHF fibroblast migration in response to gelatin after 48 hours ....... 79 
Figure 4.16: Fluorescent micrographs captured during the cytotoxicity screening 
assay for G. lucidum .......................................................................... 80 
Figure 4.17: Cytotoxicity screening of P. tinctorius comparing cell number and cell 
density for RAW 264.7 and MRHF cells ............................................ 81 
Figure 4.18: Cytotoxicity screening of R. capensis comparing cell number and cell 
density for RAW 264.7 and MRHF cells ............................................ 82 
Figure 4.19: Cytotoxicity screening of B. badius comparing cell number and cell 
density for RAW 264.7 and MRHF cells ............................................ 83 
Figure 4.20: Cytotoxicity screening of P. ostreatus comparing cell number and cell 
density for RAW 264.7 and MRHF cells ............................................ 84 
Figure 4.21: Cytotoxicity screening of G. lucidum comparing cell number and cell 
density for RAW 264.7 and MRHF cells ............................................ 85 
Figure 4.22: Antioxidant screening of P. tinctorius comparing the results from the 
FRAP, DPPH and NO scavenging assay .......................................... 86 
Figure 4.23: Antioxidant screening of R. capensis comparing the results from the 
FRAP, DPPH and NO scavenging assay .......................................... 87 
Figure 4.24: Antioxidant screening of B. badius comparing the results from the 
FRAP, DPPH and NO scavenging assay .......................................... 88 
Figure 4.25: Antioxidant screening of P. ostreatus comparing the results from the 
FRAP, DPPH and NO scavenging assay  ......................................... 89 
Figure 4.26: Antioxidant screening of G. lucidum comparing the results from the 
FRAP, DPPH and NO scavenging assay .......................................... 90 
Figure 4.27: Glycation inhibition potential of P. tinctorius comparing glycation 
inhibition with quenching ................................................................... 91 
ix 
 
Figure 4.28: Glycation inhibition potential of R. capensis comparing glycation 
inhibition with quenching ................................................................... 91 
Figure 4.29: Glycation inhibition potential of B. badius .......................................... 92 
Figure 4.30: Glycation inhibition potential of P. ostreatus ...................................... 92 
Figure 4.31: Glycation inhibition potential of G. lucidum ........................................ 93 
Figure 4.32: A comparison of the collagenase inhibitory potential of P. tinctorius, R. 
capensis, B. badius, P. ostreatus and G. lucidum ............................. 94 
Figure 4.33: Nitric oxide production of RAW 264.7 cells treated with P. tinctorius in 
the absence and presence of LPS and glycated gelatin .................... 96 
Figure 4.34: Nitric oxide production of RAW 264.7 cells treated with R. capensis in 
the absence and presence of LPS and glycated gelatin .................... 97 
Figure 4.35: Nitric oxide production of RAW 264.7 cells treated with B. badius in 
the absence and presence of LPS and glycated gelatin .................... 98 
Figure 4.36: Nitric oxide production of RAW 264.7 cells treated with P. ostreatus in 
the absence and presence of LPS and glycated gelatin .................... 99 
Figure 4.37: Nitric oxide production of RAW 264.7 cells treated with G. lucidum in 
the absence and presence of LPS and glycated gelatin .................. 100 
Figure 4.38: Dose-response effect of Polymyxin B sulfate on RAW 264.7 
macrophage cell number after 48 hours .......................................... 101 
Figure 4.39: Assessment of the presence of endotoxins using RAW 264.7 
macrophages with Polymyxin B sulfate for P. tinctorius, R. capensis, 
B. badius, P. ostreatus and G. lucidum ........................................... 102 
Figure 4.40: RAW 264.7 cell phagocytosis after treatment with P. tinctorius 
comparing acidic vacuole formation with phagocytosis ................... 103 
Figure 4.41: RAW 264.7 cell phagocytosis after treatment with R. capensis 
x 
 
comparing acidic vacuole formation with phagocytosis ................... 104 
Figure 4.42: RAW 264.7 cell phagocytosis after treatment with B. badius comparing 
acidic vacuole formation with phagocytosis ..................................... 105 
Figure 4.43: RAW 264.7 cell phagocytosis after treatment with P. ostreatus 
comparing acidic vacuole formation with phagocytosis ................... 105 
Figure 4.44: RAW 264.7 cell phagocytosis after treatment with G. lucidum 
comparing acidic vacuole formation with phagocytosis ................... 106 
Figure 4.45: Macrophage polarization following treatment with P. tinctorius using 
CD86 for M1 macrophages and CD206 for M2 macrophages ......... 107 
Figure 4.46: Macrophage polarization following treatment with R. capensis using 
CD86 for M1 macrophages and CD206 for M2 macrophages ......... 108 
Figure 4.47: Macrophage polarization following treatment with B. badius using 
CD86 for M1 macrophages and CD206 for M2 macrophages ......... 108 
Figure 4.48: Macrophage polarization following treatment with P. ostreatus using 
CD86 for M1 macrophages and CD206 for M2 macrophages ......... 109 
Figure 4.49: Macrophage polarization following treatment with G. lucidum using 
CD86 for M1 macrophages and CD206 for M2 macrophages ......... 109 
Figure 4.50: NF-ĸB nuclear translocation after treatment with P. tinctorius, R. 
capensis, B. badius, P. ostreatus and G. lucidum ........................... 110 
Figure 4.51: COX-2 antibody staining after treatment with P. tinctorius, R. capensis, 
B. badius, P. ostreatus and G. lucidum ........................................... 113 
Figure 4.52: FBS dose-response curve for MRHF fibroblast proliferation after 72 
hours ............................................................................................... 115 
Figure 4.53: MRHF fibroblast proliferation in response to treatment with P. 
tinctorius with and without glycated gelatin ...................................... 116 
xi 
 
Figure 4.54: MRHF fibroblast proliferation in response to treatment with R. 
capensis with and without glycated gelatin ...................................... 116 
Figure 4.55: MRHF fibroblast proliferation in response to treatment with B. badius 
with and without glycated gelatin ..................................................... 117 
Figure 4.56: MRHF fibroblast proliferation in response to treatment with P. 
ostreatus with and without glycated gelatin ..................................... 117 
Figure 4.57: MRHF fibroblast proliferation in response to treatment with G. lucidum 
with and without glycated gelatin ..................................................... 118 
Figure 4.58: Mitomycin c dose-response curve for MRHF fibroblast proliferation 
after 72 hours .................................................................................. 119 
Figure 4.59: MRHF fibroblast migration using the Enzo® Cell Migration Assay kit in 
response to treatment with R. capensis, B. badius and G. lucidum . 120 
 
 
xii 
 
LIST OF TABLES 
 
 
Table 1.1: A summary of the cytokines and complements involved during each 
phase of the wound healing process  .................................................. 30 
Table 1.2: Summary of the cells and their associated functions that are impaired in 
diabetic wound healing  ....................................................................... 35 
 
Table 4.1: M1/M2 ratios calculated during the macrophage polarization assay.. 107 
 
Table 5.1: A summary of the effects of the glycated gelatin model on macrophage 
and fibroblast function during wound healing ..................................... 135 
Table 5.2: A summary of the effects of P. tinctorius on RAW 264.7 macrophage 
function and inflammation during diabetic wound healing .................. 156 
Table 5.3: A summary of the effects of R. capensis on RAW 264.7 macrophage 
function and inflammation during diabetic wound healing .................. 157 
Table 5.4: A summary of the effects of B. badius on RAW 264.7 macrophage 
function and inflammation during diabetic wound healing .................. 158 
Table 5.5: A summary of the effects of P. ostreatus on RAW 264.7 macrophage 
function and inflammation during diabetic wound healing .................. 159 
Table 5.6: A summary of the effects of G. lucidum on RAW 264.7 macrophage 
function and inflammation during diabetic wound healing .................. 160 
Table 5.7: A summary of the effects of each mushroom extract on fibroblast 
proliferation and migration ................................................................. 164 
xiii 
 
LIST OF APPENDICES 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A: Materials and consumables list .................................................................... 186 
B: Reagent preparation .................................................................................... 188 
C: Phagocytosis and acidic vacuole content in RAW 264.7 cells ...................... 190 
xiv 
 
LIST OF ABBREVIATIONS 
ADP Adenosine diphosphate 
AGE Advanced glycation end product 
ASL Arginosuccinate lyase 
ASS Arginosuccinate synthetase 
BAFF B-cell activating factor 
Bcl-3 B-cell lymphoma 3-encoded protein 
BH4 Tetrahydrobiopterin 
Ca2+ Calcium ion 
CaM Calmodulin 
CD14 Cluster of differentiation 14 
COX Cyclooxygenase 
Cu-Zn-SOD Copper-zinc superoxide dismutase 
DC Dendritic cell 
DMEM Dulbecco’s Modified Eagle Medium  
DMSO Dimethyl sulfoxide 
DPPH 2,2-diphenyl-1-picrylhydrazyl 
ECM Extracellular matrix 
EGF Epidermal growth factor 
eNOS Endothelial nitric oxide synthase 
EPC Endothelial Progenitor Cell 
Erg-1 Early growth response protein 1 
FAD Flavin adenine dinucleotide 
FBS Foetal bovine serum  
Fe2+ Ferrous ion 
xv 
 
Fe3+ Ferric ion 
FeSO4 Ferrous sulfate 
FGF Fibroblast growth factor 
Fizz1 Resistin-like α 
FMN Flavin mononucleotide 
FOXO1 Forkhead box protein O1 
FRAP Ferric-Reducing/ Anti-oxidant Power 
HCS High content screening 
HNO2 Nitrous acid 
IC50 Half maximal inhibitory concentration 
IFN Interferon 
IgG Immunoglobulin G 
IĸB Inhibitor of NF-ĸB 
IKK IĸB kinase 
IL Interleukin 
iNOS Inducible nitric oxide synthase  
IRF-1 Interferon regulating factor 1 
ITAM Immunoreceptor tyrosine-based activation motif 
JAK Janus kinase 
L-NIL Nω-imino ethyl L-lysine 
LPB LPS binding  protein 
LPS Lipopolysaccharide  
LT Lymphotoxin-B receptor 
LTR LysoTracker Red 
M1 Classically activated macrophages 
xvi 
 
M2 Alternately activated macrophages 
MAPK Mitogen-activated protein kinase 
Mgl 1 Macrophage galactose-type lectin-1 
MHC Major histocompatibility complex 
MMP Metalloproteinase  
MSC Mesenchymal Stem Cell 
N2O3 Dinitrogen trioxide 
NADPH Nicotinamide adenine dinucleotide phosphate 
NED N-1-napthylethylenediamine dihydrochloride 
NEMO NF-ĸB essential modulator 
NF Nuclear factor 
NIK NF-ĸB inducing kinase 
NKT Natural killer T-cell 
nNOS Neuronal nitric oxide synthase 
NO Nitric oxide 
NOS Nitric oxide synthase 
NOX NADPH-oxidase 
O2 Oxygen 
OAT Ornithine aminotransferase 
ODC Ornithine decarboxylase 
PAMP Pattern associated molecular pattern 
pDC Plasmacytoid dendritic cell 
PDGF Platelet derived growth factor 
PD-L2 Programmed death ligand 2 
PG Prostaglandin 
xvii 
 
PGHS Prostaglandin-endoperoxide synthase 
PI Propidium iodide 
PI3K Phosphoinositide-3 kinase 
PKC Protein kinase C 
PRR Pattern recognition receptor 
RAGE Receptor for AGEs 
RANKL Receptor activator of NF-ĸB ligand 
ROS Reactive oxygen species 
STAT Signal transducer and activator of transcription 
TE Trollox equivalent 
TGF Transforming growth factor 
Th T-helper cell 
TIMP Tissue inhibitor of metalloproteinases 
TLR Toll-like receptor 
TNF Tumour necrosis factor  
TPTZ 2,3,5-triphenyl-1,3,4-triaza-2-azoniacyclopenta-1,4-diene 
chloride 
TSLP Thymic stromal lymphopoeitan 
TxA2 Thromboxane A2 
VEGF Vascular endothelial growth factor 
Ym-1 Chitinase 3-like 3 
 
 
1 
 
CHAPTER 1: LITERATURE REVIEW 
1.1. THE INCIDENCE OF DIABETES IN AFRICA 
Diabetes was estimated to affect approximately 415 million people globally in 2015 
and resulted in 5 million cases of mortality. As seen in figure 1.1, this figure is 
predicted to increase by fifty-five percent within the next two decades and diabetes is 
thus fast becoming one of the largest epidemics of the 21st century (International 
Diabetes Federation, 2015). 
 
 
 
 
 
 
 
 
Figure 1.1: Global projections of the prevalence of diabetes between the years 2015 and 
2040 in people aged 20-79 years (International Diabetes Federation, 2015). 
While the prevalence of diabetes in Africa may not rank amongst the highest 
globally, the African continent is predicted to experience the largest increase in the 
incidence of diabetes (140 %) over the next 25 years. Currently, 14.2 million adults in 
Africa between the ages of 20 and 79 have diabetes thus representing a regional 
incidence of 3.2 %. According to recent statistics, the highest number of diabetic 
cases was reported for North Africa with Egypt (7.8 million diabetics), Algeria (1.7 
million diabetics) and Sudan (1.7 million diabetics) taking the lead. South Africa (2.3 
million diabetics) recorded the highest prevalence of diabetes in Southern Africa 
while Ethiopia (1.3 million diabetics) was the leading country from East Africa. From 
West Africa, Nigeria (1.6 million diabetics) reported the highest incidence of diabetes 
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while the Democratic Republic of Congo (1.8 million diabetics) recorded the highest 
figure from the central region of Africa (International Diabetes Federation, 2015). 
1.2. THE ANATOMY OF THE SKIN 
Being the largest organ of the human body, the skin forms a protective barrier and 
acts as the primary defence mechanism preventing the invasion of pathogens from 
the external environment (Nestle et al., 2009; Kurahashi & Fujii, 2015). As shown in 
figure 1.2, the skin is composed of two layers, namely, the epidermis and the dermis. 
 
 
 
 
 
 
 
 
Figure 1.2: Skin anatomy and cellular components. The epidermis is largely composed of 
keratinocytes but also contains specialised melanocytes, Langerhans cells and 
CD8+ cytotoxic T-cells. The dermis consists of macrophages, mast cells, 
fibroblasts and specialised immune cells including dendritic cell (DC) subsets 
such as dermal DCs and plasmacytoid DCs (pDCs), T cell subsets such as 
CD4+ helper 1 (Th1), Th2 and Th17 cells, γδ T cells as well as natural killer T 
(NKT) cells. Blood vessels, lymphatic vessels and nerves can also be found 
throughout the dermis (Nestle et al., 2009). 
1.2.1. The epidermis 
The epidermis forms the outermost layer and can be divided into four strata based 
on the types of cells that are present. The bottom layer, the stratum basale, contains 
a single row of undifferentiated epidermal cells called keratinocytes and is 
responsible for the constant renewal of the cells of the epidermis. As these basal 
keratinocytes differentiate, they will move upwards to the next layer, the stratum 
spinosum, where they will either mature or divide in order to replenish the basal 
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layer. The third layer, the stratum granulosum, contains keratinocytes which actively 
produce various keratin proteins and lipids while the cells in the final layer, the 
stratum corneum, are primarily responsible for the skin’s barrier function. The 
epidermis also contains specialised cells including melanocytes, Langerhans cells 
and T-cells (Nestle et al., 2009).  
1.2.2. The dermis 
The dermis consists of a dense network of cells called fibroblasts which are 
responsible for producing the extra-cellular matrix rich in collagen. Unlike the 
epidermis, the dermis is not divided into functional layers but consists instead of 
several specialised immune cells including dendritic cells, helper T-cells and natural 
killer T-cells, as well as macrophages, mast cells and fibroblasts. The dermis also 
contains adnexal structures such as hair follicles, sebaceous glands and sweat 
glands (Brodell & Rosenthal, 2008; Nestle et al., 2009).  
Any form of skin damage may expose the body to harmful infections; however, the 
importance of the skin’s ability to promptly heal after a wound has been sustained is 
often neglected. Chronic wounds thus represent a silent epidemic affecting a rather 
large portion of the global population and with the predicted rise in the prevalence of 
diabetes, it poses a growing danger to public health (Kurahashi & Fujii, 2015). 
1.3.  ACUTE VERSUS CHRONIC WOUNDS 
Any event which compromises the integrity of the epithelial lining forming the skin will 
lead to the development of a wound. Wounds result in tissue damage, an event that 
sets into motion a series of complex cellular events in an attempt to restore some, if 
not all, of the affected tissues anatomical and functional capacity (Enoch & Leaper, 
2005). Acute wounds refer to those that progress through all the relevant stages of 
the wound healing process in a timeous and coordinated manner whereas chronic 
wounds display prolonged healing up to 12 weeks following the initial insult. This is 
due to the failure of cells to progress through the normal phases of wound healing as 
they enter, instead, into a state of pathological inflammation (Menke et al., 2007; 
Young & McNaught, 2011).  
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1.3.1. The economic burden of chronic wounds 
Several challenges exist with regards to measuring the costs associated with chronic 
wounds. To date, no research related to the economic burden of chronic wounds on 
the South African healthcare system has been carried out. Costs associated with 
chronic wounds appear to be poorly documented, hidden under general cost 
categories or centred around direct clinical care costs without considering any of the 
indirect or non-monetary repercussions of the wound on the wellbeing of the patient, 
however, the global wound care market is estimated to exceed $22 billion USD by 
the year 2020 (Hurd, 2013; Tricco et al., 2015). 
1.3.2. Current wound healing therapies 
Chronic wounds can be categorised as i) resulting from chronic diseases such as 
diabetes or venous insufficiency, ii) pressure ulcers, or iii) non-healing surgical 
wounds. Chronic wounds thus possess different etiologies with treatment strategies 
being targeted to the type of wound (Tricco et al., 2015). Conventional wound 
management involves debridement in order to remove debris and necrotized tissue. 
This is followed by the topical application of a selection of wound dressings that 
ensure adequate tissue perfusion while reducing the wound pressure as well as the 
chances of infection (Borena et al., 2015). Advances in both technology and the 
understanding of the cellular and biochemical mechanisms involved in impaired 
wound healing have led to the development of more advanced wound healing 
therapies. Some of these include negative pressure wound therapy, hyperbaric 
oxygen therapy, bioengineered skin and tissue equivalents, growth factors and stem 
cell therapies (Wu et al., 2010; Frykberg & Banks, 2015).  
1.3.3. Current wound healing models 
Currently, there is a substantial lack of both in vitro and in vivo models that 
successfully mimic the diabetic state while simultaneously being considered reliable 
and optimal wound repair models. This makes the development of effective 
treatment approaches with regards to impaired wound healing particularly 
problematic and challenging (Mendes et al., 2012). In order to fully understand both 
the function and dysfunction of the skin during wound healing, it is necessary to 
establish pure cell cultures of various cellular components of the skin. The results 
can then be reincorporated back into the context of the skin as a whole (Abdel-Naser 
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et al., 2005). While several in vitro and in vivo models have been designed and used 
to study wound repair as well as the underlying mechanisms involved, none of the 
models developed to date have been able to fully mimic wound healing as it occurs 
in humans. Each model thus has its own distinct set of advantages and 
disadvantages that must be carefully considered when selecting an appropriate 
model, however, valuable information can still be gained from each model (Ansell et 
al., 2012; Nunan et al., 2014). 
1.3.3.1. The importance of in vitro models 
Over the last two decades major developments in cell culture techniques, 
chemically-defined media, and the ease of access to commercially available 
mammalian cells, have transformed in vitro studies into an invaluable research 
asset. The utilization of in vitro test methods has many applications in research and 
avoids many of the ethical and moral dilemmas associated with animal testing 
(Freshney, 2005). In vitro models for wound healing generally involve monolayers of 
skin cells such as keratinocytes, fibroblasts or macrophages and are particularly 
useful for dose-response assays, anti-microbial studies and assessing the effect of 
various agents on the function of individual cell types. For studies related to chronic 
wound healing, the in vitro models can be adapted so that they incorporate at least 
one of the underlying etiologies of the disease of interest. More recent advances in 
wound healing models have led to the development of more complex 3-dimensional 
cell cultures as well as organ cultures such as skin explants (Perez & Davis, 2008).  
To have any relevance in the field of scientific research, experimental models must 
suitably imitate both the physiologic and pathogenic circumstances of a clinical 
condition. In vitro models form an integral part of research pertaining to wound 
healing experiments due to the coordinated manner in which multiple cells interact 
with various systems within the human body during this process. In vitro modelling 
thus provides an essential tool which can be used to elucidate various mechanistic 
and functional details of particular components involved specifically in wound 
healing. It frequently provides an easier, more rapid and cost effective method for 
analyzing molecular and cellular events; however, in vitro tests frequently reveal 
short-comings regarding adequate replication of the complex interactions occurring 
within organisms and during pathological disorders or illnesses. As a result, in vitro 
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modelling will never be able to replace in vivo testing; however, it can provide 
essential additional information that cannot be gained from complex in vivo models 
alone and can thus prove to be a powerful research tool, particularly when it is used 
in conjunction with in vivo models (Scherer et al., 2008; Stacey, 2012). 
1.3.3.2. Animal models 
Once sufficient evidence with regards to a possible wound healing therapy has been 
obtained through in vitro studies, more complex animal models can be used. The 
use of rodents and small mammals such as rabbits have emerged as fairly popular 
wound healing models due to their low cost and maintenance as well as their ability 
to produce several offspring over relatively short time periods (Perez & Davis, 2008). 
The rabbit ear ulcer model has been used to generate ischemic wounds; however, 
this model does not fully mimic hypoxic wounds in humans and is not genetically 
tractable. Rat magnet ischemia-reperfusion models have been generated to study 
pressure ulcers while diabetic mice have been used to study diabetic ulcers, 
however, anatomical differences between the skin of rodents and humans as well as 
the fact that diabetes in mice does not fully reflect diabetic complications as they 
occur in humans have raised some concerns with regards to the clinical relevance of 
these particular animal models (Nunan et al., 2014).  
Porcine wound healing models have emerged as the most clinically relevant wound 
healing models due to the structural similarities shared with human skin. These 
include epidermal thickness, the ratios of dermal-epidermal thickness, similar 
patterns of blood vessels and hair follicles, the presence of dermal collagen, dermal 
elasticity, and comparable physical and molecular responses to several growth 
factors (Perez & Davis, 2008). Pig flap ischemia has been used to study ischemic 
ulcers while pig wound infections have been used to study infected ulcers. Porcine 
models are, however, more expensive than the other animal models mentioned due 
to their size and are not genetically tractable (Nunan et al., 2014). 
1.4. ACUTE WOUND HEALING OVERVIEW 
The wound healing process is considered to be one of the body’s principle survival 
mechanisms and commences directly after an injury has been sustained (Beldon, 
2010). A healed wound is defined to be one in which complete repairing of the 
affected and surrounding connective tissues has been accomplished and where 
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regeneration has allowed for the complete re-epithelialization of the wound area. 
Furthermore, a healed wound is one where the previously damaged area has 
regained at least some, if not all, of its earlier anatomical and functional capability 
(Enoch & Leaper, 2005).  
The process of wound healing is governed by the four discrete yet overlapping 
phases of hemostasis, inflammation, proliferation and tissue remodelling. As can be 
seen in figure 1.3, this healing cascade requires the careful and precise regulation of 
several cellular activities where each phase is categorised according to the cell types 
that are present at the wound at any particular time (Enoch & Leaper, 2005; Young & 
McNaught, 2011).  
 
 
 
 
 
 
 
Figure 1.3: A schematic representation of the normal phases of wound healing and the 
functions of the major cells responsible for each phase (Li et al., 2007). 
1.4.1. Hemostasis 
Hemostasis refers to the series of events that occur directly after an injury has been 
sustained in an attempt to prevent excessive blood loss. For this phase of wound 
healing to be considered successful it must: commence rapidly directly after the 
injury has occurred; be localised to the damaged area; and must be precisely 
controlled in order to ensure that the least amount of blood possible is lost. Medical 
intervention is required in cases where more than ten percent of the body’s total 
blood volume is lost (Tortora & Derrickson, 2012; Silverthorn, 2014). 
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1.4.1.1. Vascular spasm 
When vascular damage is sustained, whether micro- or macro- vascular, the blood 
vessels will constrict in order to reduce the blood flow to the damaged region. Rapid 
constriction of the affected arterial vessel is achieved through smooth muscle 
contraction as a direct response to the trauma sustained (Young & McNaught, 2011). 
The smooth muscle is positioned in the circular layer of blood vessel walls and 
contractions are a consequence of several factors including local muscle spasm, the 
presence of local autacoids that are released from damaged tissue and platelets, 
and nervous reflexes generated from pain receptor activation. This contraction 
process appears to be regulated by the increasing levels of calcium (Ca2+) within the 
cytoplasm where the strength of the spasm is proportional to the extent of the 
damage (Guyton & Hall, 2006).  
1.4.1.2. Platelet plug formation 
Inactivated platelets appear small and disc-shaped, storing vast quantities of several 
growth factors such as platelet-derived growth factor (PDGF), transforming growth 
factor (TGF)-β, vascular endothelial growth factor (VEGF) and epidermal growth 
factor (EGF), as well as cytokines, chemokines, lysosomal enzymes, coagulation 
factors and pro-inflammatory mediators. These chemicals are stored in intracellular 
granules, each performing an important function during the process of hemostasis. 
Once cells become damaged, collagen fibres forming part of the connective tissue 
layer beneath the cells become exposed. Blood platelets adhere to these exposed 
fibres and consequently enter into an activated state (Tortora & Derrickson, 2012).  
Platelet activation is mediated by several factors including adenosine diphosphate 
(ADP), thromboxane and thrombin. Once platelets become activated, they will 
undergo morphological changes involving the extension of multiple projections which 
enables platelet aggregation. Furthermore, the vesicular contents of the alpha and 
dense granules will be liberated where ADP will function with thromboxane A2 during 
the activation of neighbouring platelets and serotonin will function with thromboxane 
A2 in vasoconstriction in order to ensure that a reduced blood flow to the damaged 
vessel is maintained through continued smooth muscle contraction. Once the initial 
platelet plug has been formed and has successfully arrested the bleeding, it is 
strengthened and reinforced by the presence of both fibrin and von Willebrand factor 
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together with the actin and myosin filaments present in the platelet (Young & 
McNaught, 2011; Tortora & Derrickson, 2012).  
1.4.1.3. Blood coagulation 
Once the platelet plug has been successfully established, a blood clot is formed in 
an attempt to restrict any further blood loss. Blood clot formation can occur via the 
intrinsic and/ or the extrinsic pathways. The extrinsic pathway occurs rapidly in 
response to the leakage of tissue factor from damaged cells surrounding the affected 
blood vessel. This sets into motion a series of Ca2+-dependent reactions resulting in 
the formation of prothrombinase. Activation of the slower intrinsic pathway does not 
require tissue damage as it is triggered by the presence of negatively charged 
surfaces and substances within the blood or in direct contact with the blood. Via a 
different series of Ca2+-dependent reactions, activated clotting factor XIII will 
ultimately lead to the formation of prothrombinase (Guyton & Hall, 2006; Tortora & 
Derrickson, 2012).  
The intrinsic and extrinsic pathways converge to form the final common pathway 
during which a strong and stable blood clot is formed. This is achieved through the 
production of thrombin which leads to the formation of insoluble fibrin threads as well 
as the activation of fibrin stabilising factor. Finally, the blood clot will retract through 
contraction of the fibrin threads, consequently drawing the edges of the damaged 
vessel towards each other in an effort to prevent further damage (Tortora & 
Derrickson, 2012). 
1.4.2. Inflammation 
 
Inflammation proceeds at the same time as hemostasis with the primary aim being to 
prevent infection of the wound area as well as to remove any dead and damaged 
tissue which might otherwise delay the normal healing process (Young & McNaught, 
2011; Kurahashi & Fujii, 2015). Once the blood vessels have been successfully 
constricted, a decreased blood flow to the affected tissues results in hypoxia and 
consequent acidosis. This will lead to the production of nitric oxide (NO), adenosine 
and a multitude of various vasoactive metabolites which cause the constricted 
arterial blood vessels to now dilate and relax. Furthermore, mast cells will release 
histamine which consequently increases vasodilation as well as vascular 
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permeability. The result is that numerous pro-inflammatory cells are able to leave the 
blood stream and enter the extracellular space surrounding the injury, explaining why 
early wounds appear red, swollen and warm to the touch (Young & McNaught, 
2011). 
Inflammation is frequently categorised into the early and late phase depending on 
the types of cells that are present at the wound area as well as the timing and 
duration of the response. The inflammatory response is stimulated not only by the 
pro-inflammatory components housed and released by platelets but also by the 
conversion of arachidonic acid, from membrane glycerophospholipids in the plasma 
membrane of the damaged cells, into potent pro-inflammatory signalling molecules 
including leukotrienes, thromboxanes and prostaglandins (Li et al., 2007; Young & 
McNaught, 2011).  
1.4.2.1. Early phase  
Complement activation occurs via the classical and alternative pathways as 
summarised in figure 1.4. Both pathways converge at the activation step of 
complement proteins C3 and C5, ultimately forming the membrane attack complex. 
Complement proteins C3a and C5a form potent chemotactic signals, resulting in the 
infiltration of leukocytes to the wound area (Sinno & Prakash, 2013). The first 
leukocytes that will arrive at the site of the injury within the first 24 to 48 hours are 
the neutrophils. Several chemo-attractants including ECM protein fragments, TGF-β, 
constituents of the complement cascade, cytokines, products secreted from mast 
cells and formyl-methionyl peptide components produced by bacteria will attract 
neutrophils to the wound bed via the process of chemotaxis (Enoch & Leaper, 2005; 
de Mendonça & Coutinho-Netto, 2009). Furthermore, various chemotactic factors will 
also up-regulate the expression of specific intercellular adhesion proteins that are 
involved in leukocyte-homing at the wound area (Li et al., 2007). 
As the neutrophils arrive at the wound area, they will leave the bloodstream and 
enter the wound area via the process of diapedesis. During this process, the 
neutrophils will adhere to the endothelial cells of the affected and adjacent blood 
vessels through specific cell surface receptors, including selectins and integrins, 
after which they squeeze between the endothelial cells in order to enter the affected 
tissues (Enoch & Leaper, 2005; Tortora & Derrickson, 2012). Here they will be able 
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to phagocytose and remove bacteria and any foreign materials by releasing several 
enzymes and free oxygen radicals (Li et al., 2007). Upon completion of their task, 
neutrophils will spontaneously apoptose and be removed by macrophages present in 
the wounded tissue (Williamson & Harding, 2004).  
 
 
 
 
 
 
 
Figure 1.4: A summary of the classical and alternative pathways of complement activation. 
Complement proteins C3a and C5a are involved in chemotaxis while the 
membrane attack complex formed is responsible for lysing foreign microbes 
(Sinno & Prakash, 2013). 
1.4.2.2. Late phase 
Within 48 to 72 hours of sustaining an injury, the second type of leukocytes known 
as monocytes will arrive at the wounded area via the process of chemotaxis. 
Monocytes are attracted to similar chemo-attractants as the neutrophils with the 
addition of clotting factors, immunoglobulin G (IgG) fragments, growth factors and 
degradation products of collagen and elastin (Enoch & Leaper, 2005). Entry into the 
damaged tissue area is achieved via the same process of margination and 
diapedesis described for the neutrophils after which monocytes will be transformed 
into phagocytic macrophages (Li et al., 2007).  
1.4.2.3. A closer look at macrophage function 
Macrophages carry out several responsibilities during inflammation including 
phagocytosis and removal of infectious agents, cellular debris and neutrophils via the 
release of various proteolytic enzymes and reactive oxygen species (ROS) (Li et al., 
12 
 
2007). Some of the more complex pathways through which macrophages carry out 
their functions are described below. 
1.4.2.3.1. Classical and alternative macrophage activation 
Macrophage activation or polarization has been categorised into two main pathways 
based on several phenotypic and metabolic differences. Classically activated (M1) 
macrophages are involved in defending the host from pathogens such as bacteria, 
viruses and protozoa while alternatively activated (M2) macrophages perform anti-
inflammatory and tissue repair functions. A useful approach to studying macrophage 
polarization in vitro has been to stimulate cells with either microbial agonists or 
cytokines and measuring the resultant cytokine production and alterations in gene 
expression, however, it is important to realise that in vivo macrophage 
responsiveness differs as macrophages represent a spectrum of polarization 
phenotypes rather than distinct subpopulations. Thus, while results obtained in vitro 
can provide important information with regards to macrophage polarization, they 
should be interpreted with great caution as M1 and M2 macrophages represent two 
extremes of the macrophage phenotype spectrum (Murray & Wynn, 2011). 
M1 macrophages are stimulated by interferon (IFN) γ secreted by T-helper (Th) 1 
cells as well as microbial products such as lipopolysaccharide (LPS) which activate 
Toll-like receptor (TLR) signalling. These macrophages respond by producing pro-
inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-6 and 
IL-12 as well as reactive oxygen and nitrogen intermediates which are generated 
during the respiratory burst in order to destroy invading pathogens. While M1 
macrophages are essential in preventing and eliminating infections, chronic and 
irregular expression has been associated with the pathogenesis of various 
metabolic, autoimmune and inflammatory diseases. M1 macrophage activation thus 
needs to undergo very tight regulation in order to prevent extensive tissue damage. 
M2 macrophage polarization is stimulated by IL-4, IL-10 and IL-13 produced by Th2 
cells and these macrophages are largely involved in producing anti-inflammatory 
cytokines and tissue repair (Chawla, 2010; Murray & Wynn, 2011). M1 and M2 
macrophage polarization triggers and responses are summarised in figure 1.5. 
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Figure 1.5: Triggers and responses for classical and alternative macrophage activation. (a) 
M1 macrophages are stimulated by IFNγ and LPS to produce pro-inflammatory 
cytokines to promote cell-mediated immunity as well as NO and ROS to destroy 
microbes. (b) M2 macrophages are stimulated by IL-4 and IL-13 and respond by 
upregulating the expression of major histocompatibility complex (MHC) class II 
proteins and costimulatory molecules (PD-L2) as well as arginase 1 expression. 
Further markers for M2 macrophages include lectins (mannose receptor, dectin-
1 and MgI1), chemokines, cytokines and secreted products (Ym-1 and Fizz1) 
(Chawla, 2010). 
The best studied gene induced by M2 macrophage activation is arginase 1 which is 
consequently acknowledged as the most reliable marker of alternative macrophage 
polarization. Arginine metabolism can occur via either arginase or nitric oxide 
synthase (NOS) activities as shown in figure 1.6. M1 macrophages express 
inducible-NOS (iNOS) and are consequently able to metabolise arginine to form NO 
and citrulline. NO can be further metabolised to form reactive nitrogen species such 
as peroxynitrite while citrulline is recycled for efficient NO synthesis through the 
action of the enzymes arginosuccinate synthetase (ASS) and arginosuccinate lyase 
(ASL). M2 macrophages express arginase which is responsible for hydrolysing 
arginine to ornithine and urea. As the arginase pathway limits the availability of 
arginine for NO synthesis, ornithine is further broken down into polyamines and 
proline by the enzymes ornithine decarboxylase (ODC) and ornithine 
aminotransferase (OAT), respectively (Rath et al., 2014). 
Additional metabolic differences that exist between M1 and M2 macrophages relate 
to glucose and iron metabolism. M1 macrophages undergo anaerobic glycolysis 
while M2 macrophages utilise oxidative glucose metabolism (fatty acid oxidation) to 
sustain their tissue remodelling and repair functions over long periods of time. With 
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regards to iron metabolism, M1 macrophages produce high levels of ferritin to store 
iron while M2 macrophages express increased levels of the iron exporter, ferroportin 
(Chazaud, 2013). 
 
 
 
 
 
 
 
Figure 1.6: Arginine metabolism in M1 and M2 macrophages. Arginine is transported into the 
cytoplasm of macrophages where it will undergo degradation to either nitric oxide 
(NO) and citrulline through the action of nitric oxide synthase (NOS) in M1 
macrophages or ornithine and urea through the action of arginase in M2 
macrophages (Rath et al., 2014).  
During the wound healing process, both M1 and M2 macrophages perform critical 
functions as summarised in figure 1.7. M1 macrophages destroy invading pathogens 
by generating NO and ROS, recruit neutrophils and helper T-cells by secreting 
various pro-inflammatory cytokines and aid in the degradation of the extracellular 
matrix (ECM) by secreting metalloproteinases (MMPs). M2 macrophages are 
essential for the transition from inflammation to the tissue repair process, secreting 
various growth factors including PDGF which stimulates myofibroblast proliferation 
and TGF-β1 which promotes the differentiation of fibroblasts into myofibroblasts, 
enhances the expression of tissue inhibitors of metalloproteinases (TIMPs) and 
promotes the interstitial production of fibrillar collagens within myofibroblasts (Murray 
& Wynn, 2011). 
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Figure 1.7: The role of M1 and M2 macrophages in cutaneous wound healing. M1 
macrophages produce antimicrobial agents including NO, ROS, IL-1 and TNF 
and regulate ECM degradation through the action of MMPs. Damaged 
epithelial cells release alarmins such as IL-25, IL-33 and thymic stromal 
lymphopoietin (TSLP) which cause the subsequent release of IL-4 and IL-13 by 
various innate and adaptive immune cells. Once all infectious agents have 
been eliminated, M2 macrophage activation will dominate thus promoting 
tissue regeneration and fibrosis through the production of TIMP-1, growth 
factors and cytokines (Murray & Wynn, 2011). 
1.4.2.3.2. NO biosynthesis 
NO is a diffusible free radical acting as an intercellular signalling molecule which 
performs a wide range of biological functions. NO biosynthesis occurs through the 
action of NOS enzymes. Three NOS isozymes exist differing in structure, regulation 
as well as distribution and are encoded by different chromosomes. Neuronal NOS 
(nNOS) is synthesised by certain neuronal cells, inducible NOS (iNOS) is 
synthesised by macrophages and endothelial NOS (eNOS) is synthesised in 
endothelial tissue, however, the expression of all three isoforms in the skin tissue 
has been reported.  Keratinocytes and melanocytes have been found to express 
nNOS while eNOS has been detected in keratinocytes forming part of the basal 
epidermal layer, dermal fibroblasts, eccrine glands as well as endothelial capillaries. 
iNOS induction has been reported in fibroblasts, endothelial cells, keratinocytes and 
Langerhans cells. NO thus forms part of important functions necessary for regulating 
skin homeostasis (Luo & Chen, 2005; Rath et al., 2014). 
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While eNOS and nNOS are both constitutively expressed, iNOS is the only inducible 
isoform. The NOS isoforms all exist as active homodimers consisting of a C-terminal 
reductase domain as well as an N-terminal oxygenase domain. Within the reductase 
domain, one binding site for each of nicotinamide adenine dinucleotide phosphate 
(NADPH), flavin mononucleotide (FMN), as well as flavin dinucleotide (FAD) can be 
found. The oxygenase domain contains heme binding sites as well as binding sites 
for the tetrahydrobiopterin (BH4) cofactor and the substrate, L-arginine. A calmodulin 
(CaM) binding site can be found between the N- and the C-terminal domains and 
performs an important role with regards to the structure and function of the NOS 
enzymes. Due to their constitutive nature, eNOS and nNOS are permanently active 
and continuously generate very low concentrations of NO with their enzyme function 
being modulated by intracellular calcium fluxes as well as exogenous CaM. iNOS 
transcription, expression and function, however, is induced by a wide range of 
inflammatory stimuli, cytokines and growth factors on target cells. The consequent 
generation of NO thus occurs at much higher concentrations than is seen for the 
other two isoforms and forms part of the host immune response (Luo & Chen, 2005).  
Regardless of the isoform, all NOS enzymes catalyse the same two-step reaction 
shown in figure 1.8 where L-arginine is oxidised to citrulline and NO through the 
formation of a N-Hydroxyarginine intermediate. NADPH serves as an electron donor 
during this reaction while heme, FMN, FAD and BH4 are important cofactors (Aktan, 
2004).  
 
 
 
Figure 1.8: NO biosynthesis from L-arginine. This reaction is regulated by NOS enzymes 
which oxidise L-arginine in the presence of NADPH and O2 to citrulline and NO 
via a N-Hydroxyarginine intermediate (Guix et al., 2005). 
iNOS is regulated at the transcriptional level through the binding of various signalling 
molecules, such as nuclear factor (NF)-ĸB and signal transducer and activator of 
transcription (STAT) proteins, to the promoter region of the iNOS gene. The 
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activation of several cellular receptor molecules regulate iNOS expression through 
various signalling pathways, some of which are shown in figure 1.9.  
 
 
 
 
 
 
 
Figure 1.9: Regulators of iNOS gene expression and consequent NO production. Through 
the action of the LPS binding protein (LBP), LPS is transferred to the CD14 cell 
membrane receptor which activates a signalling cascade that causes the 
activation and translocation of NF-ĸB to the nucleus where it regulates iNOS 
expression. Another signalling pathway involved in iNOS regulation is the JAK-
STAT pathway activated by the binding of IFNγ to its cell membrane receptor 
(Aktan, 2004). 
Receptors such as cluster of differentiation 14 (CD14) and TLRs (activated by LPS) 
together with the IL-1β receptor (activated by the binding of IL-1β) are able to 
regulate iNOS expression through the activation and consequent nuclear 
translocation of NF-ĸB. NF-ĸB exists in the cytoplasm in an inactive form bound to its 
inhibitor. Once phosphorylated in response to various pro-inflammatory stimuli, NF-
ĸB is released and undergoes subsequent translocation to the nucleus were it binds 
to the iNOS gene and promotes iNOS expression (Aktan, 2004; Giux et al., 2005).  
Another activator of iNOS expression is IFNγ which binds to the IFNγ cell-membrane 
receptor thus promoting iNOS induction and consequent NO production through the 
Janus kinase (JAK)-STAT signalling pathway. Once activated, the soluble tyrosine-
kinase receptor JAK phosphorylates several tyrosine residues on the STAT1 protein 
which is subsequently activated and translocated to the nucleus where it promotes 
iNOS expression by inducing the expression of interferon regulating factor 1 (IRF-1) 
(Aktan, 2004). Just as several pro-inflammatory cytokines, microbial products and 
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hypoxia can induce iNOS expression, there are numerous cytokines including IL-4, 
IL-10 and TGF-β which suppress iNOS transcription. There are thus multiple levels 
of regulation for iNOS expression and resultant NO production with additive or 
synergistic combinations of effectors being the most effective (Rath et al, 2014). 
NO performs several key functions during the normal wound healing process where 
it has been shown to promote angiogenesis by regulating the activity of several pro-
angiogenic cytokines such as VEGF. Studies have shown that NO directly increases 
angiogenesis in ischemic murine tissues while NOS inhibitors were found to impair 
angiogenesis as it occurs in granulation tissue during gastric ulcer healing and also 
suppressed capillary organisation during in vitro studies. Additionally, NO influences 
several cellular processes including proliferation, differentiation and apoptosis of 
various cells involved in the wound healing process. A NO donor, sodium 
nitroprusside, was shown to promote the fetal bovine serum (FBS)-induced 
incorporation of thymidine into the DNA of human skin fibroblasts as well as 
stimulating DNA synthesis induced by fibroblast growth factor (FGF) or PDGF. 
Conversely, an iNOS inhibitor, Nω-imino ethyl L-lysine (L-NIL), was shown to 
decrease keratinocyte proliferation at the wound edges thus causing a delay in the 
re-epithelialisation process. Reduced levels of NO were also found to promote in 
vitro keratinocyte proliferation. Furthermore, NO has been shown to regulate 
apoptosis in irradiated keratinocytes as the addition of a NOS inhibitor resulted in an 
increase in keratinocyte apoptosis (Luo & Chen, 2005).  
Luo and Chen (2005) further explained that NO was also shown to play an important 
role in collagen deposition during the final stage of wound healing. Studies showed 
that collagen production was increased in fibroblasts derived from both normal skin 
and skin wounds in response to treatment with a NO donor and that this 
phenomenon was reversed by treatment with a NOS inhibitor. It has been suggested 
that this effect is not due to an increase in the de novo transcription of the genes 
encoding for collagen but rather as a result of the posttranslational enhancement of 
collagen production. 
1.4.2.3.3. Phagocytosis 
The mechanisms by which cells are able to internalise particles and solutes include 
pinocytosis, receptor-mediated endocytosis as well as phagocytosis. Fluids and 
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solutes are generally incorporated into cells via pinocytosis while receptor-mediated 
endocytosis refers to the process through which macromolecules, small particles and 
viruses are taken up by cells. Both of these mechanisms are clathrin-based and 
generally proceed independently of actin filament polymerisation. Conversely, 
phagocytosis refers to the ingestion of particles larger than 0.5 μm in diameter 
through a mechanism that is actin dependent but does not rely on clathrin. 
Phagocytosis thus exists for the removal of infectious agents as well as dead and 
damaged cells with several other important roles in tissue remodelling, inflammation 
and other immune responses (Alem & Underhill, 1999; May & Machesky, 2001). 
The process of phagocytosis is a highly complex, energy-dependent process 
involving several signalling pathways determined by the particles being internalised 
as well as the receptors involved. While no single model is fully capable of describing 
exactly what occurs in vivo during phagocytosis, there are several common features 
that are shared as seen in figure 1.10 (Aderem & Underhill, 1999). Briefly, cell 
surface receptors will recognise a pathogen and bind to it after which various 
signalling pathways that mediate actin polymerisation under the cell membrane at 
the contact site are induced. As a result, membrane extensions rich in actin called 
pseudopodia will extend around the particle on either side. Once the membranes of 
the pseudopodia fuse behind the particle to form a phagosome, it is pulled in towards 
the centre of the cell as the pseudopodia regress. Via a series of various membrane 
fusion and fission events with lysosomes, the final vesicle called a phagolysosome is 
formed where the pathogen will ultimately be destroyed through various proteolytic 
enzymes, ROS and nitrogen species (Aderem, 2003). 
Both neutrophils and macrophages are capable of phagocytosis and consequently 
express several receptors including pattern recognition receptors (PRRs) such as 
TLRs, scavenger receptors and C-type lectins. PRRs recognise pathogen-
associated molecular patterns (PAMPs) which include LPS and lipoteichoic acids on 
the surface of gram-positive and gram-negative bacteria as well as formylated 
peptides in bacteria and mannans in yeast cell walls. Furthermore, several high-
affinity receptors for various opsonins including antibodies, plasma lectins and 
complement proteins exist (Aderem, 2003; Abbas et al., 2012). 
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Figure 1.10: The intracellular destruction of microbes through phagocytosis. Various 
membrane receptors exist which are able to bind directly to microbes as well 
opsonised microbes. Once internalised by pseudopodia into the phagosome, 
it fuses with a lysosome to form a phagolysosome where the microbes will be 
destroyed through the action of various proteolytic enzymes as well as ROS 
and nitrogen species (Abbas et al., 2012). 
Several mechanisms of phagocytosis have been defined including Fc-receptor 
mediated phagocytosis, complement-receptor mediated phagocytosis and 
efferocytosis (phagocytosis of apoptotic cells). Different cytoskeletal elements are 
assembled at the site of particle internalisation during Fc-receptor mediated 
phagocytosis and complement-receptor mediated phagocytosis and as a result, the 
membrane protrusions seen during the former method of phagocytosis are not seen 
in the latter where the internalised particles appear to sink into the cell with no 
significant pseudopodia formation. Furthermore, phagocytosis mediated by the Fc-
receptor is pro-inflammatory while complement-receptor mediated phagocytosis is 
non-inflammatory and efferocytosis is anti-inflammatory (May & Machesky, 2001; 
Aderem, 2003). For the purpose of this study, only Fc-receptor mediated 
phagocytosis will be discussed in more detail. 
Most of the knowledge regarding the signalling pathways involved in phagocytosis 
has been obtained through studies related to Fc-receptor mediated phagocytosis. 
Antibodies or immunoglobulins (Igs) are produced by B-cells as part of the humoral 
immune response and act as opsonins. The binding of Igs to microbes thus makes 
them more susceptible to phagocytic engulfment. Igs contain a conserved Fc domain 
as shown in figure 1.11 which is recognised by the Fc- receptors on phagocytic cells. 
Once the ligand has bound to the Fc-receptor, receptor cross-linking occurs together 
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with tyrosine phosphorylation of immunoreceptor tyrosine-based activation motifs 
(ITAMs) thus activating various downstream signalling pathways some of which 
involve phosphoinositide-3 kinase (PI3K) and phospholipase C (PLC), Rho guanine 
triphosphate GTPases, protein kinase C (PKC) and several motor proteins (Aderem 
& Underhill, 1999; May & Machesky, 2001).  
 
 
 
 
 
 
 
 
 
 
Figure 1.11: Schematic diagram of the basic antibody structure. Immunoglobulins consist of 
two heavy and two light polypeptide chains held together in a Y-shape by 
disulphide bonds. Four domains are found on the heavy chains and two 
domains on the light chains. One variable domain from each of the heavy and 
light chains form the variable region which mediates antigen specificity while the 
remaining domains form the constant region which determines the 
immunoglobulins ability to bind to the complement and Fc-receptors on 
phagocytic cells (Abbas et al., 2012). 
1.4.2.3.4. The role of NF-ĸB and COX-2 in inflammation 
NF-ĸB refers to a family of transcription factors that are present in all cell types, 
performing an important role in cellular responses to various signals or stimuli 
including cytokines, stress, free radicals and bacterial or viral antigens. The 
transcription factors belonging to the NF-ĸB family are evolutionarily conserved 
proteins sharing several structural similarities and are classified as part of the Rel 
family. These members include p65/RelA, c-Rel and RelB which contain 
transcriptional activation domains as well as the p50 and p52 proteins which do not 
contain any transcriptional activation domains and are formed through the controlled 
proteolytic processing of the large p105 and p100 precursors, respectively. These 
proteins consist of homo- or heterodimers formed from at least five subunits and are 
translocated from the cytoplasm to the nucleus of the cell in response to certain 
stimuli where they are then capable of regulating the transcription of target genes by 
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binding to the regulatory regions of consensus DNA sequences (Patel & Santani, 
2009; Wullaert et al., 2011).  
When cells are in their resting state, NF-ĸB dimers remain sequestered in the 
cytoplasm in an inactive state due to the association of inhibitory proteins belonging 
to the inhibitors of NF-ĸB (IĸB) family. Included in this family are IĸBα, IĸBβ, IĸBԑ, the 
precursor proteins p100 and p105, as well as B-cell lymphoma 3-encoded protein 
(Bcl-3), IĸBγ and IĸBNS which are atypical members (Chen et al., 2002; Wullaert et 
al., 2011). Originally it was thought that IĸB proteins were able to mask the nuclear 
localisation sequences of the NF-ĸB dimers thus retaining them in the cytoplasm, 
however, recent evidence has shown that IĸBα and IĸBγ are able to travel between 
the nucleus and the cytoplasm within NF-ĸB-IĸB complexes, consequently displacing 
NF-ĸB from the target DNA sequences and transporting it back to the cytoplasm 
(Patel & Santani, 2009). 
Once a stimulatory signal is received, IĸB kinase (IKK) will phosphorylate IĸB 
proteins at certain serine residues, ultimately triggering the ubiquitination and 
consequent proteasomal degradation of the IĸB proteins. The C-termini of the p100 
and p105 precursors also undergo partial degradation. As a result, NF-ĸB dimers are 
able to accumulate in the nucleus where they can then bind to enhancer or promoter 
regions thus regulating the transcription of target genes. The NF-ĸB consensus 
binding site consists of the GGGRNNYYCC sequence where R is a purine, N is any 
base and Y is a pyrimidine (Chen et al., 2002; Wullaert et al., 2011).  
Two catalytic subunits, namely, IKK1/IKKα and IKK2/IKKβ are found on the IKK 
together with the NF-ĸB essential modulator (NEMO)/IKKγ regulatory protein. NF-ĸB 
activation is tightly regulated through a negative feedback inhibition loop via IĸBα 
expression that is NF-ĸB dependent as well as the action of deubiquitinating 
enzymes which negatively control the activation of IKK. NF-ĸB activation can occur 
via two major signalling pathways shown in figure 1.12 to be the classical or 
canonical and the alternative pathways (Wullaert et al., 2011).  
The classical pathway of NF-ĸB activation is primarily induced by pro-inflammatory 
cytokine receptors as well as pattern recognition receptors. During this pathway, 
IĸBα undergoes degradation and dimers containing p50, p65 and c-Rel are 
23 
 
translocated to the nucleus where they will activate transcription factors of various 
pro-inflammatory as well as pro-survival genes. Activation of this signalling pathway 
requires NEMO and is mainly regulated by IKKβ, however, cells which do not contain 
IKKβ are able to partially compensate by using IKKα to induce IĸBα phosphorylation 
and consequent degradation (Lawrence, 2009; Wullaert et al., 2011). 
 
 
 
 
  
 
 
 
 
 
Figure 1.12: Classical and alternative pathways of NF-ĸB activation. The classical pathway 
(left) is triggered by Toll-like Receptors (TLRs) and pro-inflammatory cytokines 
(IL-1 and TNFα) and is mediated by IKKβ. The alternative pathway (right) is 
stimulated by Lymphotoxin-B receptor (LT), CD40 ligand, B cell activating factor 
(BAFF) and receptor activator of NF-ĸB ligand (RANKL not shown) and is 
mediated by NF-ĸB inducing kinase (NIK) activated IKKα (Lawrence, 2009). 
Activation of the alternative NF-ĸB pathway is achieved mainly by receptors which 
regulate lymphoid organogenesis as well as lymphocyte development. This pathway 
is characterized by the IKKα-dependent phosphorylation of p100 into p52 coupled to 
the accumulation of the p52/RelB dimers in the nucleus. The upstream kinase 
responsible for IKKα activation has been identified as NF-ĸB inducing kinase (NIK) 
(Lawrence, 2009). 
A large quantity of genes playing vital roles in regulating immune and inflammatory 
responses are induced by the classical pathway of NF-ĸB activation, some of which 
include chemokines, cytokines, immunoregulatory proteins as well as adhesion 
molecules. Furthermore, this pathway mediates the expression of several proteins 
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with proliferative, anti-apoptotic and antioxidant activities. This signalling pathway 
thus not only induces the inflammatory response but also shelters cells from the 
potentially harmful effects of the inflammatory response and has consequently been 
implicated in the pathogenesis of several inflammatory diseases (Wullaert et al., 
2011). 
Cyclooxygenase (COX)-1 and 2, also known as prostaglandin-endoperoxide 
synthase (PGHS) 1 and 2, perform key functions during the inflammatory process by 
converting arachidonic acid to prostaglandin (PG) H2 which undergoes subsequent 
conversion into prostanoids through the action of certain terminal synthases as 
shown in figure 1.13. Prostaglandins play critical roles in mediating the inflammatory 
process. COX-1 is classified as a constitutive COX while COX-2 expression is 
rapidly induced in most mammalian cells by various pro-inflammatory stimuli 
including bacterial components, cytokines and growth factors (Na et al., 2015).  
 
 
 
 
 
 
 
Figure 1.13: The biosynthetic pathway of prostanoids. Arachidonic acid is converted to 
prostaglandin H2 (PGH2) by the COX enzymes. PGH2 is, in turn, converted to 
several prostanoids including thromboxane A2 (TxA2) and the prostaglandins 
D2, E2, I2 and F2α (Ricciotti & FitzGerald, 2012). 
The role of COX in inflammation remains controversial due to the highly complex 
signalling cascades involved. While it is still believed that COX-2 synthesises mostly 
pro-inflammatory prostaglandins, some anti-inflammatory properties have also been 
revealed. It would thus appear that due to the wide diversity of effects of prostanoids 
on several cellular processes, the overall effect, whether pro- or anti-inflammatory, is 
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dependent on the balance of prostanoids as well as the timing of their synthesis 
within a tissue or throughout a physiological reaction (Poligone & Baldwin, 2001). In 
addition to its important role in the inflammatory cascade, COX-2 expression has 
also been linked to the function of monocytes and macrophages during wound 
healing (Na et al., 2015). 
As previously mentioned, the activation of NF-ĸB is frequently associated with the 
inflammatory response. NF-ĸB has been shown to upregulate the expression of 
COX-2 with two NF-ĸB binding sites having been found in the human COX-2 
promoter and one in the mouse. Furthermore, a rapid increase in COX-2 expression 
following LPS treatment in macrophages or macrophage cell lines has been 
observed and has been associated with NF-ĸB nuclear translocation and one or both 
of the NF-ĸB consensus sequences (Ramsay et al., 2003). A complex model of 
COX-2 expression induced by NF-ĸB during inflammation is shown in figure 1.14. 
 
 
 
 
 
 
 
 
 
Figure 1.14: Proposed model for NF-ĸB in inflammation. Once NF-ĸB undergoes nuclear 
translocation, it induces the increased expression of COX-2 (PGHS-2). Initially, 
a positive feedback loop occurs during which the expression of NF-ĸB-
dependent inflammatory genes are enhanced, however, eventually a shift 
occurs during which cyclopentenone prostaglandins become more abundant 
resulting in a negative feedback loop that inhibits NF-ĸB and resultant COX-2 
expression (Poligone & Baldwin, 2001). 
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In the model for the role of NF-ĸB during inflammation as proposed by Poligone and 
Baldwin (2001), inflammatory stimuli will initiate the classical pathway of NF-ĸB 
activation to stimulate the nuclear translocation of NF-ĸB and resultant induction of 
COX-2. As COX-2 expression is increased, there is an increase in the rate of PGE2 
formation during the early inflammatory phase as COX-2 converts arachidonic acid 
to various prostaglandins of which PGE2 is most abundant. PGE2 has been shown to 
increase the transactivation function of NF-ĸB which further enhances the expression 
of the inflammatory genes induced by NF-ĸB. During the late inflammatory phase, 
however, a shift in prostaglandin production occurs during which cyclopentenone 
prostaglandins become the most abundant. The cyclopentenone prostaglandins are 
thought to partially inhibit the activity of NF-ĸB through the inhibition of IKK thus 
sequestering NF-ĸB in the cytoplasm and consequently down-regulating NF-ĸB 
dependent expression of several inflammatory genes as the inflammatory process is 
resolved. 
1.4.3. Proliferation 
While the important function of macrophages in regulating and mediating 
inflammation is obvious, they also perform crucial functions in the resolution of 
inflammation and the resultant transition to the proliferation and repair stages of the 
wound healing process (Williamson & Harding, 2004). Following the removal of 
foreign particles and debris, macrophages will secrete several chemotactic and 
growth factors required for the stimulation of angiogenesis, the construction of 
granulation tissue as well as cell migration, proliferation and ECM synthesis. 
Fibronectin is an example of an important chemotactic factor which recruits 
fibroblasts to the wound area while examples of growth factors produced by 
macrophages during wound healing include PDGF, VEGF, FGF, TGF-α, TGF-β and 
TNF. The process of angiogenesis is induced by the gradient of angiogenesis factors 
that are secreted by macrophages under the hypoxic conditions that prevail in the 
wound area (Li et al., 2007).  
In addition to cytokines and growth factors, macrophages also synthesise numerous 
extracellular molecules that are able to combine with the products released by 
degranulated platelets in order to produce a temporary scaffold rich in proteoglycans, 
fibronectins and glycosaminoglycans which are essential for determining the success 
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of the re-epithelialisation, migration and proliferation processes (Williamson & 
Harding, 2004). 
1.4.3.1. Re-epithelialisation 
In order to re-establish an intact epidermis, various processes such as keratinocyte 
migration and proliferation, the formation of a stratified epidermis following 
neoepithelium differentiation as well as basement membrane zone reconstitution 
must ensue. The process of keratinocyte migration from the wound edge is initiated 
within the first 24 hours following an injury and it involves multiple events including 
structural modifications which prevent these cells from proliferating while they are 
migrating. Integrin receptors located on the surface of keratinocytes regulate this 
process as they interact with the fibronectin-rich provisional matrix as well as the 
collagen fibres that are produced within the wound bed. Migration is thus enabled 
through the association and disassociation of the interactions between the 
keratinocytes and the matrix fibres together with the activities of MMPs that 
ultimately determine the direction of migration (Falanga, 2005; Li et al., 2007). 
As the re-epithelialisation process continues, the keratinocytes present at the 
migrating front tongue will revert back to a structural form that enables proliferation, 
thus ensuring that there is a sufficient supply of cells to close the entire wound. Once 
keratinocytes from opposite edges of the wound come into contact with one another, 
contact inhibition causes the cessation of the migration process and the 
keratinocytes will re-establish their interactions with the under-lying stratum in an 
attempt to repair the basement membrane (Lerman et al., 2003; Li et al., 2007). 
1.4.3.2. Fibroplasia 
Fibroblasts present at the wound edge start proliferating and begin the process of 
migration into the provisional matrix that has been formed in the wound bed by day 
four of the wound healing process. Here they produce collagen, elastin and 
proteoglycans necessary to re-establish an intact ECM after which they undergo 
gradual phenotypic changes where their primary function switches to protein 
synthesis (Enoch & Leaper, 2005; Li et al., 2007). 
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1.4.3.3.  Angiogenesis 
In response to tissue injury, quiescent vessels surrounding the wound area will be 
stimulated to produce new blood vessels which branch from pre-existing vessels in 
close proximity to the wound. This response is triggered by a multitude of different 
factors produced in the wound environment, some of which include cytokine 
secretion by macrophages, tissue hypoxia, elevated lactic acid levels and biogenic 
amines. The angiogenic response is categorised by several different processes with 
the ultimate goal being to provide the tissue with enough oxygen and nutrients to 
support the tissue remodelling and repair processes. Once the provisional matrix has 
been completed, the blood vessels will once again regress due to changes in the 
growth factors within the wound environment (Williamson & Harding, 2004; Li et al., 
2007). 
1.4.3.4. Wound contraction 
Wound contraction is initiated fairly early on in the wound healing process; however, 
it only peaks approximately two weeks after the initial injury with the degree of 
contraction depending on the depth of the wound. Myofibroblasts are unique in their 
ability to lengthen and retract and it is for this reason that they are the primary 
mediators of the wound contraction process. As they align themselves along the 
lines of contraction within the wound, they extend pseudopodia which bind to 
collagen fibres and subsequently retract to draw the collagen fibres closer to them. 
As a result, the wound decreases in size incrementally until the wound edges are 
reunited. A unified response is essential for wound contraction to be successful and 
involves both cell-cell and cell-matrix interactions as it proceeds in the direction of 
skin tension lines (Li et al., 2007; Tortora & Derrickson, 2012). 
1.4.4. Tissue remodelling 
ECM synthesis and remodelling is initiated simultaneously with granulation tissue 
formation and may persist for weeks to years, depending on the severity of the 
injury, and is characterized by the action of MMPs which regulate the synthesis and 
degradation of collagen. MMPs are produced by neutrophils, fibroblasts and 
macrophages at the wound area and can be classified into three classes based on 
their function. Interstitial collagenases are responsible for the cleavage of fibrillar 
collagen while gelatinases break down amorphous collagen as well as fibrin and 
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stromelysins catabolise various components of the ECM. The activity of MMPs is 
very tightly regulated through the action of various cytokines, growth factors and 
phagocytic stimuli in an effort to prevent excess collagen degradation and 
consequent impairment of the wound healing process (Enoch & Leaper, 2005; Gill & 
Parks, 2008).  
There are at least sixteen different forms of collagen that are found in the human 
body with type I collagen being the most abundant. During the early stages of 
granulation tissue formation, however, type III collagen synthesis in fibroblasts 
becomes far more abundant than type I collagen. Maximal secretion of type III 
collagen occurs within the first five to seven days after sustaining a cutaneous injury 
and once the wound begins to close, type III collagen is once again degraded and 
replaced with type I collagen. While very little is known about the role of type III 
collagen in wound healing, this conversion is thought to be due to stimuli produced in 
response to the biomechanical strain and tension that is exerted over the wound  
area (Li et al., 2007). 
During the tissue remodelling process several factors result in a decline in MMP 
activity. Some of these include an increase in the production of TIMPs, a decline in 
macrophage and fibroblast activity, the termination of angiogenesis, a reduction in 
both blood flow and metabolic activity as well as the merging of the wound edges 
through the contraction of the underlying connective tissue. The granulation tissue 
scaffold consequently progresses towards the formation of an avascular scar which 
consists of dense collagen networks, inactive fibroblasts and several ECM 
components.  An increase in the diameter of the collagen bundles occurs through the 
action of fibronectin and hyaluronan, resulting in an increase in the tensile strength of 
the wound area; however, the same degree of tensile strength that was present 
before the injury was sustained cannot be achieved (Enoch & Leaper, 2005; de 
Mendonça & Coutinho-Netto, 2009). 
A summary of the roles of the cytokines and complements involved in the wound 
healing process is provided in table 1.1. 
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Table 1.1: A summary of the cytokines and complements involved during each 
phase of the wound healing process (Sinno & Prakash, 2013).  
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1.5. DIABETIC WOUND HEALING  
The normal wound healing process consists of multiple levels of complex regulation 
involving several cellular activities, the release of numerous cytokines, activation of 
various growth factors, and connective tissue formation. While acute wounds 
undergo a linear and coordinated progression through the different stages of wound 
healing, various regions of diabetic wounds appear to be in different phases and thus 
the synchronisation of the overlapping phases responsible for rapid healing is lost 
(Falanga, 2005; Li et al., 2007). While the exact mechanisms responsible for the 
disruption of the normal wound healing process in the diabetic state have not yet 
been conclusively established, several contributing factors have been identified as 
summarised below and in figure 1.15 (McCulloch & Kloth, 2010). 
 
 
 
 
 
 
 
 
 
Figure 1.15: A diagrammatic illustration of some of the mechanisms responsible for impaired 
wound healing in diabetes. Levels of inflammatory cytokines and chemokines 
are increased and cellular processes such as the migration and proliferation of 
keratinocytes and fibroblasts, macrophage polarization as well as mesenchymal 
stem cell (MSCs) and endothelial progenitor cell (EPC) recruitment become 
impaired (Xu et al., 2013). 
1.5.1. Hypoxia  
Oxygen is vital for most wound healing processes and the oxygenation state of a 
wound is thus crucial in determining its healing outcome. Prolonged hypoxia is 
frequently observed in chronic wounds and may be a consequence of inadequate 
perfusion as well as unsatisfactory angiogenesis, both of which are associated with 
chronic hyperglycaemia. The ensuing hypoxia is incompatible with tissue repair as it 
amplifies the early inflammatory phase, consequently promoting the production of 
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oxygen radicals at the wound area and ultimately delaying the healing process (Sen, 
2009; Guo & Dipietro, 2010).  
1.5.2. Infections 
Diabetic wounds are frequently compromised by various microorganisms due to 
factors such as tissue hypoxia and persistent hyperglycaemia. In an effort to remove 
the pathogens, the inflammatory response is prolonged and the wound healing 
process is delayed. In addition to the abnormal inflammatory profile of diabetic 
wounds, unwarranted MMP activation leads to the impairment of cellular migration 
processes while simultaneously causing the degradation of essential ECM 
components and growth factors (Falanga, 2005; Guo & Dipietro, 2010). Furthermore, 
a reduced occurrence of MMP inhibitors results in an imbalance between the 
breakdown and synthesis of the affected tissues. The rate of tissue degradation thus 
exceeds that of tissue synthesis which prevents the wound from closing and may 
even cause wound enlargement (Menke et al., 2007).  
1.5.3. AGEs 
Chronic hyperglycaemia results in the non-enzymatic glycation of various 
macromolecules, such as proteins, via the Maillard reaction as shown in figure 1.16. 
During this process, spontaneous reactions occur between free amino groups of 
proteins and the carbonyl groups of reducing sugars in order to form a reversible 
Schiff base. Further rearrangements lead to the formation of stable ketoamines 
known as Amadori products which are ultimately converted to irreversible advanced 
glycation end products (AGEs) (Gould et al., 2011; Singh et al., 2014). As glucose is 
the slowest reacting intracellular sugar it was originally though that AGEs only 
accumulated in long-lived extracellular proteins, however, several glycolytic 
intermediates including glyceraldehyde-3-phosphate, dihydroxyacetone-phosphate 
as well as the dicarbonyl compounds glyoxal, methylglyoxal and 3-deoxyglucosone 
have been shown to contribute to intracellular glycation (Alexandrescu et al., 2016).  
The glycation process is often incorrectly referred to as non-enzymatic glycosylation. 
Protein glycosylation refers to the post-translational modification of proteins that is 
essential for normal protein function. This process is mediated by several enzymes 
and is defined by the addition of a carbohydrate molecule to a predetermined region 
of the protein. While protein glycation and glycosylation thus both involve reactions 
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between proteins and carbohydrates, different reaction mechanisms have been 
established with very different intermediates and end products. Glycosylation is thus 
a highly controlled process whereas glycation is random and uncontrolled, impairing 
both protein function and stability. Furthermore, different amino acids are involved 
during each process where glycosylation requires asparagine for N-glycosylation and 
serine or threonine for O-glycosylation, glycation generally involves arginine and 
lysine residues (Xue et al., 2011; Thermo Fisher Scientific, 2017). 
 
 
 
 
 
 
 
Figure 1.16: Reactions leading to the formation of AGEs. The carbonyl groups necessary for 
AGE formation are usually generated through carbohydrate metabolism, 
however, they may also be formed during either lipid or protein degradation 
(Stirban et al., 2014). 
AGEs can contribute to the development of impaired wound healing in diabetic 
patients by interfering with the normal structure of several proteins through the 
formation of cross-links, thus altering normal protein function. AGE-modified proteins 
may also, however, cause cellular dysfunction by binding to cell-surface receptors 
such as receptors for AGEs (RAGE) which creates a cascade of inappropriate 
cellular signals that further impair the wound healing process  (McCulloch & Kloth, 
2010). While several other receptors for AGEs have been identified, RAGE remains 
the best characterized of these receptors and has been linked to several of the 
complications observed during diabetic wound healing (Oliveira et al., 2013). 
RAGE has been characterized as a type 1 transmembrane protein forming part of 
the cell surface immunoglobulin superfamily. It consists of an extracellular domain 
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which binds to extracellular ligand, a hydrophobic transmembrane section as well as 
a highly charged intracellular cytoplasmic domain which is responsible for inducing 
intracellular signals. In diabetes, RAGE is overexpressed where its activation by 
AGEs and consequent up-regulation has been shown to induce inflammation and 
oxidative stress. This induces further AGE formation and accumulation, creating a 
positive feedback loop. RAGE has been identified in several cell types including 
macrophages, fibroblasts, keratinocytes and dendritic cells (Oliveira et al., 2013; 
Alexandrescu et al., 2016). 
1.5.4. Oxidative stress 
ROS have been shown to play an important role in both the removal of pathogens 
from the wound area as well as the regulation and stimulation of the normal wound 
healing process by acting as a mediator of intracellular signalling. Oxidative stress is 
characteristic of diabetes as the hyperglycaemic environment increases 
mitochondrial activity, favouring increased ROS production. When this happens, the 
anti-oxidative capability of the cell is surpassed, leading to further tissue damage, 
protein modification and subsequent impairment of the wound healing process 
(Schafer & Werner, 2008; Kolluru et al., 2012).  
1.5.5. Cellular dysfunction 
A summary of the effects of diabetes on cell function during wound healing is 
provided in table 1.2. The process of wound healing is essentially regulated by 
fibroblasts, keratinocytes and macrophages. Several studies have revealed that both 
fibroblasts and keratinocytes demonstrate impaired proliferation, migration and 
collagen producing abilities in the diabetic state (McCulloch & Kloth, 2010; Xu et al., 
2013). It has also been shown that the efferocytic activity of macrophages in diabetic 
wounds becomes impaired. This results in an increased apoptotic cell burden at the 
wound area, ultimately prolonging and amplifying the inflammatory phase.  
Also contributing to impaired wound healing is the fact that diabetic macrophages 
produce larger amounts of pro-inflammatory cytokines than their non-diabetic 
counterparts and diabetic wounds are thus characterized by a larger infiltration of 
inflammatory M1 macrophages than the M2 macrophages required for the 
generation of new tissue. Furthermore, the stage of M1 macrophage polarization 
which is usually relatively short-lived in the normal wound healing process is 
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extended in the diabetic state and consequently the wound healing process is 
hindered (Khanna et al., 2010; Xu et al., 2013).  
Table 1.2: Summary of the cells and their associated functions that are impaired in diabetic 
wound healing (McCulloch & Kloth, 2010). 
Phase Cells involved Impairment with diabetes Outcome with diabetes 
Hemostasis 
 
Platelets - Delayed fibrin plug formation 
- Delay/decrease in release of 
growth factors and cytokines 
- Impairment of microvascular 
hemodynamics 
- Abnormal vascular 
autoregulatory capacity 
- Platelet irregularity 
- Delayed fibrin plug formation 
leaving wound open for longer 
- Decreased local growth factor 
and cytokine production 
- Delayed recruitment of 
inflammatory cells 
Inflammation Neutrophils and 
macrophages 
- Decreased release of growth 
factors and cytokines  
- Impaired migration, adherence 
and phagocytosis 
- Thickened arterial basement 
membrane 
- Delayed inflammatory response 
- Poor endogenous debridement 
- Chronic inflammatory state 
- Increased bioburden and risk of 
infection 
Proliferation Fibroblasts, 
myofibroblasts and 
keratinocytes  
- Poor cellular response to growth 
factors and chemokines 
- Impaired fibroblast and 
keratinocyte proliferation, 
migration and function 
- Excessive activation of 
proteases 
- Impaired contraction of 
myofibroblasts 
- Reduced angiogenesis 
- Impaired granulation tissue 
formation 
- Diminished wound contraction 
- Friable and poorly functioning 
granulation tissue 
- Wound stuck in cycle of chronic 
inflammation 
Tissue 
remodelling 
Fibroblasts and 
keratinocytes 
- Ineffective matrix turnover - Collagen matrix cross-linked 
- Reduced ultimate strength of 
repair tissue 
 
1.6. MACROFUNGI AND DIABETIC WOUND HEALING 
Approximately 1.5 million species of fungi are thought to exist globally, 140 000 of 
which can be classified as mushrooms. Of these, it is estimated that only 200 
species have been traditionally gathered as food or medicine. It is well known that 
fungi have been poorly collected and studied and as a result, only 10% of 
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mushroom-forming species have been identified thus making them a valuable 
unexplored resource of potentially useful substances (Crous et al., 2006; Erjavec et 
al., 2012). 
Mushrooms are defined as macrofungi whose fruiting bodies are visible to the naked 
eye and may grow above (epigeous) or below (hypogeous) the ground. Mushrooms 
are classified as functional foods and have thus become attractive as a source of 
medicine that demonstrates strong physiological benefits. There are several 
advantages of using mushrooms as a source of bioactive compounds over plants 
due to the fact that their fruiting bodies are produced over greatly reduced time 
periods, their mycelia and fruiting bodies can be produced fairly rapidly in liquid 
culture and finally, the medium in which they are cultured can be manipulated in 
order to produce the desired concentrations of the active compounds (Ferreira et al., 
2009). 
Currently, several synthetic drugs are used during the treatment of diabetes; 
however, many of these drugs are associated with unwanted side-effects while 
simultaneously failing to significantly alter the progression of complications 
associated with diabetes. As a result, natural bioactive compounds isolated from 
medicinal plants as alternative treatment strategies have gained increasing 
popularity amongst the scientific community. The potential of medicinal mushrooms 
in treating several diseases have been exploited by traditional folk medicines for 
centuries. In addition to having a favourable ratio of macronutrients, it has also been 
shown that mushrooms contain several essential micronutrients and phenolic 
compounds which provide a high source of anti-oxidants. Today, many of the health-
promoting benefits of mushrooms are attributed to the bioactive metabolites such as 
polysaccharides, peptides, enzymes, terpenoids, as well as various other small 
molecules (De Silva et al., 2012).  
As previously summarised, diabetic wounds frequently enter a state of pathological 
inflammation and are characterized by the increased occurrence of infection as well 
as the production of excess ROS and AGEs (McCulloch & Kloth, 2010). A literature 
search revealed very limited information regarding the wound healing properties of 
mushrooms, however, any mushroom species that displays strong anti-inflammatory, 
anti-oxidative or general antidiabetic properties could be useful in promoting 
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functional wound healing. The five mushrooms selected for this study are shown in 
figure 1.17 and were chosen based on their reported bioactivities pertaining to 
wound healing as summarised below. 
  
 
  
 
 
  
 
 
 
 
 
 
 
 
 
Figure 1.17: Photographs of the mushroom species collected for this study. (A) P. tinctorius, 
(B) R. capensis, (C) B. badius, (D) P. ostreatus and (E) G. lucidum (Photo 
credit: Gerhardt Boukes). 
1.5.1. Boletus badius (Bay Bolete) 
B. badius, also known as Xerocomus badius, is classified as part of the Boletaceae 
family. It is found growing under conifers in pine needles or under deciduous trees 
and is identified by its shiny brown cap which starts out convex and then flattens as 
well as its white to lemon-yellow flesh. The pores on the underside of the cap turn 
blue or green when touched (The Great Encyclopedia of Mushrooms, 1998:26; 
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Gryzenhout, 2010). While knowledge regarding the composition and properties of 
this mushroom species is lacking, it has been shown to contain several anti-oxidant 
substances including polyphenols, flavonoids, vitamins C and E, β-carotene, 
tocopherols and lycopene (Jaworska et al., 2015) as well as several micronutrients 
such as zinc, iron and copper that are essential for wound healing. Zinc is a co-
enzyme for several enzymatic reactions and promotes cell proliferation while copper 
and iron are involved in collagen synthesis and these three minerals could thus play 
crucial roles in promoting wound healing (Guo & Dipietro, 2010; Reczynski et al., 
2013). 
1.5.2. Ganoderma lucidum (Reishi) 
G. lucidum is classified as part of the Ganodermataceae family and is widely sought-
after due to its wide range of medicinal properties. It can be found growing on the 
rotting stumps of several broad-leaved trees, on tree trunks or on the ground 
emerging from roots. It is recognised by its circular to bracket, often kidney-shaped 
fruiting body which grows singly or in groups where it can fuse with others or grow in 
tiers. It has a cork-like texture which turns woody as it ages and is covered with a 
thin, shiny, varnished crust that ranges in colour from yellow to red to chestnut, often 
with a white margin (The Great Encyclopedia of Mushrooms, 1998:215; Gryzenhout, 
2010). The principal bioactive compounds that have been isolated from this 
mushroom species are considered to be mainly polysaccharides, triterpenes, sterols 
and some proteins such as lectin (Saltarelli et al., 2015). Some of the biological 
activities that have been identified for G. lucidum include anti-oxidative and free 
radical scavenging, anti-inflammatory and antidiabetic effects. Studies have also 
shown that the polysaccharides isolated from G. lucidum were able to reduce the 
levels of AGEs, promote the activities of anti-oxidant enzymes and accelerate wound 
closure as well as wound angiogenesis in streptozotocin-induced diabetic mice (De 
Silva et al., 2012; Cheng et al., 2013). 
1.5.3. Pisolithus tinctorius (Puffball mushroom) 
P. tinctorius belongs to the Sclerodermataceae family of fungi with the most frequent 
and traditional uses reported for the puffball mushroom as a wound dressing as well 
as for the treatment of burns and itches (Burk, 1983; Gill & Watling, 1986). It is 
identified by its large fruiting body which occurs as an irregularly lobed ball, tapering 
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into a root-like base on the ground near eucalyptus or black wattle trees. The outer 
skin is shiny, ranging from ocre to bright yellow which darkens to a rust colour with 
mottled black markings. The flesh is divided into different compartments in which the 
spores develop as can be seen from figure 1.17 (Branch, 2001). While information 
regarding the properties and bioactive molecules of P. tinctorius are severely lacking, 
the traditional uses of puffballs provides sufficient evidence that this mushroom 
species might promote wound healing (Burk, 1983; Gill & Watling, 1986). 
1.5.4. Pleorotus ostreatus (Oyster mushroom) 
P. ostreatus has been identified as a member of the Pleurotaceae family of gilled 
mushrooms (Opletal, 1993). It is typically found growing on the dead wood of broad-
leaved trees, tree stumps and logs in large, compact tufts. It is recognised by its 
large cap which has a definitive semi-circular to elongate fan-shape, the colour of 
which can vary from black to white, violet grey or yellowish (The Great Encyclopedia 
of Mushrooms, 1998:68; Gryzenhout, 2010). The presence of numerous nutritional 
components and active ingredients in P. ostreatus has led to reported antidiabetic, 
antibacterial, anti-inflammatory and anti-oxidant activities. Most of these activities are 
attributed to the presence of β-glucans and lectin. Combining these activities with the 
high content of several essential micronutrients presents strong evidence that this 
mushroom species could overcome some of the negative influences of diabetes on 
wound healing (Patel et al., 2012). 
1.5.5. Russula capensis (Cape Russula) 
R. capensis belongs to the Russulaceae family, consisting of a crumbly flesh and an 
often bright fruiting body, ranging from pink-purple to a deep purple-red, with white 
gills that extend to the straight, cylindrical stem (The Great Encyclopedia of 
Mushrooms, 1998:46; Laessoe, 2013).  As with most other mushroom species, the 
Russula species contain β-glucans and lectins and thus display anti-oxidative 
properties. Traditional uses of Russula species as a wound healing agent have also 
been reported (Jaengklang et al., 2015). 
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CHAPTER 2: RESEARCH AIMS AND OVERVIEW OF CHAPTERS 
2.1. PROBLEM IDENTIFICATION 
Impaired wound healing has been recognised as a complication of diabetes for 
almost three decades and is associated with high rates of amputation and mortality. 
There is, however, a highly intricate and multi-faceted pathophysiological relationship 
between diabetes and chronic wound healing which is not yet fully understood 
(McCulloch & Kloth, 2010). Current treatment strategies for chronic wounds are 
mainly based on the optimisation of healing factors that can be regulated such as the 
removal of infection and the provision of mechanical protection as well as nutritional 
support. To date, very few targeted approaches have been developed with the 
topical application of growth factors demonstrating very limited clinical efficacy. Due 
to the dearth of knowledge with regards to the molecular mechanisms behind the 
pathology of diabetes as well as the absence of suitable chronic wound models, 
current treatment regimens are limited and non-specific thus emphasising the need 
to identify new therapeutic targets and develop more efficient treatment approaches 
(McLennan et al., 2006; Landén et al., 2016).  
In an attempt to discover a treatment modality that will address the pain, poor quality 
of life and excessive healthcare costs that diabetic patients suffering from impaired 
wound healing are burdened with, natural substances from plants and mushrooms 
are under current investigation. Several mushroom species have demonstrated 
various anti-oxidant, anti-inflammatory and blood glucose regulating activities which 
suggests that mushrooms could prove to be very useful in the search for safe and 
efficacious wound healing agents that could potentially serve as alternative treatment 
strategies for chronic diabetic wounds (Brem & Tomic-Canic, 2007; Cheng et al., 
2013). 
2.2. AIMS AND OBJECTIVES 
The aim of this study was to characterize a low-cost, more convenient and more 
comprehensive in vitro diabetic wound healing model using glycated gelatin in order 
to explore the potential of five wild mushroom species commonly found in South 
Africa to promote wound healing by restoring the correct functioning back to 
fibroblasts and macrophages. 
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In order to achieve this aim, the following objectives were met: 
 To derive a suitable method for glycating the gelatin and confirming the 
presence of AGEs. 
 To assess the cytological effects of the glycated gelatin model on fibroblast 
and macrophage functions. 
 To explore the fundamental biochemical mechanisms through which AGEs 
impair wound healing in diabetes using high content screening. 
 To establish a more comprehensive wound healing screening platform which 
incorporates other potential therapeutic benefits such as antioxidant capacity, 
collagen turnover, glycation inhibition as well as cytotoxicity amongst others.  
 To screen and prioritise five wild mushroom species for potential wound 
healing properties. 
 To provide enough scientific evidence to support further studies related to the 
use of macrofungi as a potential diabetic wound healing therapy. 
2.3. OVERVIEW OF CHAPTERS 
Chapter 3 provides a brief overview of the methodology used throughout this study 
including the principles and protocols of all techniques used, cell culture conditions 
and background information related to some of the more complex methods. 
Chapter 4 presents the results that were obtained from this study. Section 4.1 
focuses on the characterization of the glycated gelatin model as a suitable diabetic 
wound healing model by exploring its cytotoxicity and cytological effects on 
fibroblasts and macrophages. These include alterations in the phagocytic capability, 
the activity of various inflammatory markers and the phenotype (M1/M2) of 
macrophages as well as changes in fibroblast proliferation and migration. 
Section 4.2 presents the screening results of the selected mushroom species in 
terms of their cytotoxicity, anti-oxidant capacity and any other characteristics which 
could highlight their potential therapeutic benefits in wound healing such as glycation 
and collagenase inhibitory activities.  
As diabetic wounds frequently enter a state of pathological inflammation, section 4.3 
deals with the inflammatory phase of wound healing and provides more detailed 
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information regarding the cellular dysfunction observed in macrophages. The ability 
of each of the selected mushroom species to restore some or all of the correct 
macrophage functioning is assessed here in detail. 
Section 4.4 focuses on the dysfunction of fibroblasts in diabetic wound healing. As 
fibroblasts play a crucial role during the last two phases of wound healing 
(proliferation and tissue remodelling), correct fibroblast functioning is essential to 
ensure the completion of the wound healing process. The ability of the selected 
mushroom species to promote the correct fibroblast function in the diabetic state is 
investigated here in more detail. 
In chapter 5, an in-depth discussion of all the results obtained throughout this 
experiment is provided which summarises the most significant findings of this study 
and suggests some considerations for its improvement. Suggestions regarding future 
studies are also addressed.  
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CHAPTER 3: METHODOLOGY 
A comprehensive list of materials can be found in Appendix A and procedures for 
reagent preparation are listed in Appendix B. 
3.1. CELL CULTURE CONDITIONS AND MAINTENANCE 
Human Dermal Fibroblasts (MRHF) and RAW 264.7 macrophage-like cells were 
obtained from the Cellonex and the American Type Culture Collection, respectively. 
The MRHF cell line is an adherent cell line that was selected because of the 
important role that fibroblasts play in wound healing (Enoch & Leaper, 2005).  The 
RAW 264.7 cell line is an immortal cell line derived from Balb/c mice and was 
selected for its relevance in wound healing assays as well as its maintenance of 
macrophage properties including NO production and phagocytosis (Venter et al., 
2015). 
Both cell lines were maintained in 10 cm cell culture treated polystyrene petri dishes 
in complete Dulbecco’s Modified Eagle Medium (DMEM) supplemented with 10% 
foetal bovine serum (FBS) and 1% (v/v) penicillin/ streptomycin. Cells were 
incubated at 37 °C in a humidified incubator with 5% CO2 (g) and monitored daily for 
contamination using an Axiovert 40C inverted microscope (Carl Zeiss, Germany). 
Cells were sub-cultured using the technique described by Freshney (1986) when 
they reached approximately 80% confluence and the culture medium was replaced 
every fourth day to ensure optimal growth conditions.  
Cell viability and numbers were routinely monitored using a manual haemocytometer 
slide and the trypan blue exclusion assay. Trypan blue is an acidic dye with a 
molecular weight of approximately 873 g/mol. It is a large, hydrophilic, tetra-
sulphonated molecule and contains two azo chromophores as shown in figure 3.1. 
Due to its negative charge, trypan blue is unable to enter the cytoplasm of viable 
cells whose membranes are intact. Non-viable cells, however, have compromised 
cell membranes and trypan blue is thus able to enter these cells where it can bind to 
intracellular proteins within the cytoplasm of the cell effectively staining the 
cytoplasm blue. The blue colour is readily observed under a brightfield microscope 
thus allowing the easy  and rapid differentiation between live (clear cytoplasm) and 
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non-viable (blue cytoplasm) cells (Melzer et al., 2016; Santa Cruz Biotechnology, 
2016). 
 
Figure 3.1: Chemical structure of trypan blue. Trypan blue is frequently used to assess cell 
viability as this cell membrane impermeable dye is only able to stain dead cells  
(Dumitriu & Popa, 2013). 
All cells were seeded during their log phase of growth to ensure accurate and 
reproducible results. Cells were left overnight to attach to the appropriate culture 
plates prior to exposure to the relevant treatments. Seeding densities and incubation 
periods are specified under each protocol. 
3.2. GLYCATED GELATIN MODEL 
3.2.1 Preparation of gelatin 
Gelatin was dissolved in distilled water at a concentration of 20 % (w/v) with 1 M 
glucose in a 37 °C water bath for 30 minutes. Once dissolved, the mixture was 
autoclaved for 60 minutes and stored in working aliquots at 4 °C until required. 
Unglycated gelatin was prepared in the same way in the absence of glucose as a 
reference standard. Prior to use, the gelatin was heated in a 37 °C water bath for 30 
minutes and added to the culture medium at the required concentration. 
3.2.2 AGE autofluorescence 
The intrinsic fluorescence of AGEs such as pentosidine allowed for the easy 
measurement of AGE formation with the use of a Fluoroskan Ascent FL fluorometer 
(ThermoLabsystems, Finland). The glycated and unglycated gelatin as well as the 
glucose stocks were thus diluted to the specified concentrations in distilled water 
after autoclaving (see section 3.2.1) and the fluorescence was measured using the 
AGE excitation wavelength of 370 nm and an emission wavelength of 440 nm 
(Nomoto et al., 2013). 
3.3. SAMPLE COLLECTION AND EXTRACT PREPARATION 
Wild mushroom samples were collected from the Eastern and Western Cape 
provinces of South Africa by Dr. Gerhardt Boukes, a former post-doctoral researcher 
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at NMMU, and identified by a mycologist, Dr. Marieka Gryzenhout, from the 
University of the Free State. Once collected, samples were dried at 30 °C in a drying 
oven for 48 to 72 hours. The dried material was cleaned with paper towelling before 
being briefly submersed in liquid nitrogen and crushed into a fine powder using a 
mortar and pestle.  
Both ethanol and cold water extracts were prepared for each sample. Ethanol 
extracts were prepared by adding 80% ethanol (diluted with deionised distilled water) 
to the dried material using  a 1:15 (w/v) ratio while the water extract was prepared by 
adding deionised distilled water at room temperature using a 1:10 (w/v) ratio. 
Samples were extracted for 24 hours at room temperature with continuous stirring 
after which the extracts were centrifuged for 5 minutes at 3000 rpm. The pellets were 
discarded and the supernatants were collected and filtered twice through Whatman™ 
filter paper (no. 1) using a vacuum. The water extracts were frozen immediately at -
80 °C while the ethanol first had to be evaporated from the ethanol extracts using a 
rotary vacuum prior to freezing at -80 °C. Once frozen, samples were freeze-dried 
and stored in a desiccator at 4 °C protected from light prior to use.  
Ethanolic extracts were solubilised in dimethyl sulfoxide (DMSO) at a concentration 
of 50 mg/ml while water extracts were solubilised in distilled water at 50 mg/ml and 
then filter sterilised using a 0.2 μm Acrodisc® syringe filter. Samples were 
refrigerated at 4 °C and prepared fresh every week. 
3.4. SCREENING ASSAYS FOR POTENTIAL WOUND HEALING 
PROPERTIES  
3.4.1. Cytotoxicity screening 
Cytotoxicity screening was performed using Hoechst 33342 and propidium iodide 
(PI) dual staining in combination with Molecular Devices ImageXpress Micro XLS 
Widefield microscope for high content analysis. This microscope is Africa’s first high 
content analysis system and thus the accuracy and sensitivity was compared to the 
crystal violet assay, a more traditional method of quantifying cell density. 
3.4.1.1. Hoechst/ PI 
Hoechst 33342 is a bisbenzimidazole derivative commonly used as a cell permeable 
nucleic acid dye, the structure of which can be seen in figure 3.2. This dye 
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intercalates DNA at A-T rich double-stranded regions with low cytotoxicity and emits 
blue fluorescence upon binding to DNA with an excitation/emission spectra of 346 
nm and 460 nm, respectively. While Hoechst 33342 is useful for staining the nuclei 
of live or dead cells, it does not stain chromosomes that are dividing or replicating 
(Sigma-Aldrich, 2016a). Any mushroom extract that is found to be cytotoxic will be 
excluded from further experimentation. 
 
 
Figure 3.2: Chemical structure of Hoechst 33342. Hoechst is a membrane-permeable dye 
that emits blue fluorescence when bound to DNA and is used to stain the nuclei 
of living or fixed cells (Sigma-Aldrich, 2016a).  
PI, the structure of which is shown in figure 3.3, is a membrane impermeable dye 
that emits red fluorescence when bound to nucleic acids. It binds to DNA in an 
indiscriminate manner with little to no sequence preference intercalating into every 
4th or 5th base pair. When bound to nucleic acids, PI has excitation/emission maxima 
of 535 nm/617 nm. Non-viable and early apoptotic cells exclude PI from their 
cytoplasm due to the integrity of their cell membrane, however, when the integrity of 
the cell membrane is disrupted as in late apoptotic or dead cells PI is able to pass 
freely into the cell and bind to the nucleic acids (Sigma-Aldrich, 2016b; Thermo-
Fisher Scientific, 2016). 
 
 
 
Figure 3.3: Chemical structure of propidium iodide. Since PI cannot cross the cell membrane 
of living cells, it is often used to detect dead cells in a population (Sigma-Aldrich, 
2016b). 
For all cytotoxicity experiments, RAW 264.7 macrophage-like cells and MRHF 
fibroblasts were seeded into a 96-well microtitre plate at a density of 20 000 and 
4 000 cells per well, respectively. Treatment periods were 48 hours for the 
macrophages and 72 hours for the fibroblasts. The number of cells per well was 
determined using Hoechst 33342 and PI dual staining in combination with Molecular 
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Devices ImageXpress Micro XLS Widefield microscope for high content analysis. 
Briefly, the medium was gently removed and the cells were incubated in 50 μl of 
Hoechst 33342 (5 μg/ml in PBS + Ca2+/Mg2+) for 10 minutes at room temperature 
protected from light. Immediately before image acquisition, 50 μl of PI (100 μg/ml in 
PBS + Ca2+/Mg2+) was added. Nine image sites per well, covering approximately 80 
% of the well, were acquired as shown in figure 3.4 using a 10 X magnification. The 
average cell number was calculated using MetaXpress® software.  
 
 
 
Figure 3.4: Spatial distribution of image sites acquired during the cytotoxicity screening 
assay. The area covered by each of the nine image sites in a single well of a 
96-well microtitre plate is shown in green and was obtained using Molecular 
Devices ImageXpress Micro XLS Widefield microscope for high content 
analysis. 
3.4.1.2. Crystal violet 
Crystal violet is a cationic dye consisting of a chromophore and an auxochrome 
group, the structure of which can be seen in figure 3.5. The chromophore group is 
made up of three benzene rings and is responsible for the purple colour of the dye 
which readily absorbs light, while the auxochrome group aids in the binding of the 
dye to the target nuclear DNA and solubilisation of the resultant crystals that form 
(Appusamy et al., 2014).  
 
 
 
 
Figure 3.5: The chemical structure of crystal violet. Crystal violet binds to nuclear DNA and 
proteins to form crystals that can be solubilised and used to measure cell density 
(Appusamy et al., 2014). 
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The crystal violet assay was chosen to measure cell density due to its apparent 
sensitivity and reproducibility as demonstrated by Elengoe and Hamdan (2014). 
Furthermore, the crystal violet assay demonstrates a higher sensitivity than the 
trypan-blue assay and has been proven to be particularly effective for adherent cell 
lines. Several mushroom species have been shown to contain large quantities of 
anti-oxidants and the crystal violet assay was thus chosen over the MTT assay as 
anti-oxidants have been shown to readily reduce MTT to formazan crystals 
regardless of the viability of the cells that are present (Natarajan et al., 2000).  
A stock solution of crystal violet was prepared at 0.01% (w/v) in distilled water and 
stored at room temperature. The staining procedure was carried out according to 
Elengoe and Hamdan (2014) with a few modifications. Briefly, the medium was 
gently aspirated and the cells were washed with 100 μl of PBS (+ Ca2+/Mg2+). Cells 
were fixed with 100 μl of 10% (v/v in PBS + Ca2+/Mg2+) formalin for 30 minutes in 
order to increase the permeability of the viable cells thus enabling the dye to bind to 
the genetic material inside the cell nucleus. The fixative was removed and the cells 
were stained with 100 μl of crystal violet for 1 hour after which the cells were washed 
three times with distilled water to remove the excess dye. The plates were left to air-
dry overnight at room temperature. Once dry, 100 μl of 10% (v/v) acetic acid was 
added to each well and left for 20 minutes at room temperature to solubilise the 
crystals. The absorbance was the measured at 570 nm using a BioTek® PowerWave 
XS spectrophotometer (Winooski, VT, USA). The mean absorbance of the untreated 
cells represent 100% cell density and the percentage cell density of the cells 
exposed to different treatments was calculated using the following equation:  
% 𝑐𝑒𝑙𝑙 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 =  
𝐴570 𝑛𝑚 𝑜𝑓 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
𝐴570 𝑛𝑚 𝑜𝑓 𝑢𝑛𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝑐𝑒𝑙𝑙𝑠
 𝑥 100. 
3.4.2. Anti-oxidant assays 
In diabetes, chronically elevated blood glucose levels result in oxidative stress which 
has been implicated as an important factor contributing to impaired wound healing 
(Kolluru et al., 2012). Several anti-oxidants have been isolated from wild mushrooms 
including phenolic compounds, ascorbic acid, tocopherols and carotenoids. Ascorbic 
acid and phenolic compounds are classified as hydrophilic anti-oxidants while 
49 
 
carotenoids are examples of lipophilic antioxidants (Thaipong et al., 2006; Preeti et 
al., 2012). 
3.4.2.1. FRAP assay 
The Ferric-Reducing/ Anti-oxidant Power (FRAP) assay is a measure of the ability of 
antioxidants to reduce ferric iron (Fe3+). As shown in figure 3.6, the FRAP assay is 
based on the reaction where the complex formed during the interaction of Fe3+ with 
2,3,5-triphenyl-1,3,4-triaza-2-azoniacyclopenta-1,4-diene chloride (TPTZ) is reduced 
to the ferrous (Fe2+) form under acidic conditions. During this reaction, an intense 
blue colour develops with an absorption maximum of 593 nm where the intensity of 
the colour is proportional to the antioxidant capacity of the sample being tested 
(Moon & Shibamoto, 2009; Alam et al., 2013).  
 
 
 
Figure 3.6: Reaction occurring during the FRAP assay. During this reaction the Fe3+-TPTZ 
complex is reduced to form a Fe2+-TPTZ complex resulting in the development of 
an intense blue colour (Moon & Shibamoto, 2009). 
The FRAP assay is a convenient, reproducible, cost-effective, simple and rapid 
method of determining the antioxidant capacity of a sample, however, this reaction is 
not specific and thus any compound with a suitable redox potential is capable of 
driving this reaction. Furthermore, this method is not suitable for detecting 
polyphenolic compounds and thiols that react slowly or that act by radical quenching 
and has a poor correlation with other antioxidant capacity assays. The greatest 
disadvantage of the FRAP assay is that it is not mechanistically or physiologically 
relevant to antioxidant activity as it is based only upon the measurement of the 
reducing capability with regards to the ferric ion and is thus frequently coupled to 
other antioxidant assays (Prior et al., 2005). 
Briefly, samples (50 μl) were transferred into a 96-well plate and 200 μl of the FRAP 
reagent was added. After 30 minutes of incubation at 37°C, the absorbance was 
measured at 593 nm using a BioTek® PowerWave XS spectrophotometer (Winooski, 
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VT, USA). A stock solution of Catechin (25 mg/ml) was prepared in absolute ethanol 
and served as a positive control. Using a ferrous sulfate (FeSO4) standard curve, the 
absorbance readings obtained were extrapolated and the results were thus 
presented as a concentration of FeSO4 (μmol/l). 
3.4.2.2. DPPH assay  
The 2,2-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging capacity assay is a 
decolouration assay that utilises the fact that DPPH, a stable free radical, contains 
an unpaired electron that is delocalised over the entire surface of the molecule (Alam 
et al., 2013). There appears to be some controversy as to whether this reaction 
occurs via an electron transfer reaction or hydrogen atom abstraction. According to 
Prior et al. (2005) and MacDonald-Wicks et al. (2006) it is classified as an electron 
transfer reaction that occurs very rapidly followed by the slower transfer of a 
hydrogen atom which is subsequently considered to be a marginal reaction pathway. 
It is thus assumed that the reaction mechanism is based on both a single electron 
transfer and a hydrogen atom transfer reaction as shown in figure 3.7. As the DPPH 
free radical (violet) is converted to DPPH, the loss of colour is proportional to the 
antioxidant capacity of the sample being tested and can be measured using a 
spectrophotometer (Moon & Shibamoto, 2009).  
 
 
 
 
Figure 3.7: Reaction occurring during the DPPH assay. As the antioxidant donates a 
hydrogen atom to the DPPH free radical, DPPH is formed and the reaction 
colour changes from violet to clear (Moon & Shibamoto, 2009). 
During the hydrogen atom transfer reaction, a proton and an electron are transferred 
from one molecule to another in one kinetic step and thus the DPPH radical will 
remove a proton from the antioxidant and the antioxidant will subsequently become a 
radical. Here, the most important parameter that determines the antioxidant capacity 
of a sample is the bond dissociation enthalpy and thus the lower the bond 
dissociation enthalpy of the proton-donating group, the faster this reaction will 
proceed. During the single electron transfer reaction, an electron is transferred from 
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the antioxidant to the DPPH free radical where the antioxidant will then become a 
radical cation. The most important factor to consider during this reaction is the 
ionisation potential of the antioxidant and thus the lower the ionisation potential, the 
faster this reaction will proceed. The reaction mechanism will ultimately depend on 
the structure and solubility of the antioxidants present in the test sample as well the 
partition coefficient and the polarity of the solvent (Liang & Kitts, 2014).  
The advantage of the DPPH assay lies in its technical simplicity, low cost, high 
sensitivity and reproducibility. The greatest limitations of this assay include the 
physiological irrelevance of the DPPH free radical as well as the fact that DPPH is a 
lipophilic radical thus having limited accessibility to the hydrophilic compounds 
present in the test samples. As a result, an alcohol must be used to solubilise DPPH, 
however, ethanol has been shown to add background interference with regards to 
the antioxidant activity (Liang & Kitts, 2014). 
Using a 96-well plate, 5 μl of sample was transferred into the relevant wells after 
which 120 μl of Tris-HCl buffer (50 mM, pH 7.4) and 120 μl of DPPH (0.1 mM) were 
added. Following incubation for 20 minutes at room temperature protected from light, 
the absorbance was measured at 513 nm using a BioTek® PowerWave XS 
spectrophotometer (Winooski, VT, USA) and the percentage radical scavenging 
activity was calculated using the following formula: 
% 𝐷𝑃𝑃𝐻 𝑠𝑐𝑎𝑣𝑒𝑛𝑔𝑖𝑛𝑔 =  
𝐴 − 𝐵
𝐴
 𝑋 100 
where A is the absorbance value of the reference sample and B is the absorbance 
value of the test sample. 
3.4.2.3. Nitric oxide scavenging assay 
The NO scavenging assay is frequently used as a measure of anti-oxidant activity 
and is based on the principle that when sodium nitroprusside is placed in an 
aqueous solution at physiological pH, it spontaneously generates NO. The NO 
produced reacts with oxygen to form stable products (nitrite and nitrate) which can 
then be measured using the Griess reaction described in section 3.5.1. NO 
scavengers will compete with the oxygen and there will be a subsequent decrease in 
the quantity of nitrite ions (Alam et al., 2013). 
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NO is an important signalling molecule that has demonstrated several important 
functions during the wound healing process, however, diabetic wounds have been 
characterized by altered macrophage function and consequent changes in NO 
production. NO has thus been implicated in impaired diabetic wound healing. 
Because NO has also been identified as an inflammatory marker, this assay also 
serves to establish the nature of any anti-inflammatory responses during the NO 
production assay performed using RAW 264.7 cells described in section 3.5.1 (Luo & 
Chen, 2005). 
After transferring 50 μl of test sample (100 and 200 μg/ml) into a 96-well microtitre 
plate, 50 μl of sodium nitroprusside (10 mM) was added and incubated at room 
temperature under direct light for 150 minutes. This was followed by the addition of 
100 μl of Griess reagent. The reaction was protected from light and incubated for 10 
minutes at room temperature after which the absorbance was measured at 540 nm 
using a BioTek® PowerWave XS spectrophotometer (Winooski, VT, USA). Amino-
guanidine (200 μg/ml) was added as a positive control. The percentage of NO 
scavenged was calculated using the following formula: 
% 𝑁𝑂 𝑠𝑐𝑎𝑣𝑒𝑛𝑔𝑖𝑛𝑔 =  
𝐴 − 𝐵
𝐴
 𝑋 100 
where A is the absorbance value of the reference sample and B is the absorbance 
value of the test sample. 
3.4.3 Glycation inhibition 
It is common knowledge that protein glycation generates AGEs through the Maillard 
reaction and that these AGEs have been implicated in the pathogenesis of diabetic 
complications including chronic wound healing. Identifying a natural product with 
sufficient protein glycation inhibitory potential could thus be greatly beneficial in 
inhibiting diabetic complications with very few adverse effects (Wijetunge & Perera, 
2014). While glucose together with the products of glucose metabolism have been 
identified as the main culprits of protein glycation in diabetes, glucose forms a 
hemiacetal ring structure in solution which makes it poorly reactive as a glycation 
catalyst (Boonkaew et al., 2014). Consequently, glyceraldehyde was used as a 
particularly effective and reactive glycating agent during the glycation inhibition 
assay as it does not form any hemiacetal ring structures in solution. The AGEs that 
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are produced from glyceraldeyde include argpyrimidine, triosidines and pentosidine. 
Several triosidines formed from reactions between lysine, arginine and 
glyceraldehyde such as the arginine-lysine cross-link arg-hydroxy-triosidine and the 
lysine-lysine cross-link lys-hydroxy-triosidine have been shown to be fluorescent 
(Schalkwijk et al., 2004). 
After transferring 50 μl of protein sample (20 mg/ml) into the relevant wells of a 
fluorescent 96-well microtitre plate, 40 μl of sample and 10 μl of glyceraldehyde 
solution (500 mM) was added. The plate was sealed and incubated at 37 °C for 24 
hours after which the fluorescence was measured using a Fluoroskan Ascent FL 
fluorometer (ThermoLabsystems, Finland)  with an excitation wavelength of 370 nm 
and an emission wavelength of 440 nm. Amino-guanidine (20 mM) was used as a 
positive control and the percentage of glycation inhibition was calculated using the 
following formula: 
% 𝑔𝑙𝑦𝑐𝑎𝑡𝑖𝑜𝑛 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =  
𝐴 − 𝐵
𝐴
 𝑋 100 
where A is the relative fluorescence of the reference sample and B is the relative 
fluorescence of the test sample. 
In order to identify false positives due to quenching, the intrinsic fluorescence of 
glycated gelatin was exploited by transferring 50 μl of pre-glycated gelatin (20 mg/ml) 
into a fluorescent 96-well microtitre plate. Next, 40 μl of sample (mushroom extract) 
and 10 μl of water were added and the fluorescence was measured as before. When 
added to pre-glycated gelatin, a decrease in the relative fluorescence in response to 
treatment with a particular mushroom extract was taken as a potential signal for 
quenching and the percentage quenching was calculated using the same formula as 
above. 
3.4.4. Collagenase inhibition 
Collagenases are endopeptidase enzymes responsible for digesting insoluble 
collagen fibres in their triple-helical conformation with the following sequence 
speicificity: 
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where X is typically a neutral amino acid (Sigma-Aldrich, 2016c). Chronic diabetic 
wounds are characterized by a persistent inflammatory state that leads to a 
disruption in the balance of proteases and their inhibitors that are required to 
maintain equilibrium between ECM deposition and degradation. As a result, wound 
healing is delayed and the wounds become characterized by excessive levels of 
proteases and reduced levels of protease inhibitors (McCarty & Percival, 2013). 
Natural products which are able to inhibit proteases such as collagenase could thus 
prove to be useful therapeutic agents in the treatment of chronic diabetic wounds. 
Briefly, 10 μl of enzyme (40 μg/ml) was added to each well in a 96-well microtitre 
plate. Sample (10 μl) followed by 10 μl gelatin (2 mg/ml) and 10 μl assay buffer (200 
mM) was added and the plate was incubated for 1 hour at 37 °C after which 20 μl of 
Coomasie Brilliant Blue was added. Following 5 minutes of incubation at room 
temperature with gentle shaking, the plate was centrifuged at 500 rcf for 5 minutes 
and the supernatant was gently removed. The pellet was then washed in 50 μl of 40 
% methanol/ 10 % acetic acid (v/v) to remove the excess dye. Finally, the pellet was 
dissolved in 50 μl of DMSO and the absorbance was measured at 600 nm using a 
BioTek® PowerWave XS spectrophotometer (Winooski, VT, USA). Catechin (0.5 
mM) was included as a positive control. The percentage collagenase inhibition was 
calculated using the following formula: 
% 𝑐𝑜𝑙𝑙𝑎𝑔𝑒𝑛𝑎𝑠𝑒 𝑖𝑛ℎ𝑖𝑏𝑖𝑡𝑖𝑜𝑛 =  
𝐴600 𝑛𝑚 𝑜𝑓 𝑡𝑒𝑠𝑡 𝑠𝑎𝑚𝑝𝑙𝑒
𝐴600 𝑛𝑚 𝑜𝑓 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑠𝑎𝑚𝑝𝑙𝑒
 𝑥 100. 
3.5. MACROPHAGE FUNCTION 
3.5.1. Nitric oxide production  
LPS is one of the chief components of the outer membrane of Gram-negative 
bacteria and induces the inflammatory phase of the immune response. One of the 
ways in which LPS activates macrophages is through binding to their TLRs. 
Following activation, the synthesis of multiple inflammatory mediators such as NO is 
induced. The quantity of NO produced by the macrophages can then be determined 
using the Griess reaction (Amura et al., 1998; Mosser & Zhang, 2008). The Griess 
reaction measures the quantity of nitrite (NO2-) which is one of the two major 
breakdown products of NO (Bryan & Grisham, 2007).  
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The Griess reaction is a colorimetric method during which dinitrogen trioxide (N2O3) 
generated from the acid-catalysed formation of nitrous acid (HNO2) from NO2
- 
undergoes a reaction with sulphanilamide, thus resulting in the formation of a 
diazonium ion. The diazonium ion gets coupled to N-1-napthylethylenediamine 
dihydrochloride (NED) resulting in the production of an azo chromophore which 
absorbs strongly at 540 nm (Bryan & Grisham, 2007).  The reaction during which 
sulphanilamide and NED are used in an acidic environment in the presence of 
phosphoric acid is demonstrated in figure 3.8.  
 
 
 
 
Figure 3.8: Chemical reactions occurring during the quantification of NO2
- using the Griess 
reagent for nitrite (Promega, 2009). 
Briefly, 100 μl of RAW 264.7 cells were seeded at a density of 100 000 cells per well 
into a 96-well microtitre plate and left to attach overnight at 37 °C. The medium was 
gently aspirated and cells were treated with 100 μl of the indicated treatment as well 
as 200 ng/ml LPS and incubated for a further 24 hours at 37 °C after which the 
Griess reaction was carried out. During this reaction, 50 μl of the culture medium 
from each well was transferred into corresponding wells of a new 96-well plate and 
50 μl of Griess reagent for nitrite was added to each well. The reaction was protected 
from light and incubated for 10 minutes at room temperature after which the 
absorbance was measured at 540 nm using a BioTek® PowerWave XS 
spectrophotometer (Winooski, VT, USA). Amino-guanidine (100 μg/ml) was included 
as a positive control for NO inhibition.  
The presence of endotoxins in the mushroom extracts was assessed using 
Polymyxin B sulfate. Polymyxins are a group of polypeptide antibiotics isolated from 
various strains of Bacillus polymyxa. They are capable of penetrating bacterial cell 
membranes thus disrupting their structure and ultimately exerting their bactericidal 
properties by causing permeability changes and subsequent death. They are basic 
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surface-active cationic detergents and consequently interact with cell membrane 
phospholipids. Polymyxin B, the structure of which is shown in figure 3.9, acts as a 
chelating agent thus binding to the lipid A component of endotoxin in a 1:1 ratio, 
effectively neutralising LPS (Papich, 2016). 
 
 
 
 
Figure 3.9: Chemical structure of Polymyxin B sulfate. Polymyxin B sulfate a mixture of 
polymyxins B1 and B2 and contains a cyclic heptapeptide unit together with a  
tripeptide side chain that is N-acetylated by a  fatty acyl residue (Sigma-Aldrich, 
2016d). 
RAW 264.7 cells were seeded into a 96-well plate at 100 000 cells per well and left 
to attach overnight. Cells were then treated with the mushroom extracts (100 and 
200 μg/ml) together with Polymyxin B sulfate at a concentration of 10 μg/ml for 24 
hours after which the griess reaction was carried out as described above. 
3.5.2. Phagocytosis 
It has previously been shown that the function of macrophages at wound-sites in 
diabetic patients is compromised such that their phagocytic capability is impaired. 
Furthermore, AGEs resulting from hyperglycaemia have been shown to directly 
suppress the phagocytic activity of macrophages. The removal of dead cells by 
macrophages is an essential step in the normal wound healing process as it protects 
the surrounding tissues from being exposed to the toxic contents of the dead and 
damaged cells while simultaneously producing anti-inflammatory cytokines and 
chemokines in an effort to prevent further tissue damage. Furthermore, phagocytosis 
of microbes is essential in preventing wound infections and thus once the phagocytic 
capability of the macrophage becomes impaired, the wound enters a state of chronic 
inflammation (Khanna et al., 2010).  
To assess the phagocytic capability of RAW 264.7 macrophage-like cells, pHrodo™ 
Green BioParticles® Conjugate (Thermo Fisher Scientific) was utilised. This is a 
highly sensitive system consisting of unopsonised Escherichia coli particles 
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conjugated to pHrodo™ Green. The pHrodo™-dye is a fluorogenic dye whose 
fluorescence intensity is determined by the surrounding pH as shown in figure 3.10. 
The pHrodo™ Green conjugate thus does not fluoresce outside the cell due to the 
neutral pH, however, as the conjugates are ingested and phagolysosomes are 
formed, the surrounding environment becomes more acidic and the fluorescence 
intensity of the BioParticles® increases thus allowing for the quantitative 
measurement of phagocytosis. The advantage of this is that the washing and 
quenching steps required when nonfluorogenic indicators of bacterial uptake are 
used can be eliminated (Life Technologies, 2013a).  
 
 
 
 
Figure 3.10: Fluorescence emission spectrum of the pHrodo™ Green conjugate utilised in the 
pHrodo™ Green BioParticles® Conjugate system for measuring phagocytosis 
(Life Technologies, 2013a). 
In addition to measuring phagocytosis, acidic vacuole formation was assessed using 
LysoTracker® Red (Thermo Fisher Scientific). LysoTracker® Red is highly sensitive 
red fluorescent dye that is used to track and label acidic organelles in live cells and is 
based on the principle that weakly basic amines accumulate in selective manner 
inside cellular compartments with a low pH such as lysosomes. LysoTracker® probes 
consist of a fluorophore attached to a weak base that becomes only partially 
protonated at neutral pH. The probes are thus able to freely cross cell membranes 
and effectively label living cells. These probes have a high specificity for acidic 
organelles and do not require any secondary antibodies for detection purposes.  
To measure phagocytosis and acidic vacuole formation, 100 μl of RAW 264.7 
macrophage-like cells were seeded into a 96-well plate at 30 000 cells per well in 
DMEM without phenol red supplemented with 10 % FBS. Cells were left to attach 
overnight after which 50 μl of the mushroom extracts (100 μg/ml) and the specified 
controls were added and incubated for 24 hours at 37 °C. After 23 hours of 
incubation, the relevant wells were treated with Cytochalasin B (3 μg/ml) and LPS 
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(200 ng/ml) for 1 hour which served as positive controls for the inhibition and 
stimulation of phagocytosis, respectively. Next, 20 μl of pHrodo™ Green 
BioParticles® were added at a concentration of 20 μg/ml and incubated at 37 °C for 2 
hours followed by the addition of LysoTracker® Red at 50 nM (Life Technologies, 
2013b).  
Fluorescent micrographs were captured using Molecular Devices ImageXpress 
Micro XLS Widefield microscope for high content analysis. Nine image sites per well 
were acquired as shown in figure 3.11 using a 20 X magnification. The mean cell 
integrated intensity of LysoTracker® Red and the mean stain area of the pHrodo™ 
Green BioParticles® was calculated using MetaXpress® software. 
 
 
 
Figure 3.11: Spatial distribution of image sites acquired during the phagocytosis assay. The 
area covered by each of the nine image sites in a single well of a 96-well 
microtitre plate is shown in green and was obtained using Molecular Devices 
ImageXpress Micro XLS Widefield microscope for high content analysis. 
3.5.3. M1/M2 macrophage polarization 
Macrophages have been shown to display extraordinary plasticity with different 
macrophage populations exhibiting distinct physiologies depending on the stimuli 
that they receive. As different biochemical methods of identifying these macrophage 
populations have been developed, our understanding of macrophage function has 
also progressed together with the potential to target specific populations of activated 
macrophages for therapeutic intervention (Mosser & Zhang, 2008).  
M1 and M2 macrophage activation was assessed using the Alexa-Fluor® anti-mouse 
CD86 and the APC anti-mouse CD206 antibodies from BioLegend®, respectively. 
Briefly, RAW 264.7 macrophages were seeded into 12-well plates at a seeding 
density of 200 000 cells per well and left to attach overnight at 37 °C. The cells were 
then treated with the specified treatments and incubated for 24 hours. LPS (200 
ng/ml) and curcumin (20 μg/ml) were included as positive controls for CD86 and 
CD206, respectively.  
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The cells were scraped from the wells and transferred into Eppendorf tubes where 
they were washed twice with 500 μl PBS (+ Ca2+/Mg2+) by centrifugation at 500 rcf 
for 5 minutes. Cells were blocked with 500 μl of 1 % BSA for 15 minutes at room 
temperature after which they were washed once. The antibodies were prepared 
using 1 % BSA in PBS using a 1:300 dilution for CD86 and a 1:400 dilution for 
CD206. Samples were stained with 100 μl of antibody for 30 minutes at 37 °C 
protected from light. An isotype control for each fluorophore was included using a 
1:400 dilution for the APC-conjugate and a 1:300 dilution for the Alexa-Fluor® 
conjugate. The cells were washed twice as before and resuspended in 350 μl of PBS 
(+ Ca2+/Mg2+). Samples were then transferred into a 96-well microtitre plate (175 μl 
per well) and stained with Hoechst 33342 (5 μg/ml in PBS + Ca2+/Mg2+).  
After allowing the cells 1 hour to settle at the bottom of the plate, fluorescent 
micrographs were captured using Molecular Devices ImageXpress Micro XLS 
Widefield microscope for high content analysis. Nine image sites per well were 
acquired using a 10 X magnification as in section 3.4.1. The percentage of cells 
stained positive for CD86 and CD206 was calculated using MetaXpress® software.  
3.5.4. NF-ĸB and COX-2 antibody staining 
NF-ĸB refers to a family of transcription factors that play an important role in 
inflammation, immune responses, apoptosis and cell cycle progression. NF-ĸB 
proteins are able to bind to consensus DNA sequences that can be found in the 
regulatory regions of target genes thus regulating their transcription and enabling 
NF-ĸB to regulate the expression of numerous cytokines, iNOS and COX-2 amongst 
others (Chen et al., 2011; Wullaert et al., 2011). Inflammatory stimuli have been 
shown to induce high levels of COX-2 expression and COX-2 has thus been 
identified as a suitable target for anti-inflammatory drugs (Na et al., 2015). 
3.5.4.1. NF-ĸB 
RAW 264.7 macrophages were seeded into a 96-well mictrotitre plate at 30 000 
cells/well and left to attach overnight at 37 °C. Cells were then treated with the 
specified treatments and incubated for a further 24 hours. After 23 hours of 
incubation, LPS (200 ng/ml) was added as a positive control for one hour. Samples 
were fixed with 37 % formaldehyde by adding it directly to the culture medium to 
make up a final concentration of 4 % and incubated for 15 minutes at room 
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temperature. The fixative was aspirated and the cells were washed twice with 100 μl 
PBS (+ Ca2+/Mg2+) after which they were permeabilised with 100 μl of cold methanol 
for 10 minutes at - 20 °C. The methanol was removed and 100 μl of PBS was added 
for five minutes at room temperature. Cells were then washed twice with 100 μl of 1 
% BSA in PBS and blocked for 45 minutes at room temperature with a 3 % BSA 
solution prepared in PBS and containing 0.2 % Triton-X 100. 
Next, 50 μl of a 1:800 dilution of phospho-NF-ĸB p65 (Ser536) (93H1) Rabbit mAb in 
1 % BSA/PBS was added and the cells were incubated for 1 hour at 37 °C. After 
removing the primary antibody and washing the cells twice with 100 μl of 1 % BSA in 
PBS, 50 μl  of a 1:1000 dilution of Anti-Mouse IgG (H+L), F(ab’)2 Fragment (Alexa 
Fluor® 488 Conjugate) prepared in 1 % BSA in PBS was added and the cells were 
incubated for 1 hour at 37°C protected from light. Cells were washed three times in 
PBS (+ Ca2+/Mg2+) after which the nuclei were stained with 50 μl of Hoechst 33342 
(5 μg/ml in PBS + Ca2+/Mg2+) for 10 minutes at room temperature. 
Fluorescent micrographs were captured using Molecular Devices ImageXpress 
Micro XLS Widefield microscope for high content analysis. Nine image sites per well 
were acquired as shown in figure 3.12 using a 40 X magnification. The mean nuclear 
integrated intensity was calculated using MetaXpress® software. 
 
 
 
Figure 3.12: Spatial distribution of image sites acquired during the NF-ĸB assay. The area 
covered by each of the nine image sites in a single well of a 96-well microtitre 
plate is shown in green and was obtained using Molecular Devices 
ImageXpress Micro XLS Widefield microscope for high content analysis. 
3.5.4.2. COX-2 
RAW 264.7 macrophages were seeded into a 96-well microtitre plate at 30 000 
cells/well and left to attach overnight at 37°C after which they were treated with the 
specified treatments for 24 hours. LPS (200 ng/ml) was included as a positive control 
and added together with the treatments as indicated. After 24 hours, samples were 
fixed, permeabilised and blocked as in section 3.5.4.1. Next, cells were incubated in 
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50 μl of a 1:800 dilution of Cox2 (D5H5) XP® Rabbit mAb (Alexa Fluor® 488 
Conjugate) prepared in 1 % BSA/ PBS for 1 hour at 37 °C protected from light. Cells 
were then washed twice with 100 μl of PBS and stained with 50 μl of Hoechst 33342 
(5 μg/ml in PBS + Ca2+/Mg2+) for 10 minutes at room temperature. 
Fluorescent micrographs were captured using Molecular Devices ImageXpress 
Micro XLS Widefield microscope for high content analysis. Four image sites per well 
were acquired as shown in figure 3.13 using a 20 X magnification. The percentage of 
cells that were stained positive for COX-2 was calculated using MetaXpress® 
software. 
 
 
 
Figure 3.13: Spatial distribution of image sites acquired during the COX-2 assay. The area 
covered by each of the four image sites in a single well of a 96-well microtitre 
plate is shown in green and was obtained using Molecular Devices 
ImageXpress Micro XLS Widefield microscope for high content analysis. 
3.6. FIBROBLAST FUNCTION 
3.6.1. Proliferation 
MRHF fibroblast proliferation was measured using the same protocol as for 
cytotoxicity screening (section 3.4.1) with the only modification being that low-
glucose DMEM was supplemented with only 1 % FBS instead of 10 %. 
3.6.2. Migration 
MRHF fibroblast migration was measured using the Enzo® Cell Migration Assay kit. 
This kit provides a sensitive, reproducible and flexible way of measuring cell 
migration and does not result in any ECM or cellular damage which would interfere 
with the findings (Hulkower & Herber, 2011; Enzo, 2015). As shown in figure 3.14, this 
assay utilises Cell Seeding Stoppers produced from a medical grade silicone which 
restricts the cells that are seeded into the plate to the outer annular regions of each 
well. Once the stoppers are removed, an unseeded region of 2 mm referred to as the 
detection zone is revealed. Cells are allowed to migrate into the detection zone over 
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a certain time period after which they can be analysed using either a Microplate 
Reader or image analysis (Enzo, 2016). 
 
 
 
 
Figure 3.14: Schematic of the Cell Migration Assay adapted from Enzo® (2016). 
Briefly, MRHF fibroblasts were seeded around the Cell Seeding Stoppers at a 
density of approximately 15 000 cells/well and left to attach overnight at 37 °C. The 
stoppers were then carefully removed using the Stopper Tool and the cells were 
washed twice with 100 μl of PBS (+ Ca2+/Mg2+) to remove any detached cells. The 
cells were then treated with 100 μl of the indicated treatments for 48 hours at 37 °C. 
Mitomycin C, a DNA synthesis inhibitor, was included in the culture medium at a 
concentration of 10 μg/ml in order to inhibit any cell proliferation (Sigma-Aldrich, 
2016e). 
Images were obtained using Molecular Devices ImageXpress Micro XLS Widefield 
microscope for high content analysis. Nine image sites per well were acquired as 
shown in figure 3.4 using a 10 X magnification. The micrographs were then analysed 
using TScratch software. TScratch is a freely available image analysis technique 
which utilises the fast discrete curvelet transform in order to automate the process by 
which the area occupied by cells in an image is calculated (Gebäck et al., 2009). 
3.7. DATA- AND STATISTICAL ANALYSIS 
3.7.1. Data analysis for High Content Screening 
All images obtained from Molecular Devices ImageXpress Micro XLS Widefield 
microscope for high content analysis were analysed using MetaXpress® 6.1 High 
Content Image Acquisition and Analysis Software in combination with the Multi-
Wavelength Cell Scoring application module. Using this module, one is able to obtain 
a number of different multi-parameter measurements including cell counts, the 
percentage of positive and negative cells, the area of the nuclei as well as 
wavelength-specific intensities based on the segmentation parameters defined for 
each wavelength. The segmentation parameters are based on simple measurements 
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such as the approximate minimum and maximum widths of the nucleus or cell, the 
intensity above local background and the minimum stained area (Molecular Devices, 
2017). An example of a segmentation overlay and the filter sets that were used are 
shown in figure 3.15. 
Figure 3.15: Diagram illustrating a segmentation overlay and the filter sets used during this 
study. (A) An example of a segmentation overlay of cells stained with Hoechst 
33342 and PI obtained using MetaXpress® software where cells that stained 
positive for only Hoechst 33342 are shown in grey while those that stained 
positive for Hoechst 33342 and PI are shown in blue and (B) the filter sets used 
for each fluorescent dye and conjugate. 
3.7.2. Data analysis for fibroblast migration 
The images acquired during the migration assay were analysed using TScratch 
software. This software is freely available and utilises the fast discrete curvelet 
transform as a means of automating the process by which the area occupied by cells 
in a particular image is calculated. The results are reported as percentage values 
which correspond to the size of the wound area relative to the size of the image. A 
larger wound area is thus associated with a larger percentage value and vice versa. 
A summary of the workflow of the software is demonstrated in figure 3.16. 
 
 
 
 
 
 
Figure 3.16: The workflow of the TScratch software. Initially the images will be segmented 
and grouped automatically by the software using default parameters. Group 
thresholds of multiple images can be manually adjusted in cases where the 
algorithm did not successfully determine them automatically. Individual images 
can then be reviewed and the analysis can be modified by excluding certain 
images, adjusting individual thresholds or manually editing the results using 
drawing tools (Gebäck et al., 2009). 
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3.7.3. Statistical analysis 
Except where otherwise stated, all experiments were performed three times, each in 
triplicate for statistical analysis. Both the ANOVA and Student’s t-tests were 
performed to compare the means of the data sets using the data analysis package 
from Microsoft Excel. In cases where p<0.05 the data was considered statistically 
significant (McKillup, 2012). 
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CHAPTER 4: RESULTS 
4.1. CHARACTERIZATION OF THE GLYCATED GELATIN MODEL 
Diabetic individuals demonstrate enhanced protein glycation due to chronically 
elevated blood glucose levels. The resultant AGEs have been shown to perform 
important functions in the pathogeneses of various diabetic complications including 
impaired wound healing as protein glycation not only interferes with the function of 
the affected protein, but also influences several cell signalling pathways (Liao et al., 
2009; Singh et al., 2014). The validation of an in vitro screening model forms an 
important part of the research process as it is crucial in determining the possibilities 
and limitations of the model across various cell lines. 
4.1.1. The autofluorescence of advanced glycation end products  
AGEs are known to autofluoresce at excitation/emission wavelengths between 370 
and 440 nm, respectively; this property is widely used as a means to quantify AGEs. 
AGE autofluorescence was measured in order to confirm the success of the 
glycation process (figure 4.1). The unglycated gelatin (gelatin autoclaved in the 
absence of glucose) served as the control in this experiment with all other treatments 
calculated as a percentage of this control. Although statistically significant, the 
fluorescence contribution of the autoclaved glucose solution was minimal and is not 
considered relevant. 
 
 
 
 
 
 
Figure 4.1: A comparison of the relative fluorescence of unglycated gelatin and glucose 
stocks used to produce glycated gelatin after being autoclaved for 1 hour; 
results are reported as means ± SD where each experiment was performed 
three times, each in triplicate (*p<0.05; **p<0.01; ***p<0.005 compared to 
unglycated gelatin). 
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Figure 4.1 shows a robust increase in the relative fluorescence of glycated gelatin 
(p<0.005) when compared to the unglycated gelatin, glucose and the combination of 
glucose with unglycated gelatin stocks, thus confirming an effective glycation 
process. 
4.1.2. Cytotoxicity screening 
The cytotoxicity of gelatin on both RAW 264.7 macrophage-like cells and MRHF 
fibroblasts was explored in order to define the practical concentration limits suitable 
for in vitro studies and to determine an optimal concentration of gelatin that should 
be used to mimic the diabetic state. Cell numbers were determined using Hoechst 
33342 and propidium iodide staining while the crystal violet assay was performed to 
assess cell density in an attempt to confirm the accuracy of both methods. 
Figure 4.2 shows examples of the fluorescent micrographs that were captured during 
this experiment and analysed using MetaXpress® software as descried in section 
3.7.1 while figure 4.3 compares the results of the cytotoxicity screening assays on 
the macrophages and fibroblasts for both the unglycated and glycated gelatin stocks. 
The untreated sample contains no gelatin and consisted of DMEM supplemented 
with 10 % FBS and represents 100 % cell density. All treatments were calculated as 
a percentage of this control. 
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Figure 4.2: Fluorescent micrographs captured during the gelatin cytotoxicity screening assay 
comparing (A) 1 % unglycated gelatin with (B) 1 % glycated gelatin for RAW 264.7 
cells and (C) 1 % unglycated gelatin with (D) 1 % glycated gelatin for the MRHF 
fibroblasts using Hoechst 33342 (blue) and propidium iodide (red). 
From the fluorescent micrographs shown in figure 4.2 it can be seen that there are 
much fewer cells present in the wells that were treated with glycated gelatin when 
compared to treatment with unglycated gelatin for both the RAW 264.7 macrophages 
and the MRHF fibroblasts. 
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Figure 4.3: Cytotoxicity screening of gelatin comparing (A) cell number with (B) cell density 
for RAW 264.7 cells and (C) cell number with (D) cell density for MRHF cells; 
live- and dead cell numbers were obtained from Hoechst 33342 and PI staining, 
respectively and cell density from crystal violet staining. Results are reported as 
means ± SD where each experiment was performed three times, each in 
triplicate (*p<0.05; **p<0.01; ***p<0.005 compared to the untreated sample). 
Figures 4.3 A and C show a dose-dependent decrease in cell number accompanied 
by a dose-dependent increase in cell death for both the RAW 264.7 cells as well as 
for the MRHF fibroblasts in response to glycated gelatin. The unglycated gelatin did 
not show any substantial cytotoxicity for either cell line, however, there was a 
significant increase in cell death at 2 % unglycated gelatin for the RAW 264.7 cells. 
Figure 4.3 D shows the same dose-dependent decrease in cell density in response 
to an increased concentration of glycated gelatin for the MRHF fibroblasts, however, 
significant decreases in RAW 263.7 cell density were only observed at 
concentrations of 1.5 and 2 % for the glycated gelatin as seen in figure 4.3 B. No 
significant differences in cell density were observed for the RAW 264.7 cells in 
response to the unglycated gelatin, however, a significant decrease in MRHF 
fibroblast cell density was observed at concentrations of 1.5 and 2 % for the 
unglycated gelatin. 
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4.1.3. Nitric oxide production in activated macrophages 
The effect of both glycated and unglycated gelatin on the nitric oxide production in 
LPS activated RAW 264.7 cells was assessed using the Griess reaction and the 
results are shown in figure 4.4. LPS (200 ng/ml) was used to induce the pro-
inflammatory phenotype which is associated with increased iNOS expression and 
concomitant NO production. All other treatments were calculated as a percentage of 
this control and statistical differences were calculated relative to LPS stimulated 
cells. Amino-guanidine, an inhibitor of iNOS activity and expression, was used to 
confirm that the model is responsive to anti-inflammatory signals showing complete 
inhibition of nitric oxide production at a concentration of 100 μg/ml.    
 
 
 
 
 
Figure 4.4: NO production of RAW 264.7 cells in response to glycated and unglycated 
gelatin; results are reported as means ± SD where each experiment was 
performed three times, each in triplicate (°p<0.05; °°p<0.01; °°°p<0.005 
compared to LPS stimulated cells). 
From figure 4.4 it can be seen that there is a seemingly dose-dependent inhibition of 
LPS induced NO production as the concentration of the glycated gelatin increases 
and the glycated gelatin is thus altering the normal response observed for the LPS 
treated cells. No significant differences in NO production were observed for the 
unglycated gelatin, indicating that this is dependent on glycation.  
4.1.4. Nitric oxide scavenging activity  
Considering that an attenuation in NO levels may be the result of direct scavenging 
of NO, the nitric oxide scavenging ability of the glycated and unglycated gelatin 
stocks was assessed and the results presented in figure 4.5. Amino-guanidine, 
known to function as a direct NO scavenger, was used as a positive control in this 
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experiment and statistical analysis was performed relative to the sodium 
nitroprusside control. 
 
 
 
 
 
 
Figure 4.5: NO scavenging activity of glycated and unglycated gelatin; results are reported 
as means ± SD where each experiment was performed three times, each in 
triplicate (*p<0.05; **p<0.01;***p<0.005 compared to sodium nitroprusside 
control). 
Compared to the sodium nitroprusside control, glycated gelatin revealed significant 
NO scavenging capabilities (p<0.01) (figure 4.5) while no scavenging effects were 
reported for the unglycated gelatin. These results suggest that the effect of glycated 
gelatin on the NO production of LPS induced cells (figure 4.4) might be due to NO 
scavenging rather than anti-inflammatory activity. Relative to amino-guanidine, 
however, both the 0.5 % unglycated and glycated gelatin possess minimal NO 
scavenging capabilities. 
4.1.5. Phagocytosis 
The phagocytic capability of RAW 264.7 macrophage-like cells was assessed using 
the pHrodo® Green E. coli BioParticles® Conjugate together with LysoTracker Red® 
(LTR). Examples of the fluorescent micrographs that were captured are shown in 
figure 4.6. Using the MetaXpress® software, the mean stain area of the pHrodo® 
Bioparticles® inside the RAW 264.7 cells was calculated and thus an increase in the 
mean stain area suggests an increase in the number of particles phagocytosed. The 
untreated sample consisted of high-glucose DMEM supplemented with 10 % FBS 
and all samples were calculated as a percentage of this control (figure 4.7). 
Cytochalasin B, a microtubule inhibitor, was used to inhibit phagocytosis while LPS 
was included as a positive control to promote phagocytosis. 
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Figure 4.6: Fluorescent micrographs captured during the phagocytosis assay comparing the 
(A) untreated sample stained with pHrodo® Bioparticles®  with (B) untreated sample 
stained with LTR and (C) 0.5 % glycated gelatin sample stained with pHrodo® 
Bioparticles® after a 2 hour incubation period. 
From figure 4.6 it is clear that there were much fewer pHrodo® Bioparticles® 
phagocytosed by the cells that were treated with 0.5 % glycated gelatin. While a 
decrease in macrophage cell number in response to treatment with 0.5 % glycated 
gelatin was observed in figure 4.3 after a 48 hour treatment period, it is not likely that 
the same effect would be observed here due to a much shorter incubation period of 
only 24 hours. The decrease in the number of pHrodo® Bioparticles® phagocytosed 
between figures A and B are thus due to an impairment in the phagocytic capability 
of the macrophages in response to treatment with glycated gelatin rather than a 
decrease in cell number.  
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Figure 4.7: Effect of gelatin on RAW 264.7 cell phagocytosis measuring (A) acidic vacuole 
formation using LysoTracker Red® and (B) phagocytosis using pHrodo® 
Bioparticles®; results are reported as means ± SD where each experiment was 
performed three times, each in triplicate (*p<0.05; **p<0.01; ***p<0.005 
compared to the untreated sample). 
Figure 4.7 shows that while there were no significant differences in acidic vacuole 
content of the RAW 264.7 cells amongst the different treatments, there was 
significantly less phagocytosis in the cells treated with Cytochalasin B and glycated 
gelatin. The standard deviations were fairly large when the results for all three 
independent experiments were combined, however, individual experiments shown in 
appendix C show that standard deviations were much smaller. In all three individual 
experiments, the 0.5 % glycated gelatin resulted in a significant increase in acidic 
vacuole formation with varying trends for the remaining treatments. 
4.1.6. Classical (M1) and alternative (M2) macrophage polarization 
M1 and M2 macrophage polarization using RAW 264.7 macrophages was assessed 
using antibodies for the CD86 and CD206 cell-surface markers, respectively. 
Examples of the micrographs that were captured are shown in figure 4.8 while the 
experimental results are shown in figure 4.9. The untreated sample consisted of 
high-glucose DMEM supplemented with 10 % FBS and all samples were calculated 
as a percentage of this control. LPS was used as a positive control for M1 activation 
while curcumin was used as a positive control for M2 activation (Gao et al., 2015).  
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Figure 4.8: Fluorescent micrographs captured during the macrophage polarization assay 
comparing (A) untreated sample stained with CD86 (M1) with (B) LPS stained 
with CD86 (M1) and (C) untreated sample stained with CD206 (M2) with (D) 
curcumin stained with CD206 (M2). 
From figure 4.8 it is evident that there was an increase in the number of cells that 
were stained positive for both the M1 and M2 cell surface markers in the presence of 
LPS and curcumin, respectively,  when compared to the corresponding untreated 
samples. 
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Figure 4.9: Macrophage polarization following treatment with gelatin using (A) CD86 for M1 
macrophages and (B) CD206 for M2 macrophages; results are reported as 
means ± SD where each experiment was performed three times, each in 
triplicate (*p<0.05; **p<0.01; ***p<0.005 compared to the untreated sample). 
Figure 4.9 A shows that there was a 16 % increase in the expression of CD86 for the 
cells treated with LPS and a 12 % increase for the cells treated with 0.5 % glycated 
gelatin. The expression of CD206 was more than double that of the untreated 
sample for the cells treated with curcumin as seen in figure 4.9 B. While the glycated 
gelatin alone did not increase the percentage of cells that stained positive for CD206, 
the addition of curcumin resulted in a two-fold increase. A slight decrease in CD206 
expression was observed in the macrophages treated with both curcumin and 
glycated gelatin compared to cells treated with only curcumin, however, this 
difference was not found to be significant in any of the individual experiments (not 
shown) and thus glycated gelatin was not found to impair the cells’ ability to become 
M1 or M2 macrophages. 
4.1.7. NF-ĸB antibody staining 
The nuclear translocation of phospho-p65 NF-ĸB in RAW 264.7 macrophages was 
assessed in order to confirm the effect of the glycated gelatin model on macrophage 
function. Examples of the micrographs captured during this experiment are shown in 
figure 4.10 with the experimental results depicted in figure 4.11. The untreated 
sample consisted of high-glucose DMEM supplemented with 10 % FBS and all 
samples were calculated as a percentage of this control. LPS was used as a positive 
control to promote NF-ĸB nuclear translocation.  
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Figure 4.10: Fluorescent micrographs captured during the phospho-p65 NF-ĸB nuclear 
translocation assay comparing (A) untreated sample with (B) LPS treated 
sample. 
While only a very small increase in the fluorescence intensity of cells treated with 
LPS (figure B) compared to the untreated sample (figure A) can be seen from the 
micrographs in figure 4.10, the MetaXpress® analysis software is sensitive enough to 
measure these small differences with great accuracy. The increase in fluorescence 
intensity in the LPS treated cells indicates that there was increased phosphorylation 
of the p65 subunit of NF-ĸB and consequent nuclear translocation. 
 
 
 
 
 
 
Figure 4.11: NF-ĸB nuclear translocation following treatment with gelatin; results are 
reported as means ± SD where each experiment was performed three times, 
each in triplicate (*p<0.05; **p<0.01; ***p<0.005 compared to the untreated 
sample). 
The nuclear translocation of phospho-p65 NF-ĸB was significantly higher in cells 
treated with LPS than those from the untreated sample. The 0.5 % glycated gelatin 
also resulted in a significant increase in NF-ĸB nuclear translocation while the cells 
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treated with both LPS and glycated gelatin showed the highest increase of 15 % in 
phosph-p65 NF-ĸB nuclear translocation. No significant differences were reported 
between the samples treated with LPS and glycated gelatin or between LPS and the 
sample treated with both LPS and glycated gelatin. 
4.1.8. COX-2 antibody staining 
The ability of RAW 264.7 macrophages to express COX-2 was assessed in order to 
further evaluate the inflammatory status of these cells in response to different 
treatments. Some of the micrographs captured during this experiment are provided 
in figure 4.12 while the experimental results that were obtained can be found in 
figure 4.13. The untreated sample consisted of high-glucose DMEM supplemented 
with 10 % FBS while LPS was used as a positive control. 
 
 
 
 
 
 
Figure 4.12: Fluorescent micrographs captured during the COX-2 assay comparing (A) 
untreated sample with (B) 200 ng/ml LPS treated sample. 
Figure 4.12 shows that there is a robust increase in the expression and consequent 
synthesis of COX-2 in RAW 264.7 macrophages treated with 200 ng/ml LPS for 24 
hours.  
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Figure 4.13: COX-2 antibody staining following treatment with gelatin; results are reported as 
means ± SD where each experiment was performed three times, each in 
triplicate (*/°p<0.05; **/°°p<0.01; ***/°°°p<0.005 where *compared to the 
untreated sample and ° compared to LPS). 
Cells treated with LPS showed a 31 % increase in the expression of COX-2 as seen 
in figure 4.13. While neither the unglycated nor the glycated gelatin samples alone 
resulted in any significant changes with regards to the percentage of cells stained 
positive for COX-2, cells treated with both 200 ng/ml and 0.5 % glycated gelatin 
resulted in a robust increase in COX-2 expression of 49 %, a value significantly 
higher (P<0.01) than treatment with LPS alone. 
4.1.9. Fibroblast proliferation 
The effect of both glycated and unglycated gelatin on MRHF fibroblast proliferation 
was assessed in order to gain a better understanding of the possibilities and 
limitations of the glycated gelatin model with regards to adequately mimicking the 
diabetic state. Hoechst 33342 and PI staining was used as in section 4.1.2 and the 
images captured were analysed using MetaXpress® software. The untreated sample 
consisted of low-glucose DMEM supplemented with 1 % FBS and represented 100 
% proliferation with all the other samples calculated as a percentage of this control 
as demonstrated in figure 4.14. The 10 % FBS sample was used as a positive 
control. 
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Figure 4.14: MRHF fibroblast proliferation in response to gelatin; results are reported as 
means ± SD where each experiment was performed three times, each in 
triplicate (*p<0.05; **p<0.01; ***p<0.005 compared to 1 % FBS). 
From figure 4.14 it can be seen that there was a significant increase in fibroblast 
proliferation in the presence of 10 % FBS. Treatment with unglyated gelatin did not 
appear to influence fibroblast proliferation, however, the 0.5 % glycated gelatin 
significantly impaired fibroblast proliferation when compared to the 1 % FBS control. 
4.1.10. Fibroblast migration 
MRHF fibroblast migration was assessed using the Enzo® Cell Migration Assay kit 
and the experimental results are reported in figure 4.15. After the fibroblasts were 
treated with both mitomycin-C and the specified treatments, they were allowed to 
migrate for 48 hours. The untreated control consisted of low-glucose DMEM 
supplemented with 10 % FBS. The images that were captured were analysed using 
TScratch software and the values obtained were used to calculate the percentage 
wound closure. 
 
 
 
 
 
Figure 4.15: MRHF fibroblast migration in response to gelatin after 48 hours; results are 
reported as means ± SD where each experiment was performed three times, 
each in triplicate (*p<0.05; **p<0.01; ***p<0.005 compared to untreated 
sample). 
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It is evident from figure 4.16 that while the unglycated gelatin did not result in any 
significant changes in migration when compared to the untreated control, the 0.5 % 
glycated gelatin significantly impaired fibroblast migration (P<0.005). 
4.2. SCREENING OF EXTRACTS FOR POTENTIAL WOUND HEALING 
PROPERTIES 
Basal cytotoxicity screening was performed in order to ensure that the selected 
concentrations of each mushroom extract did not induce significant cell death. 
Additionally, the anti-oxidant, glycation inhibition and collagenase inhibition potential 
of each extract was assessed to investigate the potential benefits of each extract in 
combating the oxidative stress, formation of AGEs and elevated levels of MMPs in 
diabetes. 
4.2.1 Cytotoxicity screening 
Basal cytotoxicity screening was performed on both RAW 264.7 macrophages and 
MRHF fibroblasts. Cell numbers were determined using Hoechst 33342/ PI staining 
while the crystal violet assay was performed to assess cell density in an attempt to 
compare the accuracy of both methods. 
Figure 4.16 shows examples of the fluorescent micrographs that were captured 
during this experiment while figures 4.17 to 4.21 compare the results of the 
cytotoxicity screening assays on the macrophages and fibroblasts for each of the five 
mushroom species used throughout thus study. The untreated sample consisted of 
DMEM supplemented with 10 % FBS and represents 100 % cell density. All 
treatments were calculated as a percentage of this control. 
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Figure 4.16: Fluorescent micrographs captured during the cytotoxicity screening assay 
comparing (A) untreated sample with (B) 100 μg/ml ethanol extract of G. 
lucidum for RAW 264.7 cells and (C) untreated sample with (D) 100 μg/ml 
ethanol extract of G. lucidum for the MRHF fibroblasts using Hoechst 33342 
(blue) and propidium iodide (red). 
Figure 4.16 provides an example of a cytotoxic extract where the cell numbers are 
greatly reduced and the number of dead cells stained positive for PI is increased.  
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Figure 4.17: Cytotoxicity screening of P. tinctorius comparing (A) cell number with (B) cell 
density for RAW 264.7 cells and (C) cell number with (D) cell density for MRHF 
cells; live- and dead cell numbers were obtained from Hoechst 33342 and PI 
staining, respectively and cell density from crystal violet staining. Results are 
reported as means ± SD where each experiment was performed three times, 
each in triplicate (*p<0.05; **p<0.01; ***p<0.005 compared to untreated 
sample). 
Figure 4.17 shows that there was a significant decrease in RAW 264.7 cell number 
for both concentrations of the water extract of P. tinctorius with a significant increase 
in cell death (p<0.005) at 100 μg/ml. A significant decrease in MRHF cell number 
was observed at 200 μg/ml for both the water and ethanol extracts with a significant 
increase (p<0.005) in cell death at 200 μg/ml for the water extract. No decrease in 
cell density was observed for either the water or the ethanol extracts in the crystal 
violet assay for either cell line.  
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Figure 4.18: Cytotoxicity screening of R. capensis comparing (A) cell number with (B) cell 
density for RAW 264.7 cells and (C) cell number with (D) cell density for MRHF 
cells; live- and dead cell numbers were obtained from Hoechst 33342 and PI 
staining, respectively and cell density from crystal violet staining. Results are 
reported as means ± SD where each experiment was performed three times, 
each in triplicate (*p<0.05; **p<0.01; ***p<0.005 compared to untreated 
sample). 
No significant cytotoxicity was observed for either the ethanol or the water extract of 
R. capensis up to a concentration of 200 μg/ml for the RAW 264.7 cells (figure 4.18). 
A significant decrease (p<0.05) in MRHF cell number was observed for the 200 
μg/ml water extract of R. capensis while no significant alterations to cell density were 
observed for either cell line. 
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Figure 4.19: Cytotoxicity screening of B. badius comparing (A) cell number with (B) cell 
density for RAW 264.7 cells and (C) cell number with (D) cell density for MRHF 
cells; live- and dead cell numbers were obtained from Hoechst 33342 and PI 
staining, respectively and cell density from crystal violet staining. Results are 
reported as means ± SD where each experiment was performed three times, 
each in triplicate (*p<0.05; **p<0.01; ***p<0.005 compared to untreated 
sample). 
It is evident form figure 4.19 that there is a significant decrease (p<0.05) in RAW 
264.7 cell number for the 200 μg/ml ethanol extract of B. badius. No cytotoxicity was 
observed for the MRHF cells and there were no significant changes in cell death or 
cell density for either cell line. 
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Figure 4.20: Cytotoxicity screening of P. ostreatus comparing (A) cell number with (B) cell 
density for RAW 264.7 cells and (C) cell number with (D) cell density for MRHF 
cells; live- and dead cell numbers were obtained from Hoechst 33342 and PI 
staining, respectively and cell density from crystal violet staining. Results are 
reported as means ± SD where each experiment was performed three times, 
each in triplicate (*p<0.05; **p<0.01; ***p<0.005 compared to untreated 
sample). 
According to figure 4.20, no significant alterations in cell number, cell death or cell 
density were reported for the water or ethanol extracts of P. ostreatus for both RAW 
264.7 cells and MRHF cells. This mushroom species thus did not show any 
cytotoxicity. 
 
 
 
 
 
 
 
85 
 
 
 
 
 
 
 
 
 
 
Figure 4.21: Cytotoxicity screening of G. lucidum comparing (A) cell number with (B) cell 
density for RAW 264.7 cells and (C) cell number with (D) cell density for MRHF 
cells; live- and dead cell numbers were obtained from Hoechst 33342 and PI 
staining, respectively and cell density from crystal violet staining. Results are 
reported as means ± SD where each experiment was performed three times, 
each in triplicate (*p<0.05; **p<0.01; ***p<0.005 compared to untreated 
sample). 
A highly significant dose-dependent decrease in cell number and cell density were 
observed for the ethanol extract of G. lucidum in figure 4.21. This was accompanied 
by a robust increase in cell death for both RAW 264.7 and MRHF cells. No 
significant cytotoxicity was observed for the water extract in either cell line during the 
Hoechst 33342/PI method or the crystal violet assay. 
4.2.2. Anti-oxidant activity 
Due to the association of oxidative stress with impaired wound healing, the anti-
oxidant capacity of each mushroom extract was assessed using the FRAP, DPPH 
and NO scavenging assays. The selection of these assays was based on the fact 
that each of them have been associated with different anti-oxidant activities due to 
the nature of the experimental conditions and thus by choosing three methods based 
on different principles, one is able to gain a better understanding of the true anti-
oxidant capabilities of each of the five mushroom species.  
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Figure 4.22: Antioxidant screening of P. tinctorius comparing the results from the (A) DPPH 
(B) FRAP and (C) NO scavenging assays; results are reported as means ± SD 
where each experiment was performed three times, each in triplicate. 
From figure 4.22, both the water and ethanol extracts of P. tinctorius showed 
comparatively high anti-oxidant activities during the DPPH and NO scavenging 
assays, respectively, however, much lower anti-oxidant activities were reported 
during the FRAP assay in comparison to the relevant positive controls. The IC50 
values for the DPPH and NO scavenging assays appear to be below 100 μg/ml for 
the DPPH assay and between 100 and 200 μg/ml for the NO scavenging assay. As 
these values are fairly high and consequently do not suggest much promise for 
significant physiological effects, the IC50 values were not calculated. 
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Figure 4.23: Antioxidant screening of R. capensis comparing the results from the (A) DPPH 
(B) FRAP and (C) NO scavenging assays; results are reported as means ± SD 
where each experiment was performed three times, each in triplicate. 
Comparatively low anti-oxidant activities for both the water and ethanol extracts of R. 
capensis were reported during all three anti-oxidant screening assays (figure 4.23). 
The highest anti-oxidant activities of 36 % for the 200 μg/ml ethanol extract and 28 % 
for the 200 μg/ml water extract were reported for the DPPH assay. The IC50 values 
for the DPPH and NO scavenging assays are thus above 200 μg/ml. 
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Figure 4.24: Antioxidant screening of B. badius comparing the results from the (A) DPPH (B) 
FRAP and (C) NO scavenging assays; results are reported as means ± SD 
where each experiment was performed three times, each in triplicate. 
It is evident from figure 4.24 that the anti-oxidant capacities of the ethanol and water 
extracts of B. badius were comparatively low. While a dose-dependent increase in 
the anti-oxidant activity for both extracts was reported, the low values reported here 
do not suggest any physiological relevance. The highest activities of 46 % for the 
200 μg/ml ethanol extract and 44 % for the 200 μg/ml water extract were reported for 
the DPPH assay. 
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Figure 4.25: Antioxidant screening of P. ostreatus comparing the results from the (A) DPPH 
(B) FRAP and (C) NO scavenging assays; results are reported as means ± SD 
where each experiment was performed three times. 
The ethanol and water extracts of P. ostreatus showed very low anti-oxidant 
activities during the DPPH assay with little to no activity during the FRAP and NO 
scavenging assays (figure 4.25). The highest anti-oxidant activities of 28 % for the 
200 μg/ml ethanol extract and 25 % for the 200 μg/ml water extract were reported for 
the DPPH assay, indicating that the IC50 values are far above 200 μg/ml. No dose-
dependent relationship between the different concentrations of either the ethanol or 
the water extracts for any of the assays were recorded, suggesting that P. ostreatus 
does not possess any noteworthy anti-oxidant activity.  
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Figure 4.26: Antioxidant screening of G. lucidum comparing the results from the (A) DPPH 
(B) FRAP and (C) NO scavenging assays; results are reported as means ± SD 
where each experiment was performed three times. 
G. lucidum showed comparatively strong anti-oxidant activities between the ethanol 
and water extracts during the DPPH assay with an IC50 value between 100 and 200 
μg/ml for the ethanol extract and below 100 μg/ml for the water extract. While the 
200 μg/ml ethanol extract demonstrated comparatively strong activities to the 
positive catechin control during the FRAP assay, the same trends were not observed 
during and NO scavenging assay where NO scavenging capabilities below 25 % 
were reported. 
4.2.3. Glycation inhibition 
Due to the role of AGEs in the pathogenesis of diabetes, the ability of each 
mushroom extract to inhibit glycation was assessed in figures 4.27 to 4.31 in order to 
identify a mushroom species that could serve as a potential diabetic wound healing 
therapy. A positive response would be demonstrated by a reduction in the relative 
fluorescence using the AGE excitation/emission maxima of 370/440 nm and thus 
false positives due to quenching were identified using pre-glycated gelatin as 
described in section 3.4.3. Amino-guanidine was used as a positive control for the 
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inhibition of the glyceraldehyde-induced glycation. The control sample consisted of 
unglycated gelatin (20 mg/ml) without glyceraldehyde. 
 
 
 
 
 
Figure 4.27: Glycation inhibition potential of P. tinctorius comparing (A) glycation inhibition 
with (B) quenching; results are reported as means ± SD where each 
experiment was performed three times, each in triplicate (*p<0.05; **p<0.01; 
***p<0.005 compared to control sample). 
Both the ethanol and water extracts of P. tinctorius showed significant glycation 
inhibitory potentials when compared to the control sample (figure 4.27). A strong 
dose-dependent increase in their glycation inhibition potentials was reported 
between the 100 and 200 μg/ml concentrations with the 200 μg/ml ethanol extract 
demonstrating similar capabilities for inhibiting protein glycation as the positive 
amino-guanidine control. Upon further investigation of potential quenching, however, 
significantly strong (p<0.005) quenching activities of 62 % and 55 % for the 200 
μg/ml ethanol and water extracts, respectively, were reported in figure B. This 
suggests that most of the glycation inhibition observed in figure A was in fact due to 
the quenching of the intrinsic fluorescence of AGEs. 
 
 
 
 
Figure 4.28: Glycation inhibition potential of R. capensis comparing (A) glycation inhibition 
with (B) quenching; results are reported as means ± SD where each 
experiment was performed three times, each in triplicate (*p<0.05; **p<0.01; 
***p<0.005 compared to control sample). 
92 
 
From figure 4.28, the ethanol and water extracts of R. capensis showed 
comparatively low glycation inhibition potentials below 25 %. While the values 
reported for the 200 μg/ml extracts were statistically higher (p<0.05) than the control 
sample, significant quenching (p<0.05) of 18 % was reported for the water extract. 
This suggests that these results do not accurately reflect the glycation inhibition 
potential of R. capensis.  
 
 
 
 
 
Figure 4.29: Glycation inhibition potential of B. badius; results are reported as means ± SD 
where each experiment was performed three times, each in triplicate (*p<0.05; 
**p<0.01; ***p<0.005 compared to control sample). 
Figure 4.29 shows that B. badius did not show any noteworthy glycation inhibition 
potential with the water extract potentially acting as an inducer of glycation as 
evidenced by the significant increase in glycation for both the 100 and 200 μg/ml 
concentrations compared to the untreated sample. No significant quenching was 
reported (results not shown). 
 
 
 
 
 
Figure 4.30: Glycation inhibition potential of P. ostreatus; results are reported as means ± 
SD where each experiment was performed three times, each in triplicate 
(*p<0.05; **p<0.01; ***p<0.005 compared to control sample). 
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Neither the ethanol nor the water extracts of P. ostreatus showed any significant 
inhibition of glycation when compared to the control sample (figure 4.30). 
Furthermore, no significant quenching was observed (results not shown).  
 
 
 
 
 
Figure 4.31: Glycation inhibition potential of G. lucidum comparing; results are reported as 
means ± SD where each experiment was performed three times, each in 
triplicate (*p<0.05; **p<0.01; ***p<0.005 compared to control sample). 
From figure 4.31, neither the ethanol nor the water extracts of G. lucidum showed 
any statistically significant glycation inhibiton potential and no significant quenching 
was observed. 
4.2.4. Collagenase inhibition  
As diabetic wounds are characterized by the increased activity of several MMPs 
such as collagenase, the ability of each mushroom extract to inhibit collagenase 
activity in an attempt to prevent excessive ECM degradation was investigated in 
figure 4.33 using the collagenase enzyme isolated from Clostridium histolyticum. A 
positive inhibitory response is indicated by the formation of a protein pellet consisting 
of undigested gelatin which is subsequently stained with Coomassie brilliant blue. A 
larger pellet is associated with a darker colour, thus revealing a stronger collagenase 
inhibitory potential. Catechin (10 mM) was used as a positive control for collagenase 
inhibition and the uninhibited control sample consisted of gelatin (2 mg/ml) incubated 
in the absence of collagenase. 
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Figure 4.32: A comparison of the collagenase inhibitory potentials of (A) P. tinctorius (B) R. 
capensis (C) B. badius (D) P. ostreatus and (E) G. lucidum; results are reported 
as means ± SD where each experiment was performed three times, each in 
triplicate (*p<0.05; **p<0.01; ***p<0.005 compared to control sample). 
The strong collagenase inhibition (56 %) exerted by the positive catechin control 
indicates that the collagenase inhibition assay was indeed functional (figure 4.32). 
None of the five mushroom species tested during this study resulted in any 
significant collagenase inhibition compared to the control sample. Consequently, 
none of these extracts demonstrated any promising capabilities of attenuating the 
increased MMP activity observed during impaired wound healing in diabetes.  
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4.3. THE INFLAMMATORY RESPONSE 
During section 4.1, AGEs were found to reduce NO, impair macrophage 
phagocytosis, promote M1 macrophage activation and enhanced the nuclear 
translocation of NF-ĸB as well as the activity of COX-2 in macrophages stimulated 
with LPS. This reveals several potential mechanisms through which protein glycation 
impairs wound healing by disrupting several cellular functions during the 
inflammatory response. The purpose of the following section was to screen the 
selected mushroom samples in order to determine whether any of them were able to 
reverse some of the negative effects of AGEs on macrophage cell function. 
4.3.1. Nitric oxide production in activated macrophages 
Nitric oxide production in RAW 264.7 macrophages both in the absence and 
presence of LPS (200 ng/ml) was assessed using the Griess reaction (figures 4.33 to 
4.37) in order to identify any pro-inflammatory or anti-inflammatory activities, 
respectively, in each of the selected mushroom extracts to gain a better 
understanding of the potential uses of these extracts during wound healing. The 
untreated sample consisted of high-glucose DMEM (25 mM) supplemented with 10 
% FBS. LPS was used to induce NO production and thus represents the pro-
inflammatory state.  To assess the anti-inflammatory potential of test samples, LPS 
treatment alone was set to 100 % and the anti-inflammatory activity calculated as a 
percentage of this value. Amino-guanidine (100 μg/ml) was used as a positive 
control for NO inhibition. 
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Figure 4.33: Nitric oxide production of RAW 264.7 cells treated with P. tinctorius (A) without 
LPS, (B) with LPS and (C)  with glycated gelatin and LPS; results are reported 
as means ± SD where each experiment was performed three times, each in 
triplicate (*/°/∆p<0.05; **/°°/∆∆p<0.01; ***/°°°/∆∆∆p<0.005 where * compared to 
untreated sample; ° compared to LPS stimulated; ∆ compared to glycated 
gelatin). 
Figure 4.33 shows that both the ethanol and water extracts of P. tinctorius promoted 
NO production in the absence of LPS. In the presence of LPS, however, the 200 
μg/ml ethanol and water extracts of P. tinctorius significantly inhibited NO production 
compared to the LPS stimulated cells, thus demonstrating both pro-inflammatory and 
anti-inflammatory activities. From figure C it is evident that neither the ethanol nor 
the water extracts of P. tinctorius were able to overcome the significant inhibition of 
NO caused by the addition of glycated gelatin despite the robust NO production 
observed when the cells were treated with these extracts (figure A). Furthermore, 
both extracts enhanced the decrease in NO observed in the presence of glycated 
gelatin, potentially confirming the anti-inflammatory activity reported in figure B. Due 
to the comparatively strong NO scavenging capabilities of P. tinctorius demonstrated 
in figure 4.22, however, it is possible that the decrease in NO observed in the 
presence of LPS was not due to anti-inflammatory activities but rather due to NO 
scavenging. 
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Figure 4.34: Nitric oxide production of RAW 264.7 cells treated with R. capensis (A) without 
LPS, (B) with LPS and (C)  with glycated gelatin and LPS; results are reported 
as means ± SD where each experiment was performed three times, each in 
triplicate (*/°/∆p<0.05; **/°°/∆∆p<0.01; ***/°°°/∆∆∆p<0.005 where * compared to 
untreated sample; ° compared to LPS stimulated; ∆ compared to glycated 
gelatin). 
As seen in figure 4.34 A, no pro-inflammatory activities were reported for the ethanol 
extract of R. capensis as it did not promote NO production in the absence of LPS. 
Conversely, the water extract resulted in a robust dose-dependent increase in NO 
production (p<0.005) by the RAW 264.7 macrophages. In the presence of LPS, only 
the 200 μg/ml ethanol extract of R. capensis significantly inhibited NO production 
(p<0.05). Figure C demonstrates that the 200 μg/ml ethanol extract of R. capensis 
further reduced the quantity of NO measured in the presence of glycated gelatin 
when compared to the glycated gelatin control, confirming the potential anti-
inflammatory activity observed in figure B. 
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Figure 4.35: Nitric oxide production of RAW 264.7 cells treated with B. badius (A) without 
LPS, (B) with LPS and (C)  with glycated gelatin and LPS; results are reported 
as means ± SD where each experiment was performed three times, each in 
triplicate (*/°/∆p<0.05; **/°°/∆∆p<0.01; ***/°°°/∆∆∆p<0.005 where * compared to 
untreated sample; ° compared to LPS stimulated; ∆ compared to glycated 
gelatin). 
No pro-inflammatory NO production was observed in figure 4.35 in the absence of 
LPS for the ethanol extract of B. badius, however, the water extract displayed strong 
pro-inflammatory activity (p<0.005). In the presence of LPS, no significant alterations 
in NO production occurred except for treatment with the 200 μg/ml water extract 
which increased NO production to 117 % (p<0.01). Figure C shows that the 200 
μg/ml ethanol extract further reduced the quantity of NO measured in the presence 
of glycated gelatin when compared to treatment with glycated gelatin alone. As no 
measurable NO scavenging activity was reported for this particular extract (figure 
4.24), the observed decrease in NO suggests potential anti-inflammatory activities 
for the ethanol extract of B. badius. 
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Figure 4.36: Nitric oxide production of RAW 264.7 cells treated with P. ostreatus (A) without 
LPS, (B) with LPS and (C)  with glycated gelatin and LPS; results are reported 
as means ± SD where each experiment was performed three times, each in 
triplicate (*/°/∆p<0.05; **/°°/∆∆p<0.01; ***/°°°/∆∆∆p<0.005 where * compared to 
untreated sample; ° compared to LPS stimulated; ∆ compared to glycated 
gelatin). 
Figure 4.36 A shows that the ethanol extract of P. ostreatus did not promote NO 
production in the absence of LPS while a weak pro-inflammatory response was 
recorded for the water extract. In the presence of LPS, only the 200 μg/ml ethanol 
extract of P. ostreatus significantly reduced the quantity of NO measured, suggesting 
potential anti-inflammatory activity. In the presence of glycated gelatin, the 200 μg/ml 
ethanol extract resulted in a further decrease in NO compared to treatment with 
glycated gelatin alone. Since no substantial NO scavenging activity was 
demonstrated in figure 4.25, this confirms the presence of anti-inflammatory 
compounds present in the extract. 
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Figure 4.37: Nitric oxide production of RAW 264.7 cells treated with G. lucidum (A) without 
LPS, (B) with LPS and (C)  with glycated gelatin and LPS; results are reported 
as means ± SD where each experiment was performed three times, each in 
triplicate (*/°/∆p<0.05; **/°°/∆∆p<0.01; ***/°°°/∆∆∆p<0.005 where * compared to 
untreated sample; ° compared to LPS stimulated; ∆ compared to glycated 
gelatin). 
Due to the cytotoxicity of the ethanol extract of G. lucidum (figure 4.21), only the 
water extract was subjected to further cell-based screening assays. Figure 4.37 A 
shows that the water extract of G. lucidum did not stimulate NO production in the 
absence of LPS nor did it result in any anti-inflammatory decreases in NO production 
in the presence of LPS. Furthermore, no alterations in NO production were 
measured in the presence of glycated gelatin, confirming that this extract does not 
induce any noteworthy anti-inflammatory or pro-inflammatory effects with regards to 
NO production. 
In order to eliminate any false positives in NO production in the absence of LPS due 
to the presence of endotoxins in the tested mushroom extracts, NO production in 
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RAW 264.7 macrophages was re-assessed with the addition of Polymyxin B sulfate. 
The quantity of NO produced was assessed using the Griess reaction. The cytotoxic 
effect of Polymyxin B sulphate against RAW 264.7 cells was first established in order 
to select an appropriate concentration to use for further experiments. A dose-
response curve for the Polymyxin B sulfate is shown in figure 4.38 while the 
experimental results for each of the mushroom extracts are shown in figure 4.39. All 
extracts, except for the ethanol extract of G. lucidum, were tested at concentrations 
of 100 and 200 μg/ml as no physiologically significant cell death was recorded during 
the cytotoxicity screening assay (section 4.2.1) at these concentrations. The 
untreated sample consisted of high-glucose DMEM supplemented with 10 % FBS 
where LPS (200 ng/ml) represented 100 % NO production and all treatments were 
thus calculated as a percentage of the LPS control. Statistical analysis was 
performed individually for each individual extract using the response without LPS 
recorded previously (figures 4.33 to 4.37 A) as a reference sample in order to 
establish whether any statistically relevant decreases in NO production occurred in 
the presence of Polymyxin B sulfate. 
 
 
 
 
 
 
 
Figure 4.38: Dose-response effect of Polymyxin B sulfate on RAW 264.7 macrophage cell 
number after 48 hours; results are reported as means ± SD with this 
experiment being performed once in triplicate (*p<0.05; **p<0.01; ***p<0.005 
compared to 0 %). 
A dose-dependent decrease in the total RAW 264.7 cell number coupled to an 
increase in cell death can be seen in figure 4.38 as the concentration of Polymyxin B 
sulfate increases. In order to effectively identify potential false positives in the 
stimulation of NO, a non-toxic concentration of polymyxin B had to be selected. The 
concentration deemed most suitable for this assay was identified as 10 μg/ml as a 
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lower concentration might not result in any measurable effects on NO production in 
the presence of endotoxins while higher concentrations inhibited cell proliferation by 
more than 20 % and promoted substantial cell death and could thus potentially 
interfere with the results. 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 4.39: Assessment of the presence of endotoxins using RAW 264.7 macrophages with 
10 μg/ml Polymyxin B sulfate for (A) P. tinctorius (B) R. capensis (C) B. badius 
(D) P. ostreatus and (E) G. lucidum; results are reported as means ± SD where 
each experiment was performed three times, each in triplicate (ǂp<0.05; 
ǂǂp<0.01; ǂǂǂp<0.005 compared to LPS for polymyxin B and each extract 
without polymyxin B, respectively). 
Figure 4.39 shows that polymyxin B resulted in a robust decrease in the NO 
production of RAW 264.7 cells in the presence of LPS, thus confirming the 
functionality of this assay. Only two extracts were found to potentially contain 
endotoxins, namely the water extracts of R. capensis and P. ostreastus as 
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evidenced from the attenuation of NO production (p<0.005) in the presence of LPS 
when compared to the relevant treatment without polymyxin B. Further endotoxin 
analysis is thus required to confirm the presence of endotoxins. 
4.3.2. Phagocytosis  
The phagocytic capability of RAW 264.7 macrophages was assessed in figures 4.40 
to 4.44 using the pHrodo® Green E. coli BioParticles® Conjugate. As phagocytosis is 
characterized by the formation of acidic phagolysosomes, LysoTracker Red® was 
included in this assay in order to simultaneously monitor acidic vacuole formation. 
The ability of each mushroom extract to overcome the inhibition of phagocytosis 
observed in section 4.1.5 induced by glycated gelatin was assessed here. Extracts 
were tested at a concentration of 100 μg/ml in order to eliminate factors that could 
interfere with cell processes other than phagocytosis as some extracts exerted 
potential anti-proliferative effects on the RAW 264.7 cells at higher concentrations in 
section 4.2.1. The untreated sample consisted of high-glucose DMEM supplemented 
with 10 % FBS and all samples were calculated as a percentage of this control while 
cytochalasin B and LPS were included as a positive controls to inhibit phagocytosis 
and activate phagocytosis, respectively. 
 
 
 
 
Figure 4.40: RAW 264.7 cell phagocytosis after treatment with P. tinctorius measuring (A) 
acidic vacuole formation using LysoTracker Red® and (B) phagocytosis using 
pHrodo® Bioparticles®; results are reported as means ± SD where each 
experiment was performed three times, each in triplicate (*p<0.05; **p<0.01; 
***p<0.005 compared to untreated sample).  
From figure 4.40 it is evident that neither the ethanol nor the water extracts of P. 
tinctorius resulted in any noteworthy alterations in acidic vacuole formation. Figure B 
shows that there was a robust decrease in phagocytosis for both the 100 μg/ml 
ethanol and water extracts of P. tinctorius when compared to the untreated sample, 
however, this can be attributed to the negative effect of AGEs on phagocytosis 
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(figure 4.7). When all three experiments were combined, the standard deviation for 
LTR was rather large, however, individual experiments shown in figure C.2 from 
appendix C show that the standard deviations were much smaller for individual 
experiments. In all three individual experiments the mean cell integrated intensity of 
LTR for the ethanol extract of P. tinctorius was significantly higher than the glycated 
gelatin sample while the water extract was significantly higher than the glycated 
gelatin for only two of the individual experiments. An increase in acidic vacuole 
formation coupled to a decrease in phagocytosis could be an indication of 
autophagy.  
 
 
 
 
Figure 4.41: RAW 264.7 cell phagocytosis after treatment with R. capensis measuring (A) 
acidic vacuole formation using LysoTracker Red® and (B) phagocytosis using 
pHrodo® Bioparticles®; results are reported as means ± SD where each 
experiment was performed three times, each in triplicate (*p<0.05; **p<0.01; 
***p<0.005 compared to untreated sample). 
Figure 4.41 shows that the 100 μg/ml ethanol extract of R. capensis resulted in a 
significant increase in acidic vacuole formation. Furthermore, there was no 
noteworthy difference in phagocytosis between the untreated sample and the 
ethanol extract due to the large variation between individual experiments. Individual 
experiments shown in figure C.3 from appendix C show that the ethanol extract of R. 
capensis significantly increased macrophage phagocytosis when compared to the 
glycated gelatin for all three individual experiments while the water extract increased 
phagocytosis in only one of these experiments. The increase in both acidic vacuole 
content and phagocytosis suggests that the ethanol extract of R. capensis was able 
to reverse the negative effect of glycated protein on macrophage phagocytosis. 
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Figure 4.42: RAW 264.7 cell phagocytosis after treatment with B. badius measuring (A) 
acidic vacuole formation using LysoTracker Red® and (B) phagocytosis using 
pHrodo® Bioparticles®; results are reported as means ± SD where each 
experiment was performed three times, each in triplicate (*p<0.05; **p<0.01; 
***p<0.005 compared to untreated sample). 
Figure 4.42 A shows that there was no significant increase in acidic vacuole 
formation for either the ethanol or water extracts of B. badius while figure B 
demonstrates that neither the ethanol nor the water extract were able to overcome 
the negative effect of the glycated gelatin on RAW 264.7 macrophage phagocytosis. 
 
 
 
 
Figure 4.43: RAW 264.7 cell phagocytosis after treatment with P. ostreatus measuring (A) 
acidic vacuole formation using LysoTracker Red® and (B) phagocytosis using 
pHrodo® Bioparticles®; results are reported as means ± SD where each 
experiment was performed three times, each in triplicate (*p<0.05; **p<0.01; 
***p<0.005 compared to untreated sample). 
It is evident from figure 4.43 that the 100 μg/ml ethanol extract of P. ostreatus 
resulted in a significant increase in acidic vacuole formation. No significant difference 
in phagocytosis was seen for either extract when compared to the untreated sample, 
however, individual experiments in figure C.4 from appendix C show that the water 
extract of P. ostreatus resulted in a significant increase in phagocytosis when 
compared to the glycated gelatin sample for all three experiments while the ethanol 
extract significantly promoted phagocytosis in only one of these experiments. This 
suggests that the ethanol extract of P. ostreatus could potentially overcome the 
impairment of phagocytosis induced by protein glycation. 
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Figure 4.44: RAW 264.7 cell phagocytosis after treatment with G. lucidum measuring (A) 
acidic vacuole formation using LysoTracker Red® and (B) phagocytosis using 
pHrodo® Bioparticles®; results are reported as means ± SD where each 
experiment was performed three times, each in triplicate (*p<0.05; **p<0.01; 
***p<0.005 compared to untreated sample). 
Figure 4.44 shows that no significant changes in acidic vacuole formation or 
phagocytosis for the RAW 264.7 macrophages was observed for the 100 μg/ml 
water extract of G. lucidum and this mushroom extract was thus incapable of 
overcoming the negative effect of AGEs on phagocytosis. 
4.3.3. M1/M2 macrophage polarization 
The activation status of RAW 264.7 macrophages was further assessed using 
antibodies for the CD86 cell surface receptor as a measure of M1 activation (pro-
inflammatory) and the CD206 cell surface receptor for M2 activation (anti-
inflammatory) (figure 4.45 to 4.49). The untreated sample consisted of high-glucose 
DMEM (25 mM) supplemented with 10 % FBS. LPS (200 ng/ml) was used as a 
positive control for M1 activation while curcumin (20 μM) served as a positive control 
for M2 activation. A ratio of M1:M2 was calculated for each of the mushroom extracts 
by dividing the percentage of cells stained positive for CD86 by the percentage of 
cells stained positive for CD206. These results are summarised in table 4.1. As 
diabetic wounds are characterized by an increased population of M1 macrophages 
which consequently prolongs the inflammatory phase of wound healing, a favourable 
reaction in response to treatment with the mushroom extracts would be indicated by 
a reduction in the activation of M1 macrophages coupled to an increase in M2 
macrophage activation. 
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Table 4.1: M1/M2 ratios calculated during the macrophage polarization assay. 
 Glycated 
gelatin 
P. tinctorius R. capensis B. badius P. ostreatus G. 
lucidum 
Extract  EtOH H2O EtOH H2O EtOH H2O EtOH H2O H2O 
Ratio 4.5 1.24 0.51 0.94 1.24 4.06 1.55 2.4 1.59 1.41 
 
As glycated gelatin was shown to promote M1 macrophage activation in section 
4.1.6 and consequently contribute to the pathological inflammation observed during 
diabetic wound healing, a favourable outcome with regards to macrophage 
polarization would be characterized by a low M1:M2 ratio due to a decrease in M1 
activation, an increase in M2 activation, or both. Table 4.1 shows several promising 
candidates with M1:M2 ratios below 2 which are discussed in more detail below.  
 
 
 
 
Figure 4.45: Macrophage polarization following treatment with P. tinctorius using (A) CD86 
for M1 macrophages and (B) CD206 for M2 macrophages; results are reported 
as means ± SD where each experiment was performed three times, each in 
triplicate (*p<0.05; **p<0.01; ***p<0.005 compared to untreated sample). 
Neither the ethanol nor the water extracts of P. tinctorius were able to lower the 
percentage of M1 activated cells induced by glycated gelatin, however, substantial 
increases (p<0.05) in M2 activation occurred in response to both extracts (figure 
4.45). This suggests that both extracts of P. tinctorius could promote the transition 
from M1 to M2 macrophages required for the final tissue remodelling stage of wound 
healing to proceed. The results from table 4.1 and figure 4.45 provide sufficient 
evidence that both the ethanol and water extracts of P. tinctorius could promote 
favourable macrophage polarization during impaired wound healing with the water 
extract having the most potent effect of all of the tested extracts as evidenced by the 
lowest M1:M2 ratio of 0.51. 
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Figure 4.46: Macrophage polarization following treatment with R. capensis using (A) CD86 
for M1 macrophages and (B) CD206 for M2 macrophages; results are reported 
as means ± SD where each experiment was performed three times, each in 
triplicate (*p<0.05; **p<0.01; ***p<0.005 compared to untreated sample). 
From table 4.1, the M1:M2 ratios for the ethanol and water extracts of R. capensis 
were calculated to be 0.94 and 1.24, respectively. While these comparatively low 
ratios cannot be accounted for by a decrease in M1 macrophage activation, figure 
4.46 shows that both extracts caused a robust increase in the percentage of M2 
activated cells. R. capensis could thus prove to be very useful in attenuating the 
inflammatory response. 
 
 
 
 
Figure 4.47: Macrophage polarization following treatment with B. badius using (A) CD86 for 
M1 macrophages and (B) CD206 for M2 macrophages; results are reported as 
means ± SD where each experiment was performed three times, each in 
triplicate (*p<0.05; **p<0.01; ***p<0.005 compared to untreated sample). 
The 100 μg/ml ethanol and water extracts of B. badius were not able to reduce the 
percentage of M1 activated macrophages, however, the water extract appears to 
have successfully increased the M2 macrophage population as shown in figure 4.47. 
Consequently, the water extract yielded a highly promising M1:M2 ratio of 1.55 
compared to 4.06 for the water extract (table 4.1). 
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Figure 4.48: Macrophage polarization following treatment with P. ostreatus using (A) CD86 
for M1 macrophages and (B) CD206 for M2 macrophages; results are reported 
as means ± SD where each experiment was performed three times, each in 
triplicate (*/∆p<0.05; **/∆∆p<0.01; ***/∆∆∆p<0.005 where *compared to 
untreated sample; ∆ compared to glycated gelatin). 
According to table 4.1, the ethanol extract yielded an M1:M2 ratio of 2.4 compared to 
the water extract which yielded a much more promising value of 1.55. Figure 4.48 
illustrates that while both the ethanol and water extracts of P. ostreatus were equally 
capable of successfully attenuating M1 macrophage activation induced by glycated 
gelatin (p<0.05), only the water extract was able to promote M2 macrophage 
activation. Although this increase in M2 activation was not found to be statistically 
significant due to the variance between individual experiments, it can still account for 
the much reduced M1:M2 ratio recorded for the water extract which was the only 
extract able to affect both M1 and M2 macrophage polarization. 
 
 
 
 
 
 
Figure 4.49: Macrophage polarization following treatment with G. lucidum using (A) CD86 for 
M1 macrophages and (B) CD206 for M2 macrophages; results are reported as 
means ± SD where each experiment was performed three times, each in 
triplicate (*/∆p<0.05; **/∆∆p<0.01; ***/∆∆∆p<0.005 where *compared to 
untreated sample; ∆ compared to glycated gelatin). 
Figure 4.49 shows that the 100 μg/ml water extract of G. lucidum significantly 
reduced the percentage of M1 activated cells when compared to treatment with the 
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glycated gelatin alone. Furthermore, no significant changes in M2 macrophage 
activation occurred, accounting for the comparatively favourable M1:M2 ratio of 1.41. 
4.3.4. NF-ĸB translocation 
The role of NF-ĸB in inflammation has been well established and this transcription 
factor has subsequently been identified as a favourable target during the search for 
useful diabetic wound healing treatment strategies. The ability of NF-ĸB to directly 
induce the expression of several pro-inflammatory markers suggests that any 
mushroom extract capable of attenuating the enhanced nuclear-translocation and 
subsequent activation of NF-ĸB in response to protein glycation (figure 4.1.7) could 
have unparalleled advantages in promoting functional wound healing in diabetic 
individuals. The effect of each mushroom extract on the nuclear translocation of 
phsopho-p65 NF-ĸB in RAW 264.7 macrophages in the presence of glycated gelatin 
was assessed in figure 4.50. The untreated sample consisted of high-glucose DMEM 
(25 mM) supplemented with 10 % FBS with all other treatments calculated as a 
percentage of this control. LPS (200 ng/ml) was used as a positive control to 
stimulate NF-ĸB translocation.  
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Figure 4.50: NF-ĸB nuclear translocation after treatment with (A) P. tinctorius, (B) R. 
capensis, (C) B. badius, (D) P. ostreatus and (E) G. lucidum; results are 
reported as means ± SD where each experiment was performed three times, 
each in triplicate (*p<0.05; **p<0.01; ***p<0.005 compared to the untreated 
sample). 
According to figure 4.50, none of the tested mushroom extracts were able to 
attenuate the nuclear translocation of phospho-p65 NF-ĸB back to the levels 
observed in the untreated sample, suggesting that none of the selected mushroom 
species can promote normal wound healing through this pathway. While there was 
no significant difference in nuclear translocation between the untreated sample and 
the 100 μg/ml water extracts of both P. ostreatus and G. lucidum, the variation 
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between individual experiments resulted in no significant difference between these 
treatments when compared to the glycated gelatin alone. Further investigations are 
thus required to confirm the effects of these extracts on NF-ĸB nuclear translocation. 
4.3.5. COX-2 
One of the pro-inflammatory signalling molecules activated by NF-ĸB is COX-2. In 
section 4.1.8, glycated gelatin alone did not promote COX-2 activity, however, in the 
presence of LPS an additive effect on COX-2 expression was recorded. As a result, 
the effect of each mushroom extract on COX-2 activity in the absence and presence 
of LPS was analysed in figure 4.51 in order to gain a deeper understanding of the 
inflammatory status of RAW 264.7 macrophages in response to various treatments. 
The untreated sample consisted of high-glucose DMEM (25 mM) supplemented with 
10 % FBS while LPS (200 ng/ml) was used as a positive control. 
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Figure 4.51: COX-2 antibody staining after treatment with (A) P. tinctorius, (B) R. capensis, 
(C) B. badius, (D) P. ostreatus and (E) G. lucidum; results are reported as 
means ± SD where each experiment was performed three times, each in 
triplicate (Ɨ/∆p<0.05; ƗƗ /∆∆p<0.01; ƗƗƗ /∆∆∆p<0.005 where Ɨ compared to glycated 
gelatin without LPS; ∆ compared to glycated gelatin with LPS). 
Figure 4.51 shows that several of the mushroom extracts including the 100 μg/ml 
ethanol and water extracts of P. tinctorius as well as the water extracts of R. 
capensis, B. badius and P. ostreatus significantly increased COX-2 activity in the 
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absence of LPS. Four out of the five water extracts tested during this study were 
thus shown to contain compounds with substantial pro-inflammatory activities. In the 
presence of LPS, however, all the tested extracts except for the water extract of P. 
ostreatus resulted in noteworthy reductions in COX-2 activity in the presence of 
glycated gelatin. The presence of both pro-inflammatory and anti-inflammatory 
compounds in several of the selected mushroom species was thus confirmed and 
the overall effect of each mushroom on the inflammatory process has yet to be 
established.  
4.4. THE ROLE OF FIBROBLASTS IN WOUND HEALING 
Fibroblasts perform import functions during the proliferation and tissue repair 
processes of wound healing, secreting collagen and various other factors required 
for the formation of a functional ECM. In section 4.1.9, glycated gelatin was found to 
impair both the proliferation and the migration abilities of MRHF fibroblasts thus 
mimicking the effects of diabetes on in vivo fibroblast function. The ability of the 
selected mushroom extracts to overcome the observed impairment in fibroblast 
activity was addressed in this section in order to identify any sample potentially 
capable of promoting the final stage of wound healing as well as to gain deeper 
insight with regards to the capabilities and limitations of each extract. 
4.4.1. Proliferation 
MRHF fibroblast proliferation was assessed using Hoechst 33342 and PI staining. 
An FBS-dose response curve shown in figure 4.52 was used to determine the 
concentration of FBS that should be used to support sub-optimal MRHF fibroblast 
proliferation without causing any significant cytotoxicity. In this assay a sub-optimal 
proliferation rate is considered advantageous as optimal conditions leave little scope 
for the test samples to further stimulate proliferation.  
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Figure 4.52: FBS dose-response effect on MRHF fibroblast cell number after 72 hours; 
results are reported as means ± SD with this experiment being performed once 
in triplicate (*p<0.05; **p<0.01; ***p<0.005 compared to 10 % FBS). 
A steep dose-dependent decrease in fibroblast cell number was observed as the 
concentration of FBS was reduced from 10 % down to 1 %, followed by a more 
gradual decline between 1 % and 0 % FBS (figure 4.52). The absence of FBS was 
not found to exert any cytotoxic effects on the fibroblasts as no increase in cell death 
was reported at any of the tested concentrations. Based on these findings, 1 % FBS 
was selected for all further proliferation experiments as the 20 % decrease in 
proliferation was deemed sufficiently low to allow for a measurable effect without 
inducing any potentially harmful effects. 
The effect of each mushroom extract on fibroblast proliferation in the absence and 
presence of glycated gelatin are shown in figures 4.53 to 4.57. The untreated sample 
consisted of low-glucose DMEM supplemented with 1 % FBS while low glucose 
DMEM supplemented with 10 % FBS served to define optimal cell growth. The 
untreated cells cultured in 1 % FBS thus represented 100 % fibroblast proliferation 
and all other treatments were calculated as a percentage of this control. Concurrent 
assessment of the cell viability was used to confirm that proliferation is not influenced 
by cell death. 
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Figure 4.53: MRHF fibroblast proliferation in response to treatment with P. tinctorius (A) 
without glycated gelatin and (B) with glycated gelatin; results are reported as 
means ± SD where each experiment was performed three times, each in 
triplicate (*/∆p<0.05; **/∆∆p<0.01; ***/∆∆∆p<0.005 where *compared to 
untreated control containing 1 % FBS; ∆ compared to glycated gelatin). 
From figure 4.53 A it is evident that the 100 μg/ml water extract of P. tinctorius was 
the only extract that significantly increased fibroblast proliferation in the presence of 
1 % FBS while the 200 μg/ml ethanol extract significantly impaired fibroblast 
proliferation when compared to the untreated sample. The 200 μg/ml ethanol extract 
and both concentrations of the water extracts were able to restore fibroblast 
proliferation back to the levels observed for the 1 % FBS control sample and were 
thus shown to overcome the negative effect observed in response to the AGEs 
(figure B). 
 
 
   
 
Figure 4.54: MRHF fibroblast proliferation in response to treatment with R. capensis (A) 
without glycated gelatin and (B) with glycated gelatin; results are reported as 
means ± SD where each experiment was performed three times, each in 
triplicate (*/∆p<0.05; **/∆∆p<0.01; ***/∆∆∆p<0.005 where *compared to 
untreated control containing 1 % FBS; ∆ compared to glycated gelatin). 
The 100 μg/ml ethanol extract of R. capensis significantly impaired fibroblast 
proliferation in (figure 4.54 A) in the presence of 1 % FBS while the 200 μg/ml 
ethanol extract appears to have killed all the fibroblast cells. The same cytotoxicity 
was not reported in section 4.2.1 in the presence of 10 % FBS, thus demonstrating 
the importance of assessing both parameters. The 100 μg/ml water extract also 
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appears to have impaired fibroblast proliferation, however, the same was not 
observed for the fibroblasts treated with the 200 μg/ml water extract. From figure B, 
neither the ethanol nor the water extracts were able to overcome the impairment in 
fibroblast proliferation caused by the glycated gelatin with the ethanol extract causing 
more damage than the glycated gelatin alone. 
 
 
 
 
Figure 4.55: MRHF fibroblast proliferation in response to treatment with B. badius (A) without 
glycated gelatin and (B) with glycated gelatin; results are reported as means ± 
SD where each experiment was performed three times, each in triplicate 
(*/∆p<0.05; **/∆∆p<0.01; ***/∆∆∆p<0.005 where *compared to untreated control 
containing 1 % FBS; ∆ compared to glycated gelatin). 
The ethanol extract of B. badius was found to significantly impair fibroblast 
proliferation in a dose-dependent manner in the presence of 1 % FBS while the 
water extract did not cause any measurable alterations when compared to the 
untreated sample (figure 4.55 A). Consequently, figure B shows that only the water 
extract of B. badius was able to overcome the impairment in MRHF fibroblast 
proliferation caused by the glycated gelatin (p<0.05), suggesting that it might prove 
useful in restoring the correct fibroblast function. 
 
 
 
 
Figure 4.56: MRHF fibroblast proliferation in response to treatment with P. ostreatus (A) 
without glycated gelatin and (B) with glycated gelatin; results are reported as 
means ± SD where each experiment was performed three times, each in 
triplicate (*/∆p<0.05; **/∆∆p<0.01; ***/∆∆∆p<0.005 where *compared to 
untreated control containing 1 % FBS; ∆ compared to glycated gelatin). 
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Figure 4.56 A shows that the ethanol and water extracts of P. ostreatus did not have 
any significant effects on the proliferative capability of MRHF fibroblasts in the 
presence of 1 % FBS in comparison to the untreated sample. Furthermore, only the 
200 μg/ml water extract significantly enhanced fibroblast proliferation in the presence 
of glycated gelatin, suggesting very limited potential for this extract to overcome the 
impairment in fibroblast proliferation caused by the glycated gelatin in figure B.  
 
 
 
 
 
Figure 4.57: MRHF fibroblast proliferation in response to treatment with G. lucidum (A) 
without glycated gelatin and (B) with glycated gelatin; results are reported as 
means ± SD where each experiment was performed three times, each in 
triplicate (*/∆p<0.05; **/∆∆p<0.01; ***/∆∆∆p<0.005 where *compared to 
untreated control containing 1 % FBS; ∆ compared to glycated gelatin). 
From figure 4.57 A, the 100 and 200 μg/ml concentrations of the water extract of G. 
lucidum both significantly impaired fibroblast proliferation in the presence of 1 % FBS 
when compared to the untreated sample, however, figure B shows that the water 
extract was indeed able to overcome the impairment in proliferation caused by the 
glycated gelatin. Several of the tested mushroom extracts were thus able to promote 
fibroblast proliferation in the presence of glycated gelatin and could potentially 
overcome the impairment in the proliferative capacity of fibroblasts demonstrated by 
fibroblasts isolated from diabetic wounds. 
4.4.2. Migration 
Considering the variable effects of the mushroom extracts on fibroblast proliferation, 
MRHF fibroblast migration was assessed in the presence of the proliferation inhibitor 
mitomycin C (from Streptomyces caespitosus) using the Enzo® Cell Migration Assay 
kit. A mitomycin C dose-response toxicity curve was established (figure 4.58) and 
used to select an appropriate concentration for the migration experiments (figure 
4.59). The untreated sample consisted of low-glucose DMEM supplemented with 10 
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% FBS. The micrographs captured after 48 hours were analysed using T-Scratch 
software in order to calculate the percentage wound closure. The scratch assay was 
performed prior to this migration assay in an attempt to identify suitable candidates 
for promoting fibroblast migration in the presence of glycated gelatin (results not 
shown) and consequently, only the most promising extracts were selected for this 
assay.   
 
 
 
 
 
Figure 4.58: Mitomycin C dose-response curve for MRHF fibroblast proliferation after 72 
hours where live and dead cell numbers were obtained using Hoechst 33342 
and PI staining, respectively; results are reported as means ± SD with this 
experiment being performed once in triplicate (*p<0.05; **p<0.01; ***p<0.005 
compared to 0 % sample). 
Figure 4.58 shows that mitomcyin C resulted in a significant decrease in MRHF 
fibroblast proliferation in comparison to the untreated sample. A statistically 
significant dose-dependent increase in cell death was observed at concentrations of 
2.5 μg/ml and above, however, these values were not considered physiologically 
relevant as the difference in cell death between the untreated sample (0 %) and the 
10 μg/ml treatment was only 4 %. Consequently, a mitomycin C concentration of 10 
μg/ml was selected for further experimentation. 
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Figure 4.59: MRHF fibroblast migration using the Enzo® Cell Migration Assay kit in response 
to treatment with (A) R. capensis, (B) B. badius and (C) G. lucidum; results are 
reported as means ± SD where each experiment was performed three times, 
each in triplicate (*/∆p<0.05; **/∆∆p<0.01; ***/∆∆∆p<0.005 where *compared to 
untreated sample; ∆ compared to glycated gelatin). 
According to figure 4.59, the 100 μg/ml ethanol and water extracts of R. capensis 
and B. badius as well as the water extract of G. lucidum all resulted in significant 
increases in MRHF fibroblast migration when compared to treatment with glycated 
gelatin alone (p<0.005). The water extract of G. lucidum, however, was able to 
restore the migratory potential of the fibroblasts back to that seen in the untreated 
sample and was subsequently identified as the most promising extract for promoting 
normal fibroblast migration in diabetes. 
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CHAPTER 5: DISCUSSION 
Increasing evidence suggests that the dermal accumulation of AGEs remains the 
underlying cause of impaired wound healing in diabetic individuals (Liao et al., 2009). 
While several models have been used to study diabetic wound healing, many of 
these do not suitably mimic the diabetic state while the high cost associated with 
purified proteins such as collagen and albumin poses a limitation to many 
laboratories (Mendes et al., 2012; Boonkaew et al., 2014). Furthermore, the process 
during which glycated proteins are produced in sufficient quantities for screening 
purposes is extremely challenging as the glycation of native proteins is very time 
consuming, taking several weeks to months, with a consequently large risk of 
microbial contamination. For these reasons, this study aimed to develop and 
characterize a more convenient and cost effective in vitro model to study diabetic 
wound healing using glycated gelatin as a surrogate protein. 
5.1. CHARACTERIZATION OF THE GLYCATED GELATIN MODEL 
Collagen is a major constituent of dermal tissue making up approximately 70 to 80 % 
of the dry weight of skin. Collagen consequently performs several important 
functions during the wound healing process including the provision of a structural 
scaffold and the regulation of cellular functions such as differentiation, migration and 
protein synthesis (Brett, 2008). Gelatin is a denatured form of collagen and was 
consequently identified as a suitable, more cost-effective, abundantly available 
alternative to collagen. Gelatin has been classified as a useful hydrocolloid with low 
toxicity and comprises all the amino acids except tryptophan. Furthermore, only very 
few tyrosine, methionine and cysteine residues are present as most of them are 
degraded during the hydrolysis of collagen to produce gelatin (Raja Mohd Hafidz et 
al., 2011; Duconseille et al., 2015).  
Collagen consists of three α-chains which interact together to form a triple helix. The 
presence of the Gly-Pro-Hyp motif in the α-chain causes it to adopt an unstable left-
handed helical conformation. Consequently, three α-chains will interact to form a 
highly stable right-handed triple helix stabilised by both intra and inter-chain 
hydrogen bonds where the glycine residues are buried within the centre of the helix 
and the side chains containing the X and Y residues remain exposed to the solvent 
(Duconseille et al., 2015). While the amino acid composition and sequence of gelatin 
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differs according to its source and method of extraction and purification, the primary 
sequence consists of the same repetitive Gly-X-Y unit found in collagen where 
glycine is the most abundant amino acid and X and Y can be any amino acid but are 
usually proline and hydroxyproline, respectively (Raja Mohd Hafidz et al., 2011).  
During the denaturation process to form gelatin, the native triple-helical conformation 
of collagen is lost. The hydrolytic cleavage of collagen yields several fragments and 
gelatin thus consists of a mixture of fragments that are joined by peptide bonds to 
form polymers of varying mass. Upon cooling, the individual fibres are able to only 
partially recover their helical structure as water becomes trapped in the mesh of 
chains. Gelatin thus consists of junction zones composed of individual triple-helixes 
or triple-helix aggregates where the quantity of helix structures is directly proportional 
to the concentration of the gelatin (Pena et al., 2010; Duconseille et al., 2015).  
The structure of gelatin is influenced by several factors including pH, temperature 
and concentration. An important characteristic of gelatin is its ability to form thermo-
reversible gels in water. When aqueous solutions containing gelatin concentrations 
greater than 0.5 % are cooled to between 35 and 40 °C, an increase in viscosity 
followed by the formation of a gel occurs. The helical structures formed in gelatin 
gels are stabilised by several interactions including hydrogen bonds, hydrophobic 
interactions, electrostatic interactions and cross-links (Gelatin Manufacturers Institute 
of America, 2012; Duconseille et al., 2015). 
There has been much controversy with regards to the three-dimensional structure of 
gelatin. The “fringed-micelle” model describes the presence of microcrystallites 
interconnected with amorphous segments of randomly coiled fragments. In another 
model, however, local regions of protein quaternary structure have been proposed. 
These structures are deemed to be self-limiting in terms of their size and can exist as 
either a triple-helix or a partial triple-helix and may include β-turn as well as β-sheet 
motifs (Pena et al., 2010).  
5.1.1. The autofluorescence of advanced glycation end products 
While gelatin naturally contains several cross-links which help to stabilise its 
structure, certain environmental conditions such as temperature and UV light have 
been shown to increase the formation of these cross-links. No specification with 
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regards to the time or rate of exposure required to produce the cross-links have been 
defined, however, it has been suggested that high temperatures above 105 °C 
should lead to an increase in cross-link formation. Furthermore, little knowledge with 
regards to which cross-links are formed in response to environmental factors as well 
as their mechanism of action is available (Duconseille et al., 2015). 
As previously explained, chronically elevated blood glucose levels witnessed in 
diabetic individuals leads to the formation of AGEs through the glycation process. 
During glycation, glucose forms covalent adducts with collagen, haemoglobin and 
several plasma proteins including albumin and fibrinogen (Singh et al., 2014). 
Various sugars have been successfully used as cross-linking agents of gelatin, 
however, at physiological temperatures this process requires several days to weeks 
(Masutani et al., 2014). Due to the previously mentioned ability of gelatin to form 
thermo-reversible gels, the glycation process can be carried out within minutes under 
the correct conditions without disrupting the structure of the protein. This is in 
contrast to most other proteins which denature at high temperature and 
subsequently form insoluble precipitates, and are thus not suitable for high 
temperature glycation.   
According to a study conducted by Münch et al. (1999), sugars were shown to 
preferentially react with cysteine or tryptophan residues in peptides where the α-
amino group as well as the side chains are free. In peptides containing a blocked N-
terminus but free side chains the amino acids preferred for glycation were cysteine, 
lysine and histidine. Lastly, arginine and tryptophan were the preferred amino acids 
for the crosslinking of protein-AGEs to dipeptides containing free side chains but 
blocked N-termini. It has further been suggested that similar glycation products may 
be formed in proteins with lateral chains of serine, threonine and tyrosine residues 
and glycation reactions are thus not highly dependent on sequence specificity (Xue 
et al., 2011; Oliveira et al., 2013). 
According to this knowledge, the absence of tryptophan residues and the presence 
of very few cysteine residues in gelatin suggests that it is mostly the arginine and 
lysine residues that are glycated, however, due to the incomplete knowledge with 
regards to the three-dimensional structure of gelatin, the exact glycation residues 
have not been established. Glucose-derived AGEs that have been identified in 
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collagen and gelatin include pentosidine and glucosepane (Oliveira et al., 2013; 
Duconseille et al., 2015). 
In order to confirm that the glycation method used during this investigation was 
successful, the intrinsic autofluorescence of AGEs was exploited. Several AGEs 
such as pentosidine are fluorescent and autofluorescence is thus a commonly used 
and simple method employed to evaluate AGE formation in solution. During this 
study, glucose was selected as the carbohydrate of choice to promote the glycation 
process as high blood glucose levels have been identified as the main culprit 
responsible for AGE formation in vivo. Several studies have chosen to use more 
reactive carbohydrates such as ribose, methylglyoxal or glucose 6-phosphate to 
facilitate the glycation reaction due to the apparent low reactivity of glucose in 
solution as a result of its stable chair conformation (Boonkaew et al., 2014). During 
this study, however, the high temperature (120 °C) employed during the glycation 
process provided enough energy to overcome the activation barrier needed to open 
the hemiacetal ring structure of glucose thus allowing it to easily participate in the 
glycation reaction (Nelson & Cox, 2008). 
In figure 4.1 from the results section, the relative fluorescence of various stocks of 
unglycated gelatin, glucose and glycated gelatin were compared. The glycated 
gelatin showed a 5-fold increase in fluorescence when compared to the unglycated 
gelatin thus confirming that the glycation process was indeed successful. Minimal 
increase in the fluorescence was observed when the glycated gelatin was subjected 
to a second round in the autoclave (results not shown), suggesting that the glycation 
process is essentially completed after a single round in the autoclave. Furthermore, 
the addition of the glycation inhibitor, amino-guanidine, was found to attenuate the 
increase in fluorescence and consequent glycation (results not shown).   
5.1.2. Cytotoxicity screening 
Microscopy-based HCS is emerging as a popular tool to measure multiple cell 
parameters simultaneously with subcellular spatial resolution, thus providing much 
deeper insights into various biological processes (Boutros et al., 2015). Due to the 
high cost associated with the required equipment and the complexity to analyse such 
interrelated data, very little has been published to date using HCS, particularly on the 
African continent. For this reason it was decided to compare the accuracy of the 
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cytotoxicity screening results obtained using HCS with the more traditional method of 
measuring cell density using the crystal violet assay. Due to the fact that the 
MetaXpress® software used during this study calculated the total cells by counting 
the number of nuclei in each well, the term ‘cell number’ is used throughout this 
discussion when referring to the data obtained using HCS. Conversely, crystal violet 
stains cellular DNA and proteins and the term ‘cell density’ thus refers to the data 
obtained using the crystal violet assay as it does not give a measure of cell numbers. 
Hoechst 33342 and PI dual staining showed a dose-dependent decrease in RAW 
264.7 macrophage and MRHF fibroblast cell number coupled to a dose-dependent 
increase in cell death in the presence of glycated gelatin (figure 4.3 A and C). No 
significant decrease in cell number was observed for either cell line in response to 
the unglycated gelatin with the only increase in cell death occurring at 2 % for the 
RAW 264.7 cells. This suggests that the AGEs present in the glycated gelatin rather 
than the gelatin itself are responsible for the observed toxicity. The increase in cell 
numbers observed for the RAW 264.7 cells in response to the unglycated gelatin 
may be attributed to the presence of additional adherence factors in the gelatin.  
The same dose-dependent decrease in cell density for both the RAW 264.7 
macrophages and the MRHF fibroblasts was observed during the crystal violet assay 
in response to treatment with glycated gelatin. Upon comparison of the individual 
values obtained here with those of the Hoechst 33342/PI staining, however, it is 
evident that higher values were obtained during the crystal violet assay. Using the 1 
% glycated gelatin as an example, a 20 % decrease (p < 0.05 %)  in cell number was 
observed in the RAW 264.7 macrophages during the nuclear staining method 
compared to an 8 % decrease (not statistically significant)  in cell density during the 
crystal violet assay. The same observation was made for the MRHF fibroblasts. This 
suggests that the crystal violet assay was not as sensitive in detecting reductions in 
cell density as the nuclear staining method.  
Upon comparison of the results obtained during the nuclear staining method with 
those from the crystal violet assay, some discrepancies with regards to the 
macrophage and fibroblast responses to treatment with unglycated gelatin were 
observed. While significant increases in cell number of up to 40 % were reported for 
the macrophages treated with 0.75, 1 and 1.5 % unglycated gelatin, no significant 
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changes in cell density were observed during the crystal violet assay when 
compared to the untreated sample. Similarly for the MRHF fibroblasts, no significant 
alterations in cell number or cell death were observed during the nuclear staining 
method while significant decreases in cell density occurred in the cells treated with 
1.5 and 2% unglycated gelatin. Due to the fact that there are several washing steps 
that must be carried out during the crystal violet assay before and after the cells 
have been fixed, a plausible explanation for this phenomenon is that these 
discrepancies have arisen due to the fact that cells were washed away during the 
crystal violet assay thus leading to inaccurate results. HCS also uses a more direct 
method of analysis by counting the number of nuclei present, whereas crystal violet 
relies on an absorbance reading to determine cell density. 
From the above results, the advantages of using HCS to quantify cell numbers over 
more traditional methods such as the crystal violet assay used during this study are 
obvious. The multiplexing of Hoechst 33342 with PI allows one to accurately 
determine whether a particular treatment is stimulating cell proliferation or whether it 
is anti-proliferative or cytotoxic in one single experiment. Determining cell numbers 
and the percentage of dead cells are the simplest measurements that can be 
obtained from the MetaXpress® software utilised during this assay with much more 
complex data relating to the stain area, cytoplasmic and nuclear fluorescence 
intensities etc. being available should one require it. Further practical advantages of 
HCS include using fewer reagents, the absence of washing steps and much shorter 
incubation periods. Furthermore, the data obtained during HCS takes into account 
the events occurring in every cell that is imaged and the quality of data obtained from 
the imaging software is thus unparalleled to that obtained from experiments such as 
the crystal violet assay where only one absorbance reading is obtained per well. The 
major drawback of HCS is related to the initial cost of the instrumentation and the 
software required. 
5.1.3. The inflammatory response 
Proteins that have been modified by AGEs undergo alterations in their structure and 
consequent function while simultaneously undergoing accelerated degradation to 
free AGEs. Most AGE-induced tissue dysfunction involves receptor-mediated 
mechanisms which stimulate various signalling pathways in several cell types. While 
127 
 
multiple receptors that are able to recognise AGEs have been identified, the RAGE 
receptor is the best studied example and is believed to be responsible for the 
pathogenesis associated with AGE formation. The interaction of AGEs with the 
RAGE receptor has indeed been linked to the pathogenesis of complications 
observed in diabetic patients including impaired wound healing (Xue et al., 2011; 
Singh et al., 2014). 
Activation of the RAGE receptor results in its upregulation and this has been shown 
to stimulate the inflammatory response and oxidative stress. Some of the signalling 
cascades involved in RAGE activation include various members of the MAPK, 
JAK/STAT and Rho GTPase families. Studies have also shown that RAGE activation 
and its resultant up-regulation activates transcription factors such as NF-ĸB and 
early growth response protein 1 (Erg-1) which have been implicated in inflammation. 
The activation of these signalling pathways ultimately leads to the activation of 
several pro-inflammatory genes as well as phenotypic changes in cells relating to 
their migration, proliferation and apoptosis (Oliveira et al., 2013). 
5.1.3.1. Nitric oxide production in activated macrophages 
The addition of LPS resulted in a several-fold increase in RAW 264.7 macrophage 
NO production, confirming that the inflammatory potential of these cells has been 
activated (figure 4.4). Treatment with the glycated gelatin resulted in a significant 
dose-dependent decrease in NO production by the macrophages as the 
concentration of the glycated gelatin was increased from 0.5 % to 2 % when 
compared to the LPS control. No significant differences in NO production were 
observed in the cells treated with unglycated gelatin thus suggesting that the effect 
observed in response to treatment with glycated gelatin was due to the presence of 
AGEs. 
These results are not in agreement with literature which states that hyperglycaemia 
and the resultant formation of AGEs leads to the activation of the RAGE receptor 
whose presence has been confirmed in RAW 264.7 macrophages (Sumi & Ignarro, 
2004). Consequent NF-ĸB activation leads to the induction of several pro-
inflammatory genes including iNOS which ultimately causes an increase in the 
production of NO. Further studies have shown that AGEs induce iNOS expression in 
RAW 264.7 cells through the action of tyrosine kinase, PI3K, P38MAPK as well as 
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PKC (Chang et al., 2004; Sumi & Ignarro, 2004). According to deFronzo et al. 
(2015), a plausible explanation for the observed decrease in NO in the presence of 
AGEs could be attributed to NOS uncoupling from its essential cofactor in response 
to a restriction in the availability of L-arginine. L-arginine is an important source for 
the production of superoxide at sites that have been compromised by diabetes and 
thus superoxide production will be preferred over that of NO. There appears to be 
much controversy with regards to this explanation as temporal changes in NO 
production are observed throughout the progression of diabetic complications. Early 
on in the development of diabetes, for example, an increase in NO production within 
affected tissues is thought to occur in response to changes in NOS activity such as 
described above with regards to RAGE activation. As the disease progresses, 
however, a decline in the function of organs prone to diabetic complications together 
with a state of progressive NO deficiency is observed. This decrease in NO could be 
due to NO scavenging and inhibition by AGEs as well as post-translational 
modifications of NOS. A study conducted by Bucala et al. (1991) confirms that AGEs 
are able to scavenge NO activity both in vitro and in vivo. 
Based on the results from the cytotoxicity screening assay for both RAW 264.7 
macrophages and MRHF fibroblasts as well as those from the Griess reaction, the 
most suitable concentration of glycated gelatin selected to mimic the diabetic state 
was identified as 0.5 %.  This model displayed the lowest cytotoxicity while 
simultaneously inducing changes with regards to the functioning of the relevant cells 
under investigation. 
5.1.3.2. Nitric oxide scavenging activity 
NO has been implicated in various pathophysiological alterations during the 
inflammatory response. Due to the observed decrease in the LPS-activated 
production of NO in RAW 264.7 macrophages treated with gycated gelatin in 
combination with the explanation provided regarding the ability of AGEs to uncouple 
NOS from its essential cofactor (BH4) and consequently quench NO production, the 
NO scavenging capability of glycated and unglycated gelatin was assessed (figure 
4.5). Amino-guanidine was selected as the positive control as it is a well-known 
inhibitor of iNOS and consequently displays various anti-inflammatory properties 
(Szabo et al., 1997). The NO scavenging activity of unglycated gelatin was 
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calculated to be 7 % while that of glycated gelatin was 12 %. While these values 
seem relatively low in comparison to the positive amino-guanidine control which 
scavenged 62 % of the NO, it confirms that the decrease in NO observed in figure 
4.4 in response to the treatment of RAW 264.7 macrophages with glycated gelatin 
was indeed as a result of the quenching of NO and not due to a decrease in NO 
production. Furthermore, other markers indicative of macrophage activation 
measured in this study supports a classical pro-inflammatory response upon 
treatment with glycated gelatin. 
5.1.3.3. Phagocytosis 
As previously described, phagocytosis is essential for the removal of dead and 
damaged cells, cell debris as well as pathogens during wound healing. Macrophages 
thus play an important role in preventing wound infection and producing the 
necessary signalling molecules that will enable the wound healing process to 
transition from the inflammatory phase to the tissue repair process. During diabetes, 
the function of macrophages is compromised due to impaired chemotaxis to the 
wound area accompanied by impaired phagocytic and killing capabilities (McCulloch 
& Kloth, 2010). Due to the fact that plasma from healthy non-diabetic patients does 
not improve the phagocytic function of diabetic phagocytic cells it stands to reason 
that the impairment due to diabetes is brought about by intrinsic defects, however, 
the pathogenic mechanisms behind impaired macrophage function in diabetes 
remains unclear (Geerlings & Hoepelman, 1999). An ex vivo study investigating the 
effects of hyperglycaemia on the function of alveolar macrophages revealed a 
decreased respiratory burst, an impairment in the secretion of cytokines including 
TNF-α and IL-6 as well as a decreased responsiveness to several TLR ligands as a 
result of alterations to the normal intracellular signalling pathways of the 
macrophages (Xiu et al., 2014). The AGEs associated with hyperglycaemia have 
also been shown to directly suppress the phagocytic capability of macrophages; 
however, no further information with regards to their mechanism of action could be 
found (Khanna et al., 2010). 
Phagocytosis in macrophages involves the formation of phagolysosomes which tend 
to be fairly large, depending on the content of the ingested material. As a result, an 
increase in phagocytosis is generally associated with an increase in acidic vacuole 
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formation (Cooper, 2000). Cytochalasin B was used to inhibit phagocytosis and has 
been classified as a cell membrane permeable mycotoxin that has been shown to 
inhibit the rate of actin polymerisation as well as the interaction of actin filaments in 
solution by binding to the barbed end of the actin filaments (MacLean Fletcher & 
Pollard, 1980). LPS was used as a positive control to promote phagocytosis as it is 
one of the PAMPs that are recognised by macrophages during phagocytosis 
(Aderem, 2003). 
A decrease in acidic vacuole formation by RAW 264.7 macrophages was observed 
in response to treatment with cytochalasin B, however, a large standard deviation 
resulted in no significant differences compared to the untreated sample (figure 4.7). 
Upon closer investigation of the individual experiments in appendix C, a significant 
decrease in acidic vacuole formation in response to cytochalasin B was observed for 
two of the three experiments. The overall trend thus suggests that cytochalasin B did 
indeed result in a decrease in acidic vacuole formation. Furthermore, cytochalasin B 
resulted in a highly significant decrease (p<0.005) in phagocytosis when compared 
to the untreated sample as was expected based on its mechanism of action. It is 
important to note that phagocytosis is a highly dynamic process involving several 
steps. In the early stages of phagocytosis an increase in the formation of 
phagosomes will occur, however, they do not become acidic until they fuse with 
lysosomes during the later stages of the phagocytic process. Furthermore, LTR does 
not only quantify phagolysosomes, but also lysosomes and other acidic 
compartments within the cell (Aderem, 2003). As cytochalasin B inhibits the 
microtubule system within cells, it prevents the uptake of the pHrodo™ Bioparticles® 
which would result in less phagolysosomes, however, it does not have any effect on 
the lysosomes and consequently one would not necessarily expect any significant 
decreases in LTR staining. 
As LPS is an inducer of the inflammatory response, it was expected that LPS would 
stimulate macrophage phagocytosis. Treatment of RAW 264.7 macrophages with 
LPS (200 ng/ml) did not produce any significant alterations in acidic vacuole 
formation, however, a 20 % increase in the phagocytosis of the pHrodo® 
Bioparticles® was reported when compared to the untreated sample. This increase, 
however, was not significant due to the variation between individual experiments. As 
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the cells were only treated with LPS for one hour before the pHrodo® Bioparticles® 
were added to the medium, it is possible that the treatment period was not long 
enough for LPS to properly exert any measurable effects. 
Treatment with 0.5 % glycated gelatin resulted in a significant decrease in 
phagocytosis as expected from literature accompanied by an increase in acidic 
vacuole formation. Although this increase was not significant when the results from 
all three experiments were combined, all individual experiments suggest that this 
increase was indeed significant when compared to the untreated sample. As the 
unglycated gelatin did not affect acidic vacuole formation or phagocytosis in RAW 
264.7 macrophages, the response to glycated gelatin can be attributed to the 
presence of AGEs. While it is possible that the lysosomal compartment remained 
unaffected by treatment with the glycated gelatin and that glycation thus only affects 
the early stages of phagocytosis upstream of phagolysosome formation, a study 
conducted by Guo et al. (2016) showed that wound macrophages exposed to AGEs 
were found to undergo autophagy with an increase in autophagy inducing M1 
macrophage polarization. During autophagy, autophagosomes are formed which 
fuse with lysosomes to form autolysosomes, thus explaining the link between 
autophagy and acidic vacuole formation. Furthermore, an increase in macrophage 
autophagy was shown to have a negative effect on the normal wound healing 
process and was shown to play a role in chronic wound healing.  
5.1.3.4. M1/M2 macrophage polarization 
As previously mentioned, impaired diabetic wound healing is characterized by a 
prolonged inflammatory state defined by an increase in pro-inflammatory M1 
macrophages and a decrease in anti-inflammatory M2 macrophages. A study 
conducted by Jin et al. (2015) showed that AGEs were able to promote pro-
inflammatory M1 macrophage activation and while the mechanisms behind this 
phenomenon are not well known, their results suggested that the AGE-RAGE 
interaction is important in this activation process. Furthermore, evidence exists that 
AGEs are capable of mediating NF-ĸB activation through the action of the TLR4 
signalling pathway where TLR4 signalling has also been implicated in M1 
macrophage polarization. Several other possibilities exist and there is consequently 
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much that remains to be explored with regards to the signalling pathways involved in 
M1 macrophage activation through AGEs. 
LPS has been shown to stimulate M1 macrophage polarization and was 
consequently selected as a positive control for the up-regulation of CD86. Treatment 
of RAW 264.7 macrophages with LPS resulted in a substantial increase (p<0.05) in 
CD86 implying M1 macrophage activation as expected (figure 4.9). The 0.5 % 
unglycated gelatin sample did not have any effect on the M1 activation status of the 
RAW 264.7 macrophages, however, the glycated gelatin resulted in a significant 
11.5 % (p<0.05) increase when compared to the untreated sample. Treatment with 
both glycated gelatin and LPS resulted in the same level of activation as treatment 
with LPS alone.  
Using CD206 as a marker for M2 macrophage activation, curcumin (20 μM) was 
used as a positive control and resulted in a 5 % increase in the expression of CD206 
when compared to the untreated sample. Neither the unglycated nor the glycated 
gelatin resulted in any alterations in M2 activation when compared to the untreated 
sample while a insignificant decrease in M2 activation was observed in the sample 
treated with both glycated gelatin and curcumin when compared to cells treated with 
curcumin alone. 
There is much controversy with regards to investigating M1 and M2 macrophage 
polarization as there are multiple different aspects of macrophage function that must 
be assessed before any final conclusions can be arrived at. It would appear that the 
most reliable data can be obtained from studies related to the analysis of certain cell 
surface markers known to be specific to each macrophage phenotype (Jin et al., 
2015). It should be noted again, however, that M1 and M2 macrophages represent 
two extremes in a range of possible macrophage phenotypes in vivo and thus it is 
the ratio of M1 to M2 macrophages that is important as both phenotypes will always 
be present. The M1:M2 ratio for the unglycated gelatin was 2.3 while that of the 
glycated gelatin was 4.5 compared to the untreated sample which gave a ratio of 
1.67. The results obtained here thus concur with those of Jin et al. (2015) who found 
that AGEs up-regulated the expression of CD86 and consequent M1 activation but 
did not have any effect on the expression of CD206 and resultant M2 activation. 
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5.1.3.5. NF-ĸB  
Several reports have shown that AGEs are able to activate transcription factors such 
as NF-ĸB through various inflammatory signalling pathways. It was previously found 
that treatment with the anti-RAGE antibody only partly suppressed the activation of 
NF-ĸB confirming that the AGE-RAGE pathway was at least partly responsible for 
the observed effect of AGEs on NF-ĸB activation, however, it is believed that several 
other signalling pathways including TLR4 signalling could be involved (Jin et al., 
2015). 
The nuclear translocation of phospho-p65 NF-ĸB and consequent NF-ĸB activation 
was significantly increased in cells treated with LPS as well as 0.5 % glycated gelatin 
(figure 4.11). The unglycated gelatin did not have any significant influence on NF-ĸB 
nuclear translocation and thus the effect observed for the glycated gelatin can again 
be attributed to the presence of AGEs. The glycated gelatin had a slightly higher NF-
ĸB activating potential (111 %) than the positive LPS control (108 %), however, the 
samples treated with both LPS and glycated gelatin had the greatest NF-ĸB 
activating activity of 115 %.  
5.1.3.6. COX-2 
As COX-2 expression is directly regulated by NF-ĸB activation, it was expected that 
AGEs would also promote COX-2 expression. This, however, was not the case. 
While LPS resulted in a predictably large increase in COX-2 expression of 32 % 
(p<0.01) in comparison to 1.2 % in the untreated sample (figure 4.13), no significant 
increase in response to treatment with the glycated gelatin alone was observed.  
While COX-2 expression was slightly higher in the RAW 264.7 macrophages treated 
with glycated gelatin compared to the unglycated gelatin, this increase was 
statistically insignificant. Interestingly, it was found that cells treated with both LPS 
and glycated gelatin resulted in the largest increase in COX-2 expression of 50 % 
(p<0.005), a value 18 % higher than treatment with LPS alone.  
According to Ramsay et al. (2003), there are three levels of transcriptional regulation 
of the COX enzymes. These include initiation, alternative splicing as well as mRNA 
stability. COX-2 expression has been shown to be highly inducible by low levels of 
several transcription factors and it is well known that there is a very strong 
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correlation between NF-ĸB activation and COX-2 expression. While NF-ĸB may be 
required in most macrophage cell-lines during inflammation, it has been suggested 
that NF-ĸB activation alone may be insufficient to induce maximal COX-2 
expression. It is thus plausible that additional signalling pathways required for COX-2 
expression were not activated by the AGEs present in the glycated gelatin alone, 
however, in the presence of LPS the activation of these additional signalling 
pathways could potentially account for the 18 % increase in COX-2 expression 
described above. 
5.1.4. Fibroblast function 
Fibroblasts are important during the proliferation and tissue remodelling phases of 
the wound healing process, particularly during ECM synthesis and remodelling. In 
diabetes, however, fibroblasts have demonstrated impaired proliferation and 
migration abilities during as discussed in chapter one. RAGE receptors have been 
identified not only in macrophages but also in skin fibroblasts and the AGE-RAGE 
interaction has consequently been implicated in fibroblast dysfunction during wound 
healing including impaired proliferation, migration, collagen synthesis and ECM 
producing abilities. Furthermore, AGEs have been shown to promote fibroblast 
apoptosis, however, the associated mechanisms are still under current investigation 
(Tracy et al., 2016). 
5.1.4.1. Fibroblast proliferation  
MRHF proliferation was not significantly altered by treatment with unglycated gelatin 
when compared to the untreated sample (1 % FBS), however, a significant decrease 
(p<0.05) was observed in response to the 0.5 % glycated gelatin (figure 4.14). As no 
changes in cell death occurred, it can be confirmed that AGEs do indeed impair 
fibroblast proliferation.  
5.1.4.2. Fibroblast migration 
Similar to the results observed during fibroblast proliferation, no changes to MRHF 
fibroblast migration after treatment with 0.5 % unglycated gelatin were reported 
(figure 4.15). Conversely, treatment with 0.5 % glycated gelatin impaired fibroblast 
migration by 20 % (p<0.005) when compared to the untreated control. 
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5.1.5. Summary of the glycated gelatin model 
Table 5.1 provides a summary of the findings observed during the characterization of 
the glycated gelatin model in order to better understand the strengths and 
weaknesses of the model developed during this study. This table does not include 
the different phases of wound healing and provides a brief summary of the overall 
responses observed during diabetic wound healing. Individual responses may thus 
vary between different phases of the wound healing process. This table shows that 
the selected glycated gelatin model suitably mimics many aspects associated with 
the diabetic state and can consequently serve as an in vitro diabetic wound healing 
model as it was able to simulate the major cellular dysfunctions in macrophages and 
fibroblasts documented during diabetic wound healing.  
Table 5.1: A summary of the effects of the glycated gelatin model on macrophage and 
fibroblast function during wound healing 
Cell type Assay Effect of diabetes on 
wound healing 
Effect of 0.5 % glycated 
gelatin* 
 
 
 
 
RAW 264.7 
macrophages 
NO production ↓ 
(Witte et al., 2002) 
↓ 
(possibly due to quenching) 
Phagocytosis ↓ 
(Khanna et al., 2010;  
Xu et al., 2013) 
↑ in acidic vacuole 
formation;  
↓ in phagocytosis 
M1/M2 ↑ in M1 activation  
(Khanna et al., 2010;  
Xu et al., 2013) 
↑ in M1 activation, - on M2 
activation 
NF-ĸB ↑ 
(Patel & Santani, 2009) 
↑ 
COX-2                 ↑ 
(Kämpfer et al., 2005) 
- without LPS; ↑ with LPS 
MRHF 
fibroblasts 
Proliferation ↓ 
(McKulloch & Kloth, 2010; 
Xu et al., 2013) 
↓ 
Migration ↓ 
(McKulloch & Kloth, 2010; 
Xu et al., 2013) 
↓ 
*(↑) indicates a positive effect, (↓) indicates a negative effect and (-) indicates no effect 
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5.2. SCREENING OF EXTRACTS FOR POTENTIAL WOUND HEALING 
PROPERTIES 
Diabetic wounds have been characterized by several abnormalities including 
increased oxidative stress, increased glycation with a concomitant increase in the 
formation of AGEs as well as an imbalance in the activation of certain MMPs and 
TIMPs (Xu et al., 2013). While the traditional uses of several mushroom species as 
wound dressings have been reported, very limited research is available with regards 
to macrofungi and their associated wound healing properties, particularly on the 
African continent (Burk, 1983; Jaengklang et al., 2015). Consequently, five 
mushroom species collected from the Eastern Cape and Western Cape of South 
Africa were selected based on previous reports of anti-inflammatory, antidiabetic or 
anti-oxidant activities. The cytotoxicity, anti-oxidant capacity, glycation inhibitory and 
collagenase inhibitory potentials of each of the selected mushroom species was 
assessed in order to probe their potential diabetic wound healing properties. 
5.2.1. Cytotoxicity screening 
Basal cytotoxicity screening was carried out using RAW 264.7 macrophages and 
MRHF fibroblasts. The same protocol using Hoechst 33342 together with PI staining 
was used as in the previous section and these results were again compared to the 
crystal violet assay. Each mushroom extract was tested at a concentration of 100 
and 200 μg/ml. While some might argue that these concentrations are not 
physiologically relevant, the intended use of the tested mushroom extracts would be 
as a topical ointment rather than an oral treatment and thus fairly high concentrations 
were used in order to observe their maximal effects. 
The ethanol extract of P. tinctorius did not result in any significant cytotoxicity or 
increases in cell death in the RAW 264.7 macrophages at the tested concentrations 
during the nuclear staining method (figure 4.17), however, significant cytotoxicity was 
observed for both the 100 and 200 μg/ml concentrations of the water extract. 
Interestingly, a significant increase in cell death was observed for only the 100 μg/ml 
water extract but not at the 200 μg/ml concentration. Due to the small standard 
deviations, very small differences in cell death resulted in highly significant statistical 
data (p<0.005); however, the percentage of cell death for the 100 μg/ml water extract 
of P. tinctorius was only 2 %. Considering that the percentage of cell death for the 
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untreated sample was only 1 %, this difference does not seem very physiologically 
significant as cell death is a natural part of the cell cycle and there will thus always 
be a small population of cells that die due to natural causes such as apoptosis or 
autophagy (Thornburn, 2008; Gewirtz, 2013). For this reason, the cell death was 
only considered relevant in cases where it exceeded 5 %. According to the results 
from the crystal violet assay, no RAW 264.7 macrophage cytotoxicity was observed 
for either of the extracts.  
The MRHF fibroblasts displayed significant cytotoxic effects in response to treatment 
with the 200 μg/ml ethanol and water extracts of P. tinctorius with the only significant 
increase in cell death observed for the 200 μg/ml water extract (4 %). No significant 
changes in fibroblast cell density in response to treatment with P. tinctorius were 
observed during the crystal violet assay. The cytotoxicity results obtained here again 
emphasise the higher sensitivity of the nuclear staining protocol using HCS when 
compared to the crystal violet assay. 
No significant cytotoxicity in RAW 264.7 cells  were observed during either the 
nuclear staining method or the crystal violet assay in response to treatment with R. 
capensis for either the ethanol or the water extracts (figure 4.18). A significant 
decrease in MRHF fibroblast cell number (9 %) was evident for the 200 μg/ml water 
extract, however, this was not accompanied by an increase in cell death. 
Furthermore, no decrease in cell density was recorded during the crystal violet assay 
at this concentration, probably due to the decreased sensitivity of this assay 
compared to the nuclear staining method.  
A significant decrease in RAW 264.7 cell number was reported for the 200 μg/ml 
ethanol extract of B. badius (figure 4.19). This was not accompanied by any increase 
in cell death during the Hoechst 33342/PI method or cell density as determined by 
the crystal violet assay. No changes to MRHF fibroblast cell number, cell death or 
cell density were reported. Furthermore, no significant changes in cell number, cell 
death or cell density were observed for the RAW 264.7 macrophages or the MRHF 
fibroblasts in response to treatment with P. ostreatus either (figure 4.20). 
A robust decrease (p<0.005) in both RAW 264.7 macrophage and MRHF fibroblast 
cell number was reported for the 100 and 200 μg/ml ethanol extract of G. lucidum 
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(figure 4.21). This was accompanied by a highly significant increase in cell death (26 
and 17 %, respectively, for the RAW 264.7 cells and 15 and 30 %, respectively, for 
the MRHF cells). It is evident that the RAW 264.7 and MRHF cells present in the 
samples treated with 200 μg/ml of the ethanol extract were dead and the decrease in 
cell death observed from the 100 μg/ml to the 200 μg/ml ethanol extract in the RAW 
264.7 macrophages indicates that most of the cells had already apoptosed into cell 
fragments thus leading to a decrease in the number of intact nuclei. The same trends 
in cell density were observed during the crystal violet assay; however, higher cell 
density values were obtained for the MRHF cells thus indicating a reduced 
sensitivity. No significant cytotoxicity was observed in either cell line after treatment 
with the water extract of G. lucidum. A literature search revealed that the anti-cancer 
activity of the ethanol extracts of G. lucidum against several cancer cell lines are well 
documented (Jang et al., 2010; Mohan et al., 2016). 
Due to the severe cytotoxicity of the ethanol extract of G. lucidum observed in both 
the RAW 264.7 macrophages and the MRHF fibroblasts, it was decided that no 
further cell-based assays would be performed using this extract. Several of the 
tested mushroom extracts resulted in significant decreases in cell number with no 
increase in cell death and these extracts are thus more than likely exerting an anti-
proliferative effect rather than a cytotoxic one and consequently were not excluded 
from further investigations. The cytotoxicity results obtained in this section concur 
with those obtained in the previous section with regards to the sensitivity of the 
nuclear staining protocol using HCS and the crystal violet assay. Many examples 
were provided where decreases in cell number were not accompanied by a decrease 
in cell density and thus it would appear that the crystal violet assay frequently 
provides an over-estimation of the cell number and consequently does not provide a 
true reflection of the cytotoxic nature of a tested extract.  
5.2.2. Anti-oxidant activity 
Increased oxidative stress has been observed in chronic diabetic wounds in 
response to hyperglycaemia as well as AGE formation. Hyperglycaemia promotes 
increased mitochondrial activity and consequent ROS formation (Kolluru et al., 2012) 
while AGEs stimulate ROS production through different mechanisms including the 
stimulation of NADPH-oxidase (NOX) which induces the formation of the superoxide 
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anion. AGEs have also been shown to compromise various cellular anti-oxidant 
defence mechanisms such as the cross-linking of copper-zinc superoxide dismutase 
(Cu-Zn-SOD) which results in its inactivation and subsequent site-specific 
fragmentation. Furthermore, AGEs are highly reactive molecules and can thus act as 
electron donors during the cross-linking reaction, resulting in the formation of 
superoxide anions while the cross-linking of cation radical sites during protein 
glycation enables proteins to catalyse single-electron redox reactions through the 
formation of active enzyme-like centres and consequently stimulates ROS 
production. These redox reactions do not require oxygen or co-factors such as 
copper or iron that are usually required during redox reactions (Gkogkolou & Böhm, 
2012). 
Any mushroom extract that displays strong anti-oxidative properties might be able to 
counter-act the increased production of ROS in response to hyperglycaemia and 
AGEs at the wound area, potentially promoting normal wound healing by preventing 
further tissue damage caused by the ROS. To assess the anti-oxidative capacity of 
each mushroom species, the DPPH, FRAP and NO scavenging assays were 
performed. The choice to compare three different methods stems from the fact that 
different anti-oxidants are detected by each method, for example, the FRAP assay 
detects mostly water-soluble anti-oxidants while the DPPH assay will detect mostly 
lipophilic anti-oxidants. Perhaps the most relevant of the three assays is the NO 
scavenging assay as the non-specificity of the FRAP assay and the physiological 
irrelevance of the DPPH assay tend to raise questions with regards to the relevance 
of these methods to in vivo anti-oxidant capacities (Liang & Kitts, 2014).  
Comparatively strong anti-oxidant activities were reported for the ethanol and water 
extracts of P. tinctorius during the DPPH assay with IC50 values below 100 μg/ml 
(figure 4.22). Similar activity was reported during the NO scavenging assay with an 
IC50 value between 100 and 200 μg/ml for the ethanol extract and above 200 μg/ml 
for the water extract. Comparatively lower values were obtained during the FRAP 
assay which suggests that P. tinctorius contains more lipophilic anti-oxidants than 
hydrophilic ones. Overall, P. tinctorius displayed comparatively high anti-oxidant 
activities with the ethanol extract exhibiting the strongest activity, however, the IC50 
values are too high for the compounds in this mushroom species to be considered 
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potent anti-oxidants and further work with regards to determining the IC50 values was 
thus not justified. A literature search revealed that no published work exists on the 
anti-oxidant potential of P. tinctorius and this study thus presents the first report of 
such activities. 
During the DPPH, NO scavenging and FRAP assays, comparatively low anti-oxidant 
activities were reported for the ethanol and water extracts of R. capensis with IC50 
values above 200 μg/ml for the DPPH and NO scavenging assays (figure 4.23). 
Overall, the anti-oxidant activity of R. capensis appears to be relatively low with the 
ethanol extract being richer in anti-oxidants than the water extract. The anti-oxidant 
capacities of B. badius and P. ostreatus were comparatively low with the highest 
values obtained from the DPPH assay (figures 4.24 and 4.25). Both the ethanol and 
the water extracts exhibited equal anti-oxidant capacities. No published data was 
found on the anti-oxidant capacity of R. capensis while only one journal article 
reporting the anti-oxidant activities for B. badius could be found. Using an 80 % 
methanol extract prepared with heat treatment, Jaworska et al. (2015) reported for 
the first time the anti-oxidant activity of B. badius. Here they reported anti-oxidant 
activities of 25.2 mmol Trollox Equivalents (TE) during the DPPH assay and 36.4 
mmol Fe2+ during the FRAP assay per 100 g dry weight of fresh mushrooms while 
Taofiq et al. (2016) reported an IC50 value of 7.69 mg/ml for an ethanol extract of P. 
ostreatus during the DPPH assay. This highlights the difficulties associated with 
comparing anti-oxidant activities by different authors as there is no consistency or 
standardisation in the way that these results are expressed. Further complicating this 
matter is the fact that mushrooms are known to have slightly different compositions 
depending on where they are cultivated and the same species of mushroom 
collected from different sources might thus reveal different quantities of individual 
anti-oxidant compounds (Taofiq et al., 2016). 
The results from the DPPH scavenging assay show that the 200 μg/ml ethanol 
extract (65 %) and both concentrations of the water extract (61 % and 76 %, 
respectively) of G. lucidum had comparatively high anti-oxidant activities with IC50 
values between 100 and 200 μg/ml for the ethanol extract and below 100 μg/ml for 
the water extract (figure 4.26). The FRAP assay revealed comparatively high anti-
oxidant activities for the 200 μg/ml ethanol extract. The lowest anti-oxidant activities 
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were reported during the NO scavenging assay. A study conducted by Rajasekaran 
and Kalaimagal (2011) found that the ethanol extract of G. lucidum was able to 
scavenge 72.4 % of the DPPH radicals at a concentration of 250 mg/ml and 
calculated the IC-50 value to be 172.52 mg/ml for the ethanol extract and 5.28 mg/ml 
for a hot water extract. Rajasekaran and Kalaimagal (2011) further reported that the 
ethanol extract of G. lucidum resulted in 65.87 % NO scavenging at 200 mg/ml. 
While the percentage DPPH scavenging activity obtained for the ethanol extract is 
comparable to the results obtained by Rajasekaran and Kalaimagal (2011), the 
difference in NO scavenging activity can be attributed to the much lower 
concentrations used during this study. Overall, the anti-oxidant capacity of P. 
tinctorius and G. lucidum appear to be the highest of all the tested mushroom 
species. 
5.2.3. Glycation inhibition 
As AGEs have been identified to be largely responsible for the dysregulation of 
wounds in impaired diabetic wound healing, a mushroom species displaying strong 
anti-glycation activities could serve as a very useful treatment approach. The ethanol 
extract of P. tinctorius showed a very strong anti-glycation potential (figure 4.27) with 
the highest activity recorded for the 200 μg/ml ethanol extract (68 % with p<0.005). 
Upon further investigation, however, both the ethanol and water extracts resulted in 
significant quenching of the fluorescence signal and thus the results obtained for P. 
tinctorius were deemed to be unreliable. In order to assess the true glycation 
inhibitory potential of P. tinctorius, an alternative assay during which the proteins are 
precipitated in order to remove any interfering substances will have to be utilised. 
The remaining four mushroom samples did not show any promising glycation 
inhibitory activities with both the ethanol and water extracts of B. badius and P. 
ostreatus as well as the ethanol extract of G. lucidum seemingly promoting glycation 
(figures 4.28 to 4.31). No published information with regards to the glycation 
inhibitory potential of any of the mushroom species used during this study except for 
G. lucidum could be found. A study conducted by De Silva et al. (2012) showed that 
in diabetic rats, the polysaccharides isolated from G. lucidum were able to ameliorate 
collagen cross-linking of the myocardium of diabetic rats and consequently 
decreased the levels of AGEs. It is thus possible that the active compounds 
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responsible for the observed decrease in AGEs by De Silva et al. (2012) were not 
present in the extracts prepared during this study as polysaccharides, for example, 
precipitate out of solution in the presence of ethanol. 
5.2.4. Collagenase inhibition 
Chronic wounds have been characterized by enhanced levels of the collagenase 
enzymes MMP-1 and MMP-8 coupled to abnormally low levels of TIMPs. As a result, 
these wounds experience increased ECM degradation, an altered cytokine profile as 
well as the destruction of growth factors (Sabino & auf dem Keller, 2015). 
Furthermore, collagen that is modified by glycation has been shown to be resistant to 
degradation by various collagenase enzymes. Consequently, wound healing 
becomes impaired as the collagen turnover required to ensure that the collagen 
remains functional is prevented (Gkogkolou & Böhm, 2012).  In diabetes, increased 
MMP activity has been attributed to oxidative stress and/ or the presence of AGEs 
(Ayuk et al., 2016). Any mushroom species which is thus able to inhibit collagenase 
activity could prove useful in the treatment of diabetic wounds, however, none of the 
mushroom extracts tested during this study showed any promising collagenase 
inhibitory activities with all the recorded activities being below 20 % (figure 4.32).  
5.3. THE INFLAMMATORY RESPONSE 
The wound healing process in diabetes becomes impaired due to different regions of 
diabetic wounds becoming stuck in different phases and consequently, the wound is 
unable to progress to the final phase of tissue remodelling due to the loss of 
synchronisation of several cellular events. Furthermore, diabetic wounds tend to 
enter a state of pathological inflammation as a result of persistent hyperglycaemia, 
chronically elevated levels of various pro-inflammatory cytokines and microbial 
infections (Tellechea et al., 2010). The inflammatory phase thus provides a very 
attractive therapeutic target for encouraging normal wound healing in diabetic 
individuals with several possible mechanisms and signalling pathways that can be 
exploited. Due to the complex nature of the inflammatory response and the close 
relationship between multiple different signalling molecules, the results from each 
experiment are described individually and the findings from different assays are 
integrated later on in this section. 
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5.3.1. Nitric oxide production in activated macrophages 
An important way of distinguishing classically activated and alternatively activated 
macrophages from one another is through their metabolism of arginine. M1 
macrophages express iNOS which promotes the metabolism of arginine to NO in an 
attempt to kill invading microbes. M2 macrophages, however, do not express iNOS 
and consequently convert arginine to ornithine, a precursor molecule to various 
polyamines and collagen. NO production is one of the simplest measures used to 
assess the activation status of macrophages. Diabetic wounds are characterized by 
an increased burden of M1 macrophages which have been shown to be responsible 
for producing several inflammatory cytokines and mediators, consequently 
prolonging the inflammatory phase of wound healing. Theoretically then, an increase 
in M1 activation would be demonstrated by an increase in NO production while an 
increase in M2 activation would correlate to lower levels of NO being produced 
(Mosser & Zhang, 2008). Given the important role of NO in wound healing and the 
complex nature of diabetic wounds, both the anti-inflammatory and pro-inflammatory 
potentials of each mushroom extract were assessed.  
Given the relevance of microbial infections in promoting chronic wound healing in 
diabetes, LPS was identified as a suitable inducer of the inflammatory response in 
RAW 264.7 macrophages by activating signalling pathways that are also activated in 
vivo in response to bacterial infections. In the absence of LPS, both the ethanol and 
water extracts of P. tinctorius resulted in significant increases in the measured NO 
with the ethanol extract having a stronger effect (figure 4.33 A). This suggests then 
that this mushroom species displays strong pro-inflammatory properties and 
consequently promotes M1 activation. In the presence of LPS, however, both the 
ethanol and water extracts demonstrated seemingly anti-inflammatory activities 
resulting in a robust decrease in the quantity of NO measured as the concentration 
of each extract increased. This leads one to believe that this mushroom species 
displayed both pro-inflammatory and anti-inflammatory activities with the pro-
inflammatory activity being more dominant. It is thus possible that P. tinctorius 
contains different compounds that display different activities which would suggest 
that the current experimental setup is not suitable to assess the true potential of this 
particular mushroom species. Before such statements can be made, however, it is 
necessary to consider the NO scavenging potential of P. tinctorius. In the previous 
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section (figure 4.22 C) it was shown that both the ethanol and water extracts of P. 
tinctorius displayed fairly strong NO scavenging activities with the 200 μg/ml ethanol 
extract demonstrating a similar NO scavenging ability as the positive amino-
guanidine control. The ethanol extract resulted in a larger decrease in NO in the 
presence of LPS than the water extract. As this same trend was observed in figure 
4.22 C, it stands to reason that the observed decrease in the presence of LPS was 
not due to a decrease in the NO produced by the RAW 264.7 macrophages but 
rather as a result of the NO scavenging capability of P. tinctorius. As NO scavenging 
is also considered to be an anti-inflammatory mechanism, the ethanol and water 
extracts of P. tinctorius were shown to display both pro-inflammatory and anti-
inflammatory activities with the anti-inflammatory activity being attributed to strong 
NO scavenging capabilities.  Due to the complex nature of the extracts investigated, 
these findings emphasise the importance of using more than one assay to gain an 
accurate perspective of the capabilities and limitations of each extract in terms of 
their effects on macrophage activation. 
Based on the results discussed in section 5.1 and the findings from literature it was 
established that the decrease in NO in the presence of glycated gelatin was due to 
scavenging rather than a decrease in the production of NO. Both the ethanol and 
water extracts of P. tinctorius resulted in significantly lower quantities of NO in the 
presence of glycated gelatin when compared to the sample treated with glycated 
gelatin alone (figure 4.33 C). As P. tinctorius was shown to demonstrate significantly 
pro-inflammatory activities with a strong NO scavenging potential, it appears that the 
combined effect of the NO scavenging capability of each extract as well as that of 
glycated gelatin acted in an additive manner. Consequently, the lowest levels of NO 
were recorded during this experiment.  
From these results it is tempting to state that because NO is a marker for 
inflammation, a decrease in NO should surely be coupled to a decrease in 
inflammation. The process of wound healing is, however, extremely complex and 
involves several signalling pathways and mechanisms. This frequently makes the 
interpretation of results obtained from in vitro experiments very difficult. While NO 
has been shown to perform several important functions during wound healing and 
diabetic wounds have been characterized by decreased levels of NO in the wound 
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milieu (Witte et al., 2002), diabetic wounds have also been characterized by 
pathological inflammation. NO is frequently used as a marker for inflammation and 
M1 macrophage activation, however, in diabetes it would appear that NO production 
is not a suitable measure of M1 activation as the situation is further compounded by 
the ability of AGEs to quench NO. The results obtained here must thus be 
interpreted with great caution, highlighting the importance of using a combination of 
different methods to measure a specific response before arriving at any definitive 
conclusions during in vitro investigations. 
The ethanol extract of R. capensis did not promote NO production in the absence of 
LPS, however, a dose-dependent decrease in NO was observed in LPS stimulated 
cells (figure 4.34). These results indicate that the ethanol extract of R. capensis 
demonstrates anti-inflammatory activities; however, the results from the NO 
scavenging assay suggest that the observed decrease in NO could be due to 
scavenging rather than a reduction in NO production. In the presence of glycated 
gelatin a further decrease in NO was observed with the 200 μg/ml ethanol extract 
resulting in a robust decrease (p<0.005) in NO compared to treatment with glycated 
gelatin alone. Further studies involving the quantification of iNOS are needed to 
establish whether the reduction in NO was due to quenching or a decrease in the 
production of NO. In the absence of LPS, the water extract of R. capensis resulted in 
a noteworthy increase (<0.005) in NO production and consequently displays strong 
pro-inflammatory activities. In the presence of glycated gelatin, however, no 
significant alterations in NO levels were reported when compared to the samples 
treated with glycated gelatin alone and the pro-inflammatory activity of the water 
extract was thus not strong enough to overcome the NO scavenging activities of the 
glycated gelatin.  
No significant alterations in NO production in the absence and presence of LPS were 
recorded for the ethanol extract of B. badius (figure 4.35). The ethanol extract thus 
did not demonstrate any pro-inflammatory or anti-inflammatory activities. In the 
absence of LPS, however, the water extract of B. badius was shown to be as potent 
an inducer of NO production as LPS. Treatment of the RAW 264.7 macrophages 
with 200 μg/ml of the water extract together with LPS appears to have produced an 
additive effect and consequently resulted in a significant increase in NO production 
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compared to the sample treated with LPS alone. In the presence of glycated gelatin, 
a significant decrease in the quantity of NO was recorded for the 200 μg/ml ethanol 
extract of B. badius compared to treatment with glycated gelatin alone. As negligible 
NO scavenging was reported for this extract, it would appear that the ethanol extract 
does indeed possess anti-inflammatory activities. No significant alterations in the 
quantity of NO were observed for the water extract when compared to glycated 
gelatin alone. 
The ethanol extract of P. ostreatus did not show any pro-inflammatory activities in 
the absence of LPS, however, a dose-dependent decrease in NO was recorded in 
LPS stimulated cells (figure 4.36 B). Negligible levels of NO scavenging were 
reported for this particular extract in section 5.2 and thus the ethanol extract of P. 
ostreatus showed anti-inflammatory activities with a consequent decrease (p<0.01) 
in NO production in the presence of glycated gelatin. A weak pro-inflammatory 
response was reported for the water extract of P. ostreatus in the absence of LPS 
while no significant anti-inflammatory activities were observed in LPS stimulated 
cells. Furthermore, treatment of the RAW 264.7 macrophages with the water extract 
of B. badius as well as glycated gelatin did not result in any significant changes in 
the quantity of NO measured when compared to treatment with glycated gelatin 
alone. 
The water extract of G. lucidum did not result in any significant pro-inflammatory or 
anti-inflammatory activities (figure 4.38 A and B). Consequently, no significant 
changes in NO production were recorded in the presence of glycated gelatin when 
compared to treatment with glycated gelatin alone.  
In order to ensure that the seemingly pro-inflammatory activities of the tested 
mushroom extracts were not due to the presence of endotoxins, the possibility of 
false positives was assessed using polymyxin B sulfate. A dose response curve was 
constructed in order to define the toxicity of polymyxin B and to select a tolerable 
concentration for further cell based assays (figure 4.38).  A dose-dependent 
decrease in cell number was recorded up to a concentration of 25 μg/ml after which 
the cell number appears to have stabilised around 50 %. While a statistically 
significant (p<0.05) increase in cell death (1.9 %) was recorded at 15 μg/ml due to 
minor deviations between individual replicates, this was not considered to be 
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physiologically relevant and thus an increase in cell death was only observed at 
concentrations of 25 μg/ml and above. This suggests that polymyxin B exerted an 
anti-proliferative effect typical for cytostatic agents up to a concentration of 20 μg/ml 
after which polymyxin B became cytotoxic. A concentration of 10 μg/ml was selected 
for further studies as higher concentrations resulted in an unacceptably large decline 
in cell number (> 20 %). 
As a result of the ability of endotoxins to induce NO synthesis, the addition of 
polymyxin B to the culture medium should dampen NO production due to its 
endotoxin scavenging ability and may thus be seen as an indication of possible 
endotoxin contamination. In the presence of polymyxin B, a decrease in NO 
production in response to treatment with a particular extract compared to the 
response observed for that same extract in the absence of polymyxin B would 
consequently suggest the presence of endotoxins. The water extract of R. capensis 
showed a strong pro-inflammatory response in the absence of LPS, however, in the 
presence of polymyxin B the production of NO was greatly reduced (p<0.005) (figure 
4.39 B). This suggests that the pro-inflammatory activity observed for the water 
extract of R. capensis could possibly be due to the presence of endotoxins and 
further investigations thus need to be carried out in order to confirm this. Similarly, a 
weak pro-inflammatory increase in NO production was observed in response to 
treatment of RAW 264.7 macrophages with the water extract of P. ostreatus, 
however, no such increases in NO production were observed in the presence of 
polymyxin B (figure 4.39 D). As the pro-inflammatory response observed for the 
water extract of P. ostreatus in the absence of LPS was very weak, the fact that the 
concentration of polymyxin B chosen resulted in a 15 % decrease in cell number 
suggests that it was this decrease in cell number and not necessarily the presence of 
endotoxins that affected the NO production of the macrophages treated with the 
water extract of P. ostreatus in the presence of polymyxin B. Again, a more specific 
endotoxin analysis assay would be required to confirm this. 
Due to the saprophytic nature of mushrooms, they are known to absorb various 
substances from their surroundings (including nutrients and various toxins) and the 
composition of a particular mushroom species can thus differ as a result of varying 
surroundings (Taofiq et al., 2016). The presence of endotoxins in mushrooms is thus 
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a very real possibility. The polysaccharide component of LPS is known to perform an 
important function during the recognition of endotoxins by TLRs, for example, and it 
is thus plausible that this same component is involved in the recognition of 
endotoxins by polymyxin B. Since it should then be possible for compounds sharing 
similar structural characteristics to endotoxins to be bound by polymyxin B, no final 
conclusions with regards to the potential presence of endotoxins in the water 
extracts of R. capensis and P. ostreatus could be made due to the possibility of false 
positives. Consequently, the results from this assay alone do not provide sufficient 
evidence for the presence of endotoxins. 
5.3.2. Phagocytosis 
The process of phagocytosis is crucial during the inflammatory response as it 
ensures the removal of infectious agents as well as cell debris. Furthermore, the 
process of efferocytosis is vital in protecting surrounding cells and tissues from the 
harmful substances present in apoptotic cells (Khanna et al., 2010). As diabetic 
wounds are characterized by bacterial infections and impaired macrophage function 
including phagocytosis, any mushroom species capable of promoting phagocytosis 
could provide great benefits to diabetic patients suffering from non-healing wounds. 
The 0.5 % glycated gelatin model was used to impair phagocytosis and thus a 
favourable response would be indicated by an increase in the phagocytic capability 
of RAW 264.7 macrophages treated with a certain mushroom extract. All extracts 
were tested at a concentration of 100 μg/ml as some extracts showed anti-
proliferative effects at higher concentrations which could potentially affect the 
phagocytic capability of the macrophages. 
Treatment of RAW 264.7 macrophages with the ethanol and water extracts of P. 
tinctorius appears to have had no significant effects on acidic vacuole formation or 
phagocytosis when compared to the sample treated with glycated gelatin only (figure 
4.40). According to the results from the individual experiments shown in appendix C, 
a significant increase in acidic vacuole formation was observed during all three 
experiments for the ethanol extract when compared to treatment with glycated 
gelatin alone. A similar response was recorded for the water extract for two of the 
three experiments. This suggests that both extracts of P. tinctorius enhanced the 
autophagic response observed in the RAW 264.7 cells induced by the glycated 
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gelatin, however, the magnitude of this response appears to be low in comparison to 
the effect of glycated gelatin on phagocytosis. 
A significant increase in acidic vacuole formation was observed in RAW 264.7 cells 
treated with the ethanol extract of R. capensis. Conversely, no significant differences 
in phagocytosis between the untreated sample and the sample treated with both 
glycated gelatin and the ethanol extract were observed (figure 4.41). The individual 
experiments in appendix C show that a significant increase in phagocytosis was 
recorded in all three individual experiments in RAW 264.7 cells treated with the 
ethanol extract of R. capensis when compared to the glycated gelatin alone. The 
same observation was recorded for only one of the three individual experiments for 
the water extract. Considering the results from both the acidic vacuole formation and 
the individual experiments for the phagocytosis assay, it would appear that the 
ethanol extract of R. capensis substantially increased the phagocytic capability of the 
RAW 264.7 cells when compared to treatment with the glycated gelatin alone. This is 
an important finding as it provides evidence that the suppressive effects of protein 
glycation on the phagocytic function of macrophages is reversible, thus providing an 
attractive therapeutic target for future studies. 
Similar to what was observed for the ethanol extract of R. capensis, the ethanol 
extract of P. ostreatus resulted in a significant increase in acidic vacuole formation 
(figure 4.43). Furthermore, no significant difference in phagocytosis between the 
macrophages treated with the ethanol extract and the untreated sample were 
recorded. Upon examination of the results from the individual experiments shown in 
appendix C, it is evident that the phagocytosis of the RAW 264.7 macrophages was 
consistently higher for cells treated with the ethanol extract of P. ostreatus compared 
to the glycated gelatin alone; however, these results were only significantly higher for 
one of the three experiments. When considering the results from the acidic vacuole 
formation as well as those from the individual phagocytosis experiments, it would 
appear that the ethanol extract of P. ostreatus does indeed promote RAW 264.7 
macrophage phagocytosis in the presence of glycated gelatin. No significant 
differences in acidic vacuole formation or phagocytosis were reported for the water 
extract. 
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Treatment of RAW 264.7 macrophages with the ethanol and water extracts of B. 
badius (figure 4.42) as well as treatment with the water extract of G. lucidum (figure 
4.44) did not result in any significant changes in acidic vacuole formation or 
phagocytosis and were thus not found to have any advantages in promoting or 
restoring the phagocytic function of the macrophages in the presence of glycated 
gelatin. 
5.3.3. M1/M2 macrophage polarization 
While impaired macrophage function has been associated with the chronic 
inflammation observed in diabetic wounds, much remains to be revealed about the 
exact mechanisms involved in macrophage dysfunction during diabetes. The 
activation status of macrophages is largely determined by the wound environment 
and thus early on in the wound healing process, pro-inflammatory M1 macrophages 
are required while the anti-inflammatory M2 macrophages are required during the 
final stage of tissue repair. Diabetic wounds have been characterized by an 
unrestrained M1 macrophage population which demonstrate an impaired ability to 
transition to the M2 phenotype required for the completion of the wound healing 
process (Jetten et al., 2014). Consequently, a favourable outcome would be 
indicated by a decrease in M1 macrophage polarization coupled to an increase in M2 
activation resulting in a lower M1:M2 ratio. Any extract that is capable of promoting 
M2 macrophage polarization could have significant advantages in promoting the 
completion of the wound healing process in diabetic individuals. Due to the 
complexity of macrophage polarization, more than one in vitro assay is required to 
confirm the activation status of macrophages with the most accurate data being 
obtained from studies incorporating cell-surface marker expression (Jin et al., 2015). 
Neither the ethanol nor the water extracts of P. tinctorius were able to overcome the 
increase in M1 activation in response to the glycated gelatin, however, both extracts 
significantly promoted M2 activation (figure 4.45). The M1:M2 ratios were 
consequently calculated to be 1.24 and 0.51, respectively. When compared to the 
M1:M2 ratio calculated for glycated gelatin (4.5), both extracts appear to have 
promoted favourable macrophage activation statuses with the water extract having 
the strongest effect. During the analysis of NO production (figure 4.33), both the 
ethanol and water extracts displayed strong pro-inflammatory activities in the 
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absence of LPS together with possible anti-inflammatory activities that were 
attributed to NO scavenging. The results from this section thus confirm that the water 
and ethanol extracts of P. tinctorius could indeed possess anti-inflammatory activities 
which would explain the decreased NO production observed previously due to an 
increase in M2 macrophage activation in the presence of glycated gelatin. 
Similar to what was observed for P. tinctorius, neither the ethanol nor the water 
extracts of R. capensis were able to lower the enhanced M1 activation of RAW 264.7 
macrophages in response to glycated gelatin; however, both extracts significantly 
increased M2 activation (figure 4.46). The M1:M2 ratios were calculated to be 0.94 
and 1.24 for the ethanol and water extracts, respectively, and both extracts were 
thus able to promote favourable macrophage activation statuses. From the results in 
section 4.3.1 (figure 4.34), the ethanol extract of R. capensis showed potential anti-
inflammatory activities in LPS stimulated cells treated with glycated gelatin which 
was confirmed during this section by an increase in M2 macrophage activation. 
While an increase in M2 macrophage activation was also observed for the water 
extract, the strong pro-inflammatory activity recorded in figure 4.34 B appears to 
have dominated and thus no decrease in NO production was observed.  
The 100 μg/ml ethanol and water extracts of B. badius did not reverse the increased 
M1 activation of the RAW 264.7 macrophages in response to glycated gelatin (figure 
4.47). Furthermore, the ethanol extract did not enhance M2 activation, however, a 
significant increase in M2 activation in response to treatment with the water extract 
was observed. The M1:M2 ratios were subsequently calculated to be 4.06 for the 
ethanol extract and 1.55 for the water extract. Only the water extract was thus able 
to promote favourable macrophage polarization in the presence of glycated gelatin. 
Despite the fact that no significant anti-inflammatory or pro-inflammatory activities 
were observed for the ethanol extract of B. badius during section 4.3.1, a significant 
decrease in the available NO was recorded for the 200 μg/ml extract in the presence 
of glycated gelatin (figure 4.35 C). As this cannot be explained by a decrease in M1 
activation or an increase in M2 activation, the possibility of NO scavenging should 
not be ruled out. Furthermore, the strong pro-inflammatory activities observed for the 
water extract in the absence of LPS could explain why no significant decreases in 
NO production were observed in response to an increase in M2 activation. 
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Both the ethanol and water extracts of P. ostreatus resulted in significant decreases 
in M1 macrophage activation when compared to the treatment with glycated gelatin 
alone (figure 4.48).  Neither of the two extracts promoted M2 macrophage activation 
and the M1:M2 ratios were calculated as 2.4 and 1.59 for the ethanol and water 
extracts, respectively. Both extracts thus promoted favourable macrophage 
polarization with the water extract showing greater potential. Substantial anti-
inflammatory properties in the presence of LPS and glycated gelatin were reported 
for the 200 μg/ml ethanol extract of P. ostreatus during section 4.3.1. This was 
probably due to the decrease in M1 macrophage activation reported during this 
section. The same decrease in NO production was not observed for the water extract 
and this can potentially be attributed to the slight pro-inflammatory activity that was 
reported in the absence of LPS (figure 4.36 A). 
The water extract of G. lucidum resulted in a significant decrease in M1 macrophage 
activation with no significant effect on M2 activation (figure 4.49). The M1:M2 ratio 
was calculated to be 1.41 and the water extract thus showed great potential in 
correcting the imbalance in M1/M2 macrophage activation caused by the glycated 
gelatin. The results from section 4.3.1., however, did not reveal any significant anti-
inflammatory or pro-inflammatory properties with regards to NO production. 
5.3.4. NF-ĸB translocation 
It has long been known that NF-ĸB is an important transcription factor responsible for 
the expression of several pro-inflammatory signalling molecules and it thus forms an 
important function during inflammation (Wullaert et al., 2011). In section 5.1 it was 
shown that glycated gelatin promotes the nuclear translocation of phospho-p65 NF-
ĸB. As NF-ĸB nuclear translocation and consequent activation has been identified as 
one of the potential causes of impaired wound healing, any mushroom extract that is 
able to return the levels of nuclear phospho-p65 NF-ĸB back to those observed in 
the untreated sample could potentially serve as a useful therapy in promoting normal 
wound healing in diabetic individuals.  
While none of the extracts tested appear to have been able to reduce the levels of 
nuclear phospho-p65 NF-ĸB back to those recorded for the untreated sample, no 
significant difference between the untreated sample and the water extracts of P. 
ostreatus and G. lucidum was observed (figure 4.50). This, however, was due to an 
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increase in the variation between individual experiments and further investigations 
would thus be required to confirm whether these extracts successfully overcame the 
pro-inflammatory effects exerted by the glycated gelatin or not. While no significant 
anti-inflammatory properties were reported for either of these extracts during section 
5.3.1, both extracts were shown to significantly reduce M1 macrophage activation 
and the possibility of inhibiting NF-ĸB activation in the presence of glycated gelatin 
should thus not be ruled out at this stage. 
The results from this section suggest that none of the extracts displayed any 
significant anti-inflammatory properties, however, the same findings were not 
observed in sections 5.3.1 and 5.3.3. According to Poligone and Baldwin (2001), 
dual controls exist for NF-ĸB activation and inactivation where some NF-ĸB inhibitors 
have been shown to carry out their functions without influencing the induced nuclear 
accumulation of phospho-p65. Conversley, the opposite can also be true where an 
increase in nuclear accumulation is not accompanied by gene expression due to the 
ability of certain compounds to bind directly to DNA and subsequently prevent 
transcription. This then could explain why some extracts demonstrated anti-
inflammatory activities in previous sections but did not affect NF-ĸB translocation in 
the presence of glycated gelatin. As COX-2 is frequently used as a marker for NF-ĸB 
activation, the conflicting nature of these results prompted the further investigation of 
COX-2 levels. 
5.3.5. COX-2 
While inflammation is a crucial phase of the wound healing process, an augmented 
and uncontrolled response has been associated with the chronicity of impaired 
wound healing in both humans and mice. Studies have found that COX-2 is directly 
associated with inflammation and that COX-2 dysregulation can be associated with 
cutaneous wound healing in diabetic mice. While an increase in the expression of 
COX-2 can be expected during the early stages of the wound healing process, it was 
found that COX-2 expression remained drastically augmented during the late repair 
stage in diabetic mice, thus contributing to chronic inflammation (Kämpfer et al., 
2005). 
As both pro-inflammatory and anti-inflammatory activities were reported for the 
various mushroom extracts tested during this study, COX-2 was measured both in 
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the presence and the absence of LPS (figure 4.51). Furthermore, in section 5.1 it 
was shown that glycated gelatin alone did not enhance the levels of COX-2 in RAW 
264.7 macrophages, however, in LPS stimulated cells a significant increase in COX-
2 was observed. As COX-2 is pro-inflammatory in nature and is responsible for 
promoting the synthesis of various pro-inflammatory signalling molecules, a 
decrease in the presence of COX-2 could be beneficial in attenuating the 
inflammatory response enough to promote the normal wound healing process in 
diabetic individuals. 
The levels of COX-2 were significantly increased in RAW 264.7 cells treated with 
100 μg/ml ethanol extract of P. tinctorius in the absence of LPS when compared to 
glycated gelatin without LPS. The pro-inflammatory activity observed for the ethanol 
extract during the assessment of NO production without LPS thus explains the 
observed increase in COX-2 expression. Upon the addition of LPS, however, a 
significant decrease (p<0.01) in COX-2 levels were recorded when compared to 
treatment with both glycated gelatin and LPS. These findings agree with those from 
section 4.3.1 and confirm that the ethanol extract of P. tinctorius contains 
compounds that display both pro-inflammatory and anti-inflammatory activities. 
When compared to the sample treated with glycated gelatin but not LPS, the water 
extract of P. tinctorius did not promote any significant increases in COX-2 
expression. When LPS was added, however, a robust decrease (p<0.005) in COX-2 
activity was observed in comparison to the glycated gelatin sample with LPS. While 
the pro-inflammatory activity seen in section 4.3.1 in the absence of LPS was not 
observed here, the same anti-inflammatory activity in the presence of both glycated 
gelatin and LPS was reported.  
In the absence of LPS, no significant increase in the percentage of cells stained 
positive for COX-2 was seen during treatment with the ethanol extract of R. 
capensis, confirming the results obtained in section 4.3.1 where no pro-inflammatory 
activity was observed. In the presence of LPS, a significant decrease in COX-2 was 
recorded when compared to treatment with both glycated gelatin and LPS. This 
again confirms the same anti-inflammatory trend recorded in section 4.3.1. Similar to 
the ethanol extract, no significant increase in COX-2 was recorded in the absence of 
LPS; however, a significant decrease in COX-2 expression was reported for the 
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water extract of R. capensis when compared to treatment with both glycated gelatin 
and LPS. These trends do not agree with those obtained in section 4.3.1 where 
significant increases in NO production were reported in the absence of LPS and 
consequently no NO inhibition occurred in the presence of glycated gelatin. These 
results again emphasise the importance of measuring multiple different parameters, 
particularly if inflammatory pathways are under investigation, as several possible 
signalling pathways can lead to a wide array of unexpected and often unexplainable 
responses.  
Confirming the results obtained in section 4.3.1, no significant changes in COX-2 
expression were observed in response to treatment with the ethanol extract of B. 
badius in the absence of LPS while a significant increase in COX-2 was recorded for 
the water extract. Furthermore, both the ethanol and the water extracts significantly 
reduced the number of cells stained positive for COX-2 in the presence of both 
glycated gelatin and LPS when compared to relevant control. While a similar trend 
was observed for the ethanol extract in section 4.3.1, the same cannot be said for 
the water extract.  
Neither the ethanol nor the water extracts of P. ostreatus resulted in any significant 
increases in COX-2 in the absence of LPS when compared to treatment with 
glycated gelatin alone. The same trend was observed for the ethanol extract in 
section 4.3.1; however, the water extract did not demonstrate the same weak pro-
inflammatory response during the COX-2 assay. In the presence of LPS, only the 
ethanol extract significantly decreased the percentage of cells stained positive for 
COX-2, confirming the trends observed in section 4.3.1. 
No significant alterations in COX-2 were observed in response to treatment with the 
water extract of G. lucidum in the absence of LPS; however, a significant decrease 
was recorded in the presence of LPS when compared to the relevant controls. While 
no pro-inflammatory activity for this extract was reported in section 4.3.1, the same 
anti-inflammatory activities were not observed. 
In order to gain a better understanding of the overall effect of each extract on the 
inflammatory phase of the wound healing process in diabetic wounds, the results 
from this section are summarised in table 5.2 to 5.6 below. 
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Table 5.2: A summary of the effects of P. tinctorius on RAW 264.7 macrophage function and 
inflammation during diabetic wound healing. 
Experiment Assay conditions Ethanol extract* Water extract* Putative relevance to therapeutic 
potential 
NO 
production 
without LPS ↑ ↑ May be beneficial during the early 
stages of wound healing where diabetic 
wounds display reduced NO levels. 
with LPS - at 100 μg/ml; 
↓ at 200 μg/ml 
- at 100 μg/ml; 
↓ at 200 μg/ml 
May be beneficial in attenuating the 
inflammatory response during later 
stages of chronic wound healing.
 Ɨ
 
with glycated gelatin, 
with LPS 
↓ ↓ Potential anti-inflammatory activity 
which may be beneficial in attenuating 
the chronic inflammation in diabetes 
caused by AGEs. 
Ɨ
 
Phagocytosis with glycated gelatin, 
without LPS 
- - - 
M1/M2 with glycated gelatin, 
without LPS 
- on M1; ↑ in M2 - on M1; ↑ in M2 May be beneficial in attenuating chronic 
inflammation and promoting the 
transition from inflammation to the final 
tissue repair stage. 
NF-ĸB with glycated gelatin, 
without LPS 
- - - 
COX-2 with glycated gelatin; 
without LPS 
↑ - May be beneficial in promoting 
inflammation during the early stages of 
normal wound healing. 
with glycated gelatin; 
with LPS 
↓ ↓ May be beneficial in attenuating chronic 
inflammation due to AGEs. 
*(↑) indicates a positive effect, (↓) indicates a negative effect and (-) indicates no effect 
Ɨ
 Potentially due to quenching; further tests needed to confirm this 
The same activities were reported for both the ethanol and water extracts of P. 
tinctorius with the only exception occurring during the COX-2 assay in the absence 
of LPS. Both extracts displayed pro-inflammatory activities during the measurement 
of NO production as well as anti-inflammatory activities, however, the anti-
inflammatory activities appear to dominate in the presence of glycated gelatin. No 
improvements in the phagocytic capability of RAW 264.7 cells were reported while 
significant increases in M2 macrophage activation were observed. Furthermore, 
neither extract was able to attenuate NF-ĸB translocation; however, both extracts 
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significantly reduced the percentage of cells stained positive for COX-2.  These 
results suggest that both the ethanol and water extracts could be useful in 
attenuating the inflammatory response in diabetic wound healing through pathways 
promoting an increase in M2 macrophage activation. No published data on the 
effects of P. tinctorius on inflammation has been reported to date. 
Table 5.3: A summary of the effects of R. capensis on RAW 264.7 macrophage function and 
inflammation during diabetic wound healing. 
Experiment Assay conditions Ethanol extract* Water extract* Putative relevance to therapeutic 
potential 
NO 
production 
without LPS - ↑ May be beneficial during the early stages 
of wound healing where diabetic wounds 
display reduced NO levels. 
with LPS - at 100 μg/ml; 
↓ at 200 μg/ml 
- May be beneficial in attenuating the 
inflammatory response during later 
stages of chronic wound healing.
 
 
with glycated gelatin, 
with LPS 
↓ - Potential anti-inflammatory activity which 
may be beneficial in attenuating the 
chronic inflammation in diabetes caused 
by AGEs.  
Phagocytosis with glycated gelatin,  
without LPS 
↑ - May be beneficial in promoting 
macrophage phagocytosis of microbes in 
infected diabetic wounds. 
M1/M2 with glycated gelatin,  
without LPS 
- on M1; ↑ in M2 - on M1; ↑ in M2 May be beneficial in attenuating chronic 
inflammation and promoting the transition 
from inflammation to the final tissue 
repair stage. 
NF-ĸB with glycated gelatin,  
without LPS 
- - - 
COX-2 without LPS,  
with glycated gelatin 
- - - 
with LPS, 
 with glycated gelatin 
↓ ↓ May be beneficial in attenuating chronic 
inflammation due to AGEs. 
*(↑) indicates a positive effect, (↓) indicates a negative effect and (-) indicates no effect 
The ethanol extract of R. capensis showed anti-inflammatory activities during the 
NO, macrophage polarization and COX-2 assays. Furthermore, an increase in 
phagocytosis was observed. These results suggest that the ethanol extract of R. 
capensis could thus prove to be very useful in promoting macrophage phagocytosis 
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while simultaneously attenuating the inflammatory response and promoting M2 
macrophage polarization during diabetic wound healing. The results for the water 
extract of R. capensis show that this extract was capable of promoting M2 
macrophage polarization and reducing the percentage of cells stained positive for 
COX-2, however, it did not affect NO production or phagocytosis in the presence of 
glycated gelatin. A literature search revealed that no data on the effects of R. 
capensis on inflammation could be found. 
Table 5.4: A summary of the effects of B. badius on RAW 264.7 macrophage function and 
inflammation during diabetic wound healing. 
Experiment Assay conditions Ethanol extract* Water extract* Putative relevance to therapeutic 
potential 
NO 
production 
without LPS - ↑ May be beneficial during the early 
stages of wound healing where diabetic 
wounds display reduced NO levels. 
with LPS - - at 100 μg/ml;  
↑ at 200 μg/ml 
May be beneficial in promoting the 
inflammatory response during normal 
wound healing. 
with glycated gelatin, 
with LPS 
- at 100 μg/ml;  
↓ at 200 μg/ml 
- Potential anti-inflammatory activity 
which may be beneficial in attenuating 
the chronic inflammation in diabetes 
caused by AGEs. 
Phagocytosis with glycated gelatin, 
without LPS 
- - - 
M1/M2 with glycated gelatin, 
without LPS 
- - on M1; ↑ in M2 May be beneficial in attenuating chronic 
inflammation and promoting the 
transition from inflammation to the final 
tissue repair stage. 
NF-ĸB with glycated gelatin, 
without LPS 
- - - 
COX-2 without LPS, with 
glycated gelatin 
- ↑ May be beneficial in promoting 
inflammation during the early stages of 
normal wound healing. 
with LPS, with 
glycated gelatin 
↓ ↓ May be beneficial in attenuating chronic 
inflammation due to AGEs. 
*(↑) indicates a positive effect, (↓) indicates a negative effect and (-) indicates no effect 
The ethanol extract of B. badius displayed weak anti-inflammatory activities in the 
presence of glycated gelatin with regards to NO production and COX-2 activity. No 
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improvements in macrophage phagocytosis, M2 macrophage polarization or NF-ĸB 
activation were observed and this extract thus does not show much potential in 
promoting normal wound healing in diabetic individuals. The water extract does not 
seem very promising either as it demonstrated strong pro-inflammatory properties 
during the NO assay as well as the COX-2 assay in the absence of LPS. While it 
was able to promote M2 macrophage activation and reduce COX-2 activity (in the 
presence of LPS), it did not promote phagocytosis or NF-ĸB inactivation. No 
documented reports on the effects of B. badius on the inflammatory process could 
be found. 
Table 5.5: A summary of the effects of P. ostreatus on RAW 264.7 macrophage function and 
inflammation during diabetic wound healing. 
Experiment Assay conditions Ethanol extract* Water extract* Putative relevance to therapeutic 
potential 
NO production without LPS - ↑ May be beneficial during the early 
stages of wound healing where diabetic 
wounds display reduced NO levels. 
with LPS - at 100 μg/ml;  
↓ at 200 μg/ml 
- May be beneficial in attenuating the 
inflammatory response during later 
stages of chronic wound healing. 
with glycated gelatin, 
with LPS 
- at 100 μg/ml;  
↓ at 200 μg/ml 
- Potential anti-inflammatory activity 
which may be beneficial in attenuating 
the chronic inflammation in diabetes 
caused by AGEs. 
Phagocytosis with glycated gelatin, 
without LPS 
↑ - May be beneficial in promoting 
macrophage phagocytosis of microbes 
in infected diabetic wounds. 
M1/M2 with glycated gelatin, 
without LPS 
↓ in M1; - on M2 ↓ in M1; - on M2 May be beneficial in attenuating chronic 
inflammation due to AGEs. 
NF-ĸB with glycated gelatin, 
without LPS 
- - - 
COX-2 without LPS, with 
glycated gelatin 
- - - 
with LPS, with 
glycated gelatin 
↓ - May be beneficial in attenuating chronic 
inflammation due to AGEs. 
*(↑) indicates a positive effect, (↓) indicates a negative effect and (-) indicates no effect 
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The ethanol extract of P. ostreatus showed promising anti-inflammatory activity in 
the presence of glycated gelatin and LPS for both the NO and COX-2 assays. 
Furthermore, it was found to promote phagocytosis and reduce M1 macrophage 
activation; however, the water extract did not show any promising activities other 
than reducing M1 macrophage polarization. A study conducted by Jedinak et al. 
(2011) found similar anti-oxidant activities in RAW 264.7 macrophages where P. 
ostreatus was found to inhibit the LPS-induced NO production and COX-2 through 
mechanisms involving the down-regulation of iNOS and NF-ĸB. Furthermore, this 
mushroom species was found to inhibit inflammation in mice. 
Table 5.6: A summary of the effects of G. lucidum on RAW 264.7 macrophage function and 
inflammation during diabetic wound healing. 
Experiment Assay conditions Water extract* Putative relevance to therapeutic 
potential 
NO 
production 
without LPS - - 
with LPS - - 
with glycated gelatin, 
with LPS 
- - 
Phagocytosis with glycated gelatin, 
without LPS 
- - 
M1/M2 with glycated gelatin, 
without LPS 
↓ in M1; - on M2 May be beneficial in attenuating chronic 
inflammation due to AGEs. 
NF-ĸB with glycated gelatin, 
without LPS 
- - 
COX-2 without LPS, with 
glycated gelatin 
- - 
with LPS, with glycated 
gelatin 
↓ May be beneficial in attenuating chronic 
inflammation due to AGEs. 
*(↑) indicates a positive effect, (↓) indicates a negative effect and (-) indicates no effect 
The water extract of G. lucidum showed anti-inflammatory activities during the COX-
2 assay and was able to reduce M1 macrophage activation; however, no effects on 
phagocytosis, NO production or NF-ĸB activation were reported. This extract thus 
shows very limited potential in promoting the correct macrophage function during 
diabetes. 
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Overall, the ethanol extracts displayed the most promising abilities to attenuate 
inflammation and promote normal macrophage function in the presence of protein 
glycation. In general, more lipophilic compounds are isolated in polar solvents such 
as ethanol. These results thus concur with those of Vaskovsky et al. (1998) who 
reported that mushrooms possess larger quantities of polar compounds such as 
phenolic compounds including flavonoids and polyphenols.  Information with regards 
to the bioactive compounds present in B. badius, P. tinctorius and R. capensis are 
severely lacking and remain poorly characterized for P. ostreatus and G. lucidum. 
The principle bioactive compounds isolated from G. lucidum include mostly 
polysaccharides, sterols, triterpenes and various proteins such as lectin whereas 
most of the bioactivities of P. ostreatus have been attributed to the presence of B-
glucans and lectin (Patel et al., 2012; Saltarelli et al., 2015).  
5.4. THE ROLE OF FIBROBLASTS IN WOUND HEALING 
Fibroblasts perform important functions during the proliferative stage of the wound 
healing process as they are responsible for fibroplasia. In diabetes, however, 
fibroblasts have been shown to demonstrate premature senescence (Menke et al., 
2007). Consequently fibroblast function is altered such that their proliferation and 
migration abilities become impaired. The mechanisms responsible for the observed 
effects of diabetes on fibroblast function are still under current investigation.  
Using a glycated collagen model, Liao et al. (2010) showed that the glycation 
process observed during diabetes negatively influenced the mechanical strength and 
properties of collagen. Furthermore, it was found to influence several cell-collagen 
interactions such as cell attachment, migration and proliferation while simultaneously 
impairing fibroblast facilitated ECM remodelling and collagen contraction. As a result 
of the greatly reduced fibroblast population, a decrease in the volume of granulation 
tissue was observed. According to Li et al. (2007), fibroblasts isolated from diabetic 
ulcers showed a reduced proliferative responsiveness to TGF-β1 as well as PDGF 
and various other growth factors and cytokines necessary for regulating normal 
fibroblast function. Additionally, a decrease in the expression of TGF-β receptors 
was observed which greatly impaired signal transduction.  
It was recently shown that AGEs induce autophagy in dermal fibroblasts and diabetic 
skin tissues through a mechanism that at least partly involves the regulation of the 
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transcriptional activity of FOXO1. Excessive autophagy and resultant cell death 
could thus also explain the impairments in fibroblast function observed during 
diabetes. The signalling pathways responsible for FOXO1 mediated autophagy in 
diabetic fibroblasts have not yet been elucidated. Two possible mechanisms through 
which AGEs can induce fibroblast autophagy include suppression of the PI3K-AKT 
pathway thus promoting FOXO1 transcriptional activation and nuclear translocation 
or the inhibition of the transcriptional activity of p53 by AGEs and resultant mRNA 
suppression which would lead to a decrease in p53 dependent exclusion of FOXO1 
from the nucleus and a resultant increase in FOXO1 transcription (Sun et al., 2016). 
5.4.1. Proliferation 
A dose-response curve was carried out in order to determine the optimal 
concentration of FBS that should be used to support sub-optimal proliferation in 
MRHF fibroblasts (figure 4.52). A sharp decline in fibroblast proliferation was 
recorded when the concentration of FBS was decreased from 10 % to 1 % followed 
by a more gradual decline as the FBS concentration approached 0 %. While none of 
the concentrations of FBS tested resulted in any significant increases in cell death, 1 
% FBS was chosen as lower concentrations could potentially induce autophagy and 
subsequently interfere with the results. 
In the presence of 10 % FBS, the 200 μg/ml concentrations of the ethanol and water 
extracts of P. tinctorius were found to exert an anti-proliferative effect on MRHF 
fibroblasts (figure 4.17 C). When the serum concentration was reduced to 1 %, the 
same trend was observed for the ethanol extract whereas no negative effects of the 
water extract on MRHF proliferation were reported (figure 4.53). The anti-proliferative 
effect of the sub-optimal serum concentration thus superseded the anti-proliferative 
effect of the water extract.  
No noteworthy alterations in fibroblast proliferation were reported for the ethanol 
extract of R. capensis in the presence of 10 % FBS (figure 4.18 C). At sub-optimal 
serum concentrations, however, a robust cytotoxic effect was reported (figure 4.54), 
suggesting that the 10 % serum was able to protect the fibroblasts from the 
damaging effects of this extract. Similar activities were reported for the water extract 
at both serum concentrations. Similarly, the ethanol extract of B. badius did not affect 
MRHF cell numbers in the presence of 10 % FBS (figure 4.19 C) whereas a 20 % 
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decrease in the proliferation activity of fibroblasts at sub-optimal serum 
concentrations was reported (figure 4.55 A). The same activities were reported for 
the water extract of B. badius at both serum concentrations. 
The ethanol and water extracts of P. ostreatus did not affect the proliferation of the 
MRHF fibroblasts at both serum concentrations tested during this study. Conversely, 
the water extract of G. lucidum resulted in a significant decrease (p<0.05) in MRHF 
proliferation that was not observed in section 4.2.1. In the presence of glycated 
gelatin, several of the mushroom extracts including the ethanol and water extracts of 
P. ostreatus and the water extracts of B. badius, P. ostreatus and G. lucidum were 
capable of restoring the proliferative capacity of MRHF fibroblasts back to the levels 
observed in the 1 % FBS control. None of the tested mushroom samples were, 
however, able to promote fibroblast proliferation to levels higher than those observed 
for the 1 % FBS control. 
Overall, the water extracts displayed the strongest abilities to promote fibroblast 
migration in the presence of glycated gelatin, suggesting that the compounds 
responsible for this effect were not present in the ethanol extracts. According to a 
study conducted by Cheng et al. (2013) a hot aqueous extract of G. lucidum was 
also found to promote fibroblast proliferation in diabetic rats, however, no 
mechanism for the observed activity was provided. No published literature on the 
effects of the remaining four mushroom species on dermal fibroblast proliferation in 
diabetes has been reported to date. 
5.4.2. Migration 
A mitomycin C dose-response curve was performed in order to determine the 
concentration of mitomycin-C that should be used to inhibit fibroblast proliferation. 
Mitomycin C concentrations as low as 0.5 μg/ml significantly reduced fibroblast cell 
numbers with the greatest effect observed at 10 μg/ml. Ideally the highest non-toxic 
concentration should be selected in order to ensure maximum inhibition of 
proliferation. While statistically significant increases in cell death were observed at 
concentrations of 2.5 μg/ml and above, the difference in cell death between the 
untreated sample (0 %) and the sample treated with 10 μg/ml mitomycin C was only 
4 % and was thus not considered physiologically relevant. For this reason, 10 μg/ml 
was selected as the optimal concentration for further experimentation.   
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Based on preliminary studies performed using the scratch assay (results not 
reported), the most promising mushroom extracts were identified for further 
investigation. The 100 μg/ml ethanol and water extracts of R. capensis and B. badius 
as well as the water extract of G. lucidum were all found to significantly promote 
MRHF fibroblast migration in the presence of glycated gelatin. The water extract of 
G. lucidum showed the strongest response as it was able to restore MRHF fibroblast 
migration back to the levels observed in the untreated sample. The effects of each of 
the tested mushroom extracts of fibroblast proliferation and migration are 
summarised in table 5.7. 
Table 5.7: A summary of the effects of each mushroom extract on fibroblast proliferation and 
migration. 
Mushroom 
species 
Experiment Assay conditions Ethanol extract* Water extract* 
P. tinctorius Proliferation Without glycated gelatin - at 100 μg/ml;      
  ↓ at 200  μg/ml 
↑ at 100 μg/ml;        
 - at 200  μg/ml 
With glycated gelatin - at 100 μg/ml;       
 ↑  at 200  μg/ml 
↑at 100 μg/ml;       
 ↑  at 200  μg/ml 
Migration With glycated gelatin n/d n/d 
R. capensis Proliferation Without glycated gelatin ↓ ↓ at 100 μg/ml;      
- at 200  μg/ml 
With glycated gelatin - at 100 μg/ml;    
↓ at 200  μg/ml 
- 
Migration With glycated gelatin ↑ ↑ 
B. badius Proliferation Without glycated gelatin ↓ - 
With glycated gelatin - ↑ 
Migration With glycated gelatin ↑ ↑ 
P. ostreatus Proliferation Without glycated gelatin - - 
With glycated gelatin - - at 100 μg/ml;       
 ↑  at 200  μg/ml 
Migration With glycated gelatin n/d n/d 
G. lucidum 
 
Proliferation Without glycated gelatin n/d ↓ 
With glycated gelatin n/d ↑ 
Migration With glycated gelatin n/d ↑ 
*(↑) indicates a positive effect, (↓) indicates a negative effect, (-) indicates no effect and (n/d) indicates 
no data 
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While several of the tested mushroom extracts were seemingly capable of promoting 
normal fibroblast proliferation in the presence of glycated gelatin, only the water 
extracts of B. badius and G. lucidum were found to promote both fibroblast 
proliferation and migration and were thus identified as the most promising candidates 
for promoting the proliferative phase of wound healing in diabetes. 
5.5. LIMITATIONS OF THIS STUDY AND SUGGESTIONS FOR FUTURE 
STUDIES 
In diabetes, several factors including neuropathic, microvascular, macrovascular, 
biochemical, immune function and hormonal irregularities contribute to the 
impairment of wound healing. Consequently, diabetic individuals pose a unique 
challenge with the impact of diabetes affecting protein synthesis, leukocyte function, 
oxygen transportation and utilisation systems as well as the availability of a multitude 
of growth factors (McCulloch & Kloth, 2010).  
Due to the moral and ethical dilemmas with regards to animal testing, in vitro 
screening models are an essential tool for the initial screening phase of a research 
study as they can provide both proof of concept as well as justification for further 
research using animal models (Scherer et al., 2008; Stacey, 2012). While every 
effort is made to duplicate the in vivo environment, in vitro modelling remains unable 
to capture the complexity behind the pathology of diabetes and the results must thus 
be interpreted accordingly. The fact that single cell types are used means that the 
cell-cell interactions are different in vitro compared to in vivo and thus cellular 
signalling could be affected. Furthermore, culture conditions are continuously altered 
by the depletion of nutrients, accumulation of waste products and sudden media 
changes. While certain responses can be imitated in vitro with confidence, the fact 
remains that isolated cells that do not form part of a tissue or organ are cultured as 
monolayers and thus whole tissue or systemic responses that occur in vivo could 
cause completely different responses to those observed in vitro (Hartung & Daston, 
2009). The various end-point assays utilised during this study may be physiologically 
relevant, however, they are incapable of measuring the fluctuations that might occur 
throughout the incubation period, possibly resulting in a skewed interpretation of an 
event as it occurs in vivo. Furthermore, by measuring only the concentration of a 
given signalling molecule such as NO or COX-2, one is not able to determine 
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whether the expression and consequent synthesis of that particular molecule is 
being altered or whether it is simply the activity of that molecule that is affected.  
Future studies should be directed at incorporating dermal keratinocytes in the 
glycated gelatin model as these cells also perform important functions during the 
proliferation and tissue remodelling phases of wound healing. Co-cultures of 
macrophages and fibroblasts could be used to produce an environment that is more 
suitable in mimicking the physiological response as it occurs in vivo and could also 
provide deeper insight into the effect of different cell products on certain cell types.  
The effect of AGEs on collagen synthesis in fibroblasts as well as the cytoskeletal 
arrangement of the various skin cells should also be explored. Further investigations 
related to characterising the inflammatory response should include macrophage 
infiltration as well as the measurement of iNOS and various signalling molecules 
such as ROS, ERK1/2 and phosphorylated JNK in order to establish other 
inflammatory pathways that may be activated. The effect of the different mushroom 
species on each of the above-mentioned parameters should be assessed. Anti-
microbial studies should also be included as diabetic wounds are often characterized 
by infection. Once the most promising extracts have been selected, further in vivo 
investigations should follow. Should the in vivo studies reveal any real advantages of 
these mushrooms in diabetic wound healing, these species should be characterized 
and the active compounds should be isolated in order to gain a deeper 
understanding of the possibilities and limitations of each compound. 
5.6. CONCLUSION 
The aim of the present study was to develop and characterize a low-cost in vitro 
glycated gelatin model that reflects the cellular dysfunction observed during diabetic 
wound healing and to evaluate its use as a screening tool to identify potential 
therapeutic agents.  Characterization of the glycated gelatin model revealed a 
remarkable correlation to known features defining diabetic wound healing, thus 
providing confidence as a screening assay. This model was then used to assess the 
potential of five wild mushroom species to overcome the cellular impairments 
observed in diabetes, thus promoting normal wound healing under diabetic 
conditions. In addition, other in vitro assays with relevance to wound healing were 
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also investigated in order to build a more comprehensive screening platform relating 
to diabetic wound healing.   
The glycated gelatin model presented several advantages with regards to cost and 
convenience over other commonly used purified proteins, however, the two greatest 
advantages of using gelatin as a surrogate protein are related to the heat stability 
and resistance to thermal denaturation of gelatin during autoclaving thus allowing the 
glycation process to be carried out within one hour as well as the certified absence of 
endotoxins which allows one to accurately characterize the inflammatory response in 
macrophages treated with AGEs. This model was found to accurately reproduce 
several cellular dysfunctions observed in macrophages and fibroblasts during 
diabetic wound healing both in vivo and in vitro; however, as with all in vitro studies it 
should be noted that this model was not able to replicate the complexity of in vivo 
diabetic wound healing and the results should thus be interpreted accordingly.  
The ethanol and water extracts of P. tinctorius displayed comparatively strong anti-
oxidant activities and could thus provide several advantages during diabetic wound 
healing in combating oxidative stress, however, no significant glycation inhibition or 
collagenase inhibition activities were demonstrated. The ethanol extract displayed 
strong pro-inflammatory activity coupled to a weaker anti-inflammatory activity during 
the measurement of both NO and COX-2. The same phenomenon was observed for 
the water extract, however, no pro-inflammatory activity was observed during the 
measurement of COX-2. Furthermore, both extracts showed strong NO scavenging 
capabilities and thus further studies measuring iNOS activity are required to confirm 
the effects of these extracts on NO production. While neither extract was able to 
overcome the effect of AGEs on phagocytosis or NF-ĸB activation, they significantly 
increased M2 macrophage activation and significantly promoted fibroblast 
proliferation in the presence of AGEs which could be highly beneficial in promoting 
the transition from inflammation to tissue remodelling during impaired wound healing.  
R. capensis did not demonstrate particularly strong anti-oxidant, glycation inhibition 
or collagenase inhibition activities, however, the ethanol extract showed a strong 
potential for promoting the resolution of inflammation due to its anti-inflammatory 
activities recorded during the measurement of both NO and COX-2 as well as its 
ability to promote phagocytosis, M2 macrophage activation and fibroblast migration 
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in the presence of AGEs. The water extract was also capable of promoting M2 
macrophage activation, reducing COX-2 and promoting fibroblast migration, 
however, it did not show the same potential in promoting phagocytosis and 
demonstrated strong pro-inflammatory activity by promoting NO production. The 
potential presence of endotoxins in the water extract warrants further investigation. 
The ethanol and water extracts of B. badius did not show promising anti-oxidant, 
glycation inhibition or collagenase inhibition activities with the water extract 
seemingly promoting glycation.  The water extract showed strong pro-inflammatory 
activities during the measurement of NO and COX-2, however, it significantly 
promoted M2 macrophage activation, reduced COX-2, and promoted fibroblast 
proliferation and migration in the presence of AGEs. The ethanol extract did not 
demonstrate the same potential as the water extract as it was only capable of 
reducing COX-2 and promoting migration in the presence of AGEs. 
P. ostreatus did not demonstrate any anti-oxidant or collagenase inhibition activities 
and was found to potentially promote glycation. In the presence of AGEs, however, it 
showed great promise in attenuating the inflammatory response due to its anti-
inflammatory properties during both NO and COX-2 measurement as well as its 
ability to promote phagocytosis and reduce M1 macrophage activation. The water 
extract showed a weak pro-inflammatory response with regards to NO production, 
however, it was found to reduce M1 macrophage activation and promoted fibroblast 
proliferation in the presence of AGEs. 
The ethanol extract of G. lucidum was highly cytotoxic and was thus excluded from 
this study. The water extract displayed strong anti-oxidant activity with an IC50 below 
100 μg/ml for the DPPH assay. While no promising glycation inhibition or 
collagenase inhibition potential was demonstrated, the water extract was able to 
reduce M1 macrophage activation and COX-2 in the presence of AGEs while 
simultaneously promoting fibroblast proliferation and migration.  
The ethanol extracts of R. capensis and P. ostreatus showed the most promising 
ability to restore the correct macrophage function; however, their abilities to restore 
the correct fibroblast function were limited. Conversely, the water extract of G. 
lucidum showed the greatest potential to promote normal fibroblast function; 
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however, it demonstrated very limited capabilities in restoring the correct 
macrophage function. Different mushroom species were thus found to promote 
different macrophage and fibroblast functions and could thus provide different 
therapeutic advantages during diabetic wound healing. The results from this study 
consequently provide strong evidence to support further in vitro and in vivo studies 
related to the use of macrofungi in the treatment of diabetic wound healing. 
The findings from the present study have contributed to the understanding of the role 
of AGEs in cellular dysfunction by confirming discoveries made by other researchers 
as well as providing some unexpected and novel results. The dramatic effect of 
AGEs on macrophage phagocytosis coupled to the knowledge that this process may 
be fully reversible, for example, provides a potential therapeutic target for diabetic 
wound healing that has yet to be explored. This model can thus be used as a simple 
tool to explore the mechanisms behind the pathology of diabetic wound healing that 
have yet to be elucidated and in doing so reveal novel therapeutic targets. The 
relevance of protein glycation in skin aging and the effects of cigarette smoke on the 
skin suggest that the glycated gelatin model developed during this study could be 
relevant to the cosmetic industry during the search for novel anti-aging compounds 
and this model could thus be adapted for research in areas that are not related to 
diabetic wound healing.  
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APPENDICES 
APPENDIX A: Materials and consumables list 
The following table lists the materials and consumables that were utilised during this 
study, listed according to manufacturer. 
Product Product code Manufacturer 
Alexa Fluor
®
 488 anti-mouse CD86 105018  
 
BioLegend
 
(USA) 
Alexa Fluor
®
 488 IgG2a, ĸ Isotype Ctrl 400525 
APC anti-mouse CD206 (MMR) 141708 
APC Rat IgG2a, ĸ Isotype Ctrl 400512 
Anti-rabbit IgG (H+L), F(ab')2 Fragment (Alexa 
Fluor
®
 488 Conjugate) 
4408S  
 
Cell Signaling 
Technology (USA) 
Cox2 (D5H5) XP
®
 Rabbit mAb (Alexa Fluor
®
 488 
Conjugate) 
13596 
Phospho-NF-κB p65 (Ser536) (93H1) Rabbit mAb 3033S 
Cell Migration Assay, Tri-Coat ENZ-KIT116-0001 Enzo (USA) 
HyClone™ DMEM (High glucose, with L-
glutamine and sodium pyruvate) 
SH30243  
 
GE Healthcare Life Sciences 
(USA) 
HyClone™ DMEM (Low glucose with L-glutamine, 
sodium pyruvate) 
SH30021 
HyClone™ Foetal Bovine Serum SV30160 
BioWhittaker
®
 Dulbecco’s phosphate buffered 
saline (DPBS) with Ca2+ and Mg2+ 
17-513F  
 
 
Lonza (USA) 
BioWhittaker
®
 Dulbecco’s phosphate buffered 
saline (DPBS) without Ca2+ and Mg2+ 
 
17-512F 
Trypsin-EDTA CC-5012 
Aminoguanidine hemisulfate salt A7009  
 
 
 
 
 
 
 
Sigma-Aldrich (USA) 
Collagenase C0130 
Curcumin 28260 
Cytochalasin B C2743 
D-(+)-Glucose G7021 
Dulbecco’s Modified Eagle’s Medium (low 
glucose, with glucose and sodium bicarbonate; 
without L-glutamine and phenol red) 
 
D5921 
Griess’ Reagent for nitrite 03553 
Mitomycin C M4287 
Polymyxin B sulfate salt P4932 
Propidium iodide 81845 
Tripyridyltriazine 93285 
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2,2-Diphenyl-1-picrylhydrazyl D9132 
Hoechst
®
 33342 B2261  
Thermo Fisher Scientific 
(USA) 
LysoTracker
®
 Red  
pHrodo™ Green BioParticles
®
 P35366 
Acrodisc
®
 25 mm syringe filters with 0.2 μm 
Supor
®
 membrane 
103484D Pall Corporation (USA) 
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APPENDIX B: Reagent preparation 
The reagents required for the FRAP assay were prepared as follows: 
 Acetate buffer (300 mM) 
Dissolve 3.1 g sodium acetate in 800 ml distilled water; add 16 ml glacial 
acetic acid and fill to 1 L with distilled water. Store at 4 °C. 
 Dilute HCl (40 mM) 
Add 1.5 ml HCl to 500 ml distilled water. 
 TPTZ (10 mM) 
Dissolve 0.031 g TPTZ in 10 ml dilute HCl in a water bath at 50 °C; freshly 
prepared. 
 Ferric chloride (20 mM) 
Dissolve 0.108 g FeCl3·6H2O to 20 ml distilled water; freshly prepared. 
 FRAP reagent 
The FRAP reagent should be prepared fresh on the day. Add 20 ml sodium 
acetate buffer (300 mM), 2 ml TPTZ (10 mM), 2 ml FeCl3 (20 mM in distilled 
water; freshly prepared) and 2.4 ml distilled water. 
 The reagents required for the DPPH assay were prepared as follows: 
 Tris-HCl buffer (50 mM) 
Dissolve 0.606 g Tris in 80 ml distilled water; adjust the pH to 7.4 using HCl 
then fill to 100 ml with distilled water. 
 DPPH (0.1 mM) 
Dissolve 0.002 g DPPH in 50 ml ethanol; prepare freshly and protect from 
light. 
The reagents required for the glycation inhibition assay were prepared as follows: 
 Glyceraldehyde solution (500 mM) 
Dissolve 0.225 g of glyceraldehyde in 5 ml distilled water in a boiling water 
bath; store in working aliquots at -20 °C. 
 Protein solution (20 mg/ml) 
Dissolve 0.1 g gelatin in 5 ml distilled water in a 37 °C water bath. 
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The reagents required for the collagenase inhibition assay were prepared as follows: 
 Assay buffer (200 mM) 
Dissolve 2.4 g Tris, 0.44 g CaCl2 and 3.51 g NaCl in 80 ml distilled water; 
adjust the pH to 7.4 using HCl then fill to 100 ml with distilled water. 
 Protein solution (2 mg/ml) 
Dissolve 0.006 g gelatin in 3 ml distilled water in a 37 °C water bath. 
 Enzyme (40 μg/ml) 
Dissolve 0.08 mg collagenase in 0.5 ml assay buffer and 1.5 ml distilled 
water. 
 Coomassie Brilliant Blue (0.25 % in 40 % methanol/10 % acetic acid) 
Dissolve 25 g of Coomassie Brilliant Blue in 100 ml of a solution containing 40 
ml methanol, 10 ml acetic acid and 50 ml distilled water. Filter through 
Whatman™ filter paper (no. 1) and heat three times for three minutes in a 
microwave. 
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APPENDIX C: Phagocytosis and acidic vacuole content in RAW 264.7 cells 
 
Experiment 1: 
 
 
 
 
 
 
Experiment 2: 
 
 
 
 
 
  
Experiment 3: 
 
 
 
 
 
Figure C.1: Effect of gelatin on RAW 264.7 cell phagocytosis measuring (A) acidic vacuole 
formation using LysoTracker Red® and (B) phagocytosis using pHrodo® 
Bioparticles®; results are reported as means ± SD where each experiment was 
performed once in triplicate (*p<0.05; **p<0.01; ***p<0.005 compared to 
untreated sample). 
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              Experiment 1:                                        Experiment 2: 
 
              Experiment 3: 
 
 
 
 
 
Figure C.2: Effect of P. tinctorius on RAW 264.7 cell phagocytosis measuring acidic vacuole 
formation using LysoTracker Red®; results are reported as means ± SD where 
the experiment was performed once in triplicate (*/∆p<0.05; **/∆∆p<0.01; 
***/∆∆∆p<0.005 where *compared to untreated sample; ∆ compard to glycated 
gelatin). 
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              Experiment 1:                                        Experiment 2: 
         
      Experiment 3: 
 
 
 
 
 
Figure C.3: Effect of R. capensis on RAW 264.7 cell phagocytosis using pHrodo® 
Bioparticles®; results are reported as means ± SD where the experiment was 
performed once in triplicate (*/∆p<0.05; **/∆∆p<0.01; ***/∆∆∆p<0.005 where 
*compared to untreated sample; ∆ compard to glycated gelatin). 
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               Experiment 1:                                       Experiment 2: 
               Experiment 3: 
 
 
 
 
 
Figure C.4: Effect of P. ostreatus on RAW 264.7 cell phagocytosis using pHrodo® 
Bioparticles®; results are reported as means ± SD where the experiment was 
performed once in triplicate (*/∆p<0.05; **/∆∆p<0.01; ***/∆∆∆p<0.005 where 
*compared to untreated sample; ∆ compard to glycated gelatin). 
  
 
 
